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Abstract        
Abstract 
The diagnosis of non-small cell lung cancer (NSCLC) usually occurs when the disease has 
locally advanced or spread into distant sites. Patients with early-stage NSCLC have a better 
overall rate of survival than those patients with advanced stages. Assessment of tumor 
progression is therefore critical for treatment options. For this purpose, this study used two 
approaches to analyze the development of NSCLC. First, circulating microRNAs (miRNAs) 
were examined as prognostic markers from serum samples of early-stage lung 
adenocarcinoma patients. Secondly, this study investigated the role of miRNAs in the 
progression of lung adenocarcinoma cells after treatment with the tyrosine-kinase inhibitor 
(TKI) gefitinib and subsequent resistance.  
Genome-wide circulating miRNA expression profiling revealed miRNAs out of which miR-
142-3p was validated to be associated with poor prognosis in patients with lung 
adenocarcinoma. In order to improve the prognostic value of circulating miRNAs, a miRNA 
panel was searched to predict the overall survival and the relapse-free survival. Since no 
stable set of miRNAs was found, pre-analytical variables were identified as critical for 
miRNA analysis. In this case, the impact of blood collection and hemolysis were shown to 
have an influence on the expression level. The miRNAs, which were selected based on their 
prognostic relevance, showed a tendency to be lesser expressed in arterial blood than miRNAs 
derived from venipuncture. Moreover, miR-20b-5p and miR-486-5p were affected by 
hemolysis.  
In order to further investigate the progression of the tumor, the role of miRNAs and mRNAs 
in the development of resistance to EGFR-TKI gefitinib was studied. Therefore, a gefitinib 
resistance model was used by co-culturing lung fibroblasts (MRC-5) with the two different 
gefitinib-sensitive NSCLC cell lines HCC827 and PC-9. Global miRNA analysis revealed 
expression changes associated with EGFR-TKI resistance. A total of eleven miRNAs were 
selected, from which miR-503-5p was validated in both EGFR-TKI NSCLC cell lines. 
Subsequently, global gene expression profiling revealed 211 differentially expressed mRNAs 
in the resistant HCC827 and PC-9 cells. Putative target genes of miR-503-5p were determined 
by comparing global gene expression profiling with miRNA prediction databases. The 
autophagy gene GABARAPL1 was validated at both the mRNA and protein level. Ectopic 
overexpression of miR-503-5p resulted in significant reduction of GABARAPL1. Moreover, 
luciferase reporter assays showed the direct interaction between miR-503-5p and the 3’UTR 
of GABARAPL1. Different autophagy markers were analyzed in co-cultured HCC827 cells 
after gefitinib treatment. Thereby, the accumulation of the SQSTM1, as well as a decrease of 
LC3B-II and GABARAPL1 levels were observed. In accordance with this finding, siRNA-
mediated knockdown of GABARAPL1 resulted in an accumulation of SQSTM1 (p62). In 
conclusion, these data suggest that inhibiting GABARAPL1 through miR-503-5p modulates 
autophagic activity in gefitinib resistant EGFR-mutant lung adenocarcinoma cells. 
 
 
Zusammenfassung        
Zusammenfassung 
Die Diagnose des nicht-kleinzelligen Bronchialkarzinoms (NSCLC) erfolgt meistens, wenn 
die Krankheit lokal fortgeschritten ist oder schon Metastasen gebildet hat. Patienten im 
Frühstadium von NSCLC haben eine bessere Überlebensrate als jene mit fortgeschrittenen 
Tumorstadien. Daher ist die Einschätzung der Tumorprogression von entscheidender 
Bedeutung für die Abwägung von Therapieoptionen. Zu diesem Zweck wurden in dieser 
Arbeit zwei Ansätze verfolgt, um die Entwicklung von NSCLC zu studieren. Zunächst 
wurden zirkulierende microRNAs (miRNAs) als prognostische Marker von Serumproben von 
NSCLC-Patienten im Frühstadium untersucht. Zweitens wurde im in-vitro Modell die Rolle 
von miRNAs in der Progression von Adenokarzinomzellen der Lunge nach einer Resistenz 
gegenüber dem Tyrosinkinase-Inhibitor (TKI) Gefitinib untersucht. 
In einem genomweiten Screening-Ansatz wurden zirkulierende miRNAs in Serumproben von 
NSCLC-Patienten im Frühstadium identifiziert und miR-142-3p wurde mit einer schlechten 
Prognose assoziiert. Um den prognostischen Wert von zirkulierenden miRNAs zu verbessern, 
wurde nach einem miRNA Panel gesucht. Es konnte jedoch keine stabile Gruppe von 
miRNAs für das Gesamtüberleben oder Rezidiv-freie Überleben gefunden werden. Daher 
wurde der potentielle Einfluss verschiedener prä-analytischer Variablen untersucht, die 
entscheidend für die Analyse von zirkulierenden miRNAs aus dem Serum sind. Es konnte 
gezeigt werden, dass die Art der Blutentnahme und das Auftreten von Hämolyse 
Auswirkungen auf die Abundanz verschiedener miRNAs hat. Die vorher wegen ihrer 
prognostischen Aussagekraft selektieren zirkulierenden miRNAs zeigten eine niedrigere 
Expression im arteriellem- im Vergleich zum venösen Blut. Darüber hinaus waren miR-20b-
5p und miR-486-5p durch Hämolyse beeinflusst.  
Bei den Untersuchungen zur Progression von NSCLC Tumoren wurde die Rolle von miRNAs 
und mRNAs bei der Resistenzentwicklung gegenüber dem EGFR-TKI Gefitinib im in-vitro 
Modell erforscht. Mittels Ko-kultur von Lungenfibroblasten (MRC-5) mit den Gefitinib-
sensitiven NSCLC Zelllinien HCC827 und PC-9 konnte eine Resistenz gegenüber Gefitinib 
entwickelt werden. Aus einer globalen miRNA-Analyse von ko-kultivierten Zellen wurden elf 
Kandidaten selektiert, wobei die miR-503-5p in beiden NSCLC-Zelllinien validiert werden 
konnte. Bei der Analyse des globalen Genexpressionsprofils wurden 211 differentiell 
exprimierte mRNAs in den resistenten HCC827 und PC-9 Zellen identifiziert. Durch den 
Vergleich des Genexpressionsprofils mit miRNA-Vorhersage-Datenbanken konnten putative 
Zielgene von miR-503-5p ermittelt werden. Dabei wurde das Autophagie-Gen GABARAPL1 
auf mRNA und Protein-Ebene validiert. Die transiente Überexpression von miR-503-5p führte 
zu einer signifikanten Reduktion von GABARAPL1. Luziferase-Reporter Assays zeigten eine 
direkte Interaktion zwischen miR-503-5p und dem 3’UTR von GABARAPL1. Weiterhin 
wurden verschiedene Marker der Autophagie nach Ko-Kultur von Gefitinib behandelten 
HCC827-Zellen gemessen. Dabei konnte ein Anstieg von SQSTM1 (p62) und eine Senkung 
des LC3B-II und GABARAPL1 Proteingehalts beobachtet werden. Entsprechend führte ein 
siRNA-vermittelte Knockdown von GABARAPL1 zu einer Akkumulation von SQSTM1. 
Zusammenfassend deuten diese Daten darauf hin, dass die Inhibition von GABARAPL1 durch 
miR-503-5p die autophagische Aktivität in Gefitinib resistenten EGFR-mutierten 
Adenokarzinomzellen der Lunge reguliert. 
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Abbreviations 
4IPBA 4‐iodophenylboronic acid 
5-PL  Fifth Party Logistik Model  
ADc Adenocarcinoma 
AKT Protein kinase B 
ATP Adenosine-5'-triphosphate 
AUC Area under the curve  
BCA Bicinchoninic acid 
bp base pair 
BRAF 
Murine sarcoma viral oncogene  
homolog B1 
BSA bovine serum albumin 
CDK Cyclin-dependend kinase  
cDNA  complementary DNA 
cel Caenorhabditis elegans 
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oncogene  
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Cp crossing point 
Ct cycle threshold 
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del deletion 
DFS disease-free surival 
DMEM Dulbecco's modified eagle medium  
DMSO  Dimethylsulfoxid 
DNA deoxyribonucleic acid 
DNase deoxyribonuclease 
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Dulbecco's phosphate buffered  
saline  
E. coli  Escherichia coli 
ECL enhanced chemiluminescence 
ECM extracellular matrix 
EDTA ethylenediaminetetraacetic acid 
EGF  Epidermal growth factor 
EGFP enhanced green fluorescent protein 
EGFR Epidermal growth factor receptor 
ELISA enzyme‐linked immunosorbent assay  
EMEM Eagle's modified eagle medium  
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ERBB Erythroblastic leukemia viral oncogene 
ERK  Extracellular signal-regulated kinase  
EtOH ethanol 
FACS fluorescence activated cell sorting 
FBS  fetal bovine serum 
FC fold change 
FDA  Food and Drug Administration  
FFPE formalin fixed paraffin embedding 
FISH fluorescence in‐situ hybridization 
GABARAP
L1 
Gamma-aminobutyric acid receptor- 
Associated protein like 1 
GRB2 Growth factor receptor-bound protein 2  
GSK3α/β  Glycogen synthase kinase 3 alpha/beta 
HGF hepatocyte growth factor 
HR hazard ratio 
HSA Homo sapiens 
IC50 Half maximal inhibitory concentration 
ID Identity 
IGF Insulin-like growth factor 
IGF-1R  Insulin-like growth factor 1 receptor 
IgG Immunoglobulin G  
INS Insulin 
IPA Ingenuity Pathway Analysis 
IR Insulin receptor 
IRS Insulin receptor substrate 
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Kyoto Encyclopedia of Genes  
and Genomes 
KRAS  
V-Ki-Ras2 kirsten rat sarcoma  
viral oncogene homolog 
LC3B Light chain 3B 
LNA locked nucleic acid 
mAb Monoclonal antibody 
MAPK Mitogen-activated kinase  
MEK Mitogen-activated kinase kinase  
MEM Minimum essential media  
MeOH methanol 
Met 
Mesenchymal epithelial transition  
factor 
MFI mean fluorescent intensity 
miR micro RNA  
mRNA messenger RNA  
MTOR Mammalian target or rampamycin  
NA not available  
ND not detected  
NF-κB 
Nuclear factor of kappa light  
polypeptide gene enhancer in 
B-cells 
NSCLC Non-small-cell lung carcinoma 
NT non targeting  
ORF open reading frame  
OS overall-survival 
p53 Tumor protein p53 
p62/ 
SQSTM1 
ubiquitin-binding protein p62, 
Sequestosome-1 
p70 S6K 
Ribosomal protein S6 kinase,  
70kDa, polypeptide 
PAGE polyacrylamide gel electrophoresis  
PBS  Phosphate buffered saline 
PCR polymerase chain reaction  
PE Phycoerythrin  
PI propidium iodide 
PI3K Phosphatidylinositol 3-kinase  
pre precursor 
pri primary 
PTEN Posphatase and tensin homolog  
PVDF  Polyvinylidenfluorid 
qRT‐PCR  quantitative RT‐PCR  
RAF 
Rapidly growing fibrosarcoma  
protein 
RAS Rat sarcoma protein 
RFS recurrence-free survival 
RIN RNA integrity number 
RIPA Radioimmunoprecipitation assay  
RISC RNA induced silencing complex 
RNA ribonucleic acid  
RNase  ribonuclease 
RPMI 
Rosell park memorial institute 
medium  
RT 
room temperature/reverse  
transcription  
RTK Receptor tyrosine kinase 
SCLC small-cell lung cancer 
SD standard deviation 
SDS  sodium dodecyl sulfate  
sh small-hairpin 
SHC 
Src homology 2 domain-containing  
transforming protein 
siRNA small intefering RNA  
TBST Tris‐buffered saline Tween‐20  
TGF α transforming growth factor α  
TKI Tyrosine-kinase inhibitor 
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TNM Tumor, Nodes, Metastases Classification  
of Malignant Tumours 
Tris Tris(hydroxymethyl)aminomethane  
TSC2 Tuberous sclerosis 2 protein 
Tyr Tyrosine 
U Unit 
UPL universal probe library  
UTR untranslated region 
UV  ultraviolet 
VEGF Vascular endothelial growth factor  
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WT wild-type 
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1 Introduction 
1.1 Lung cancer biology 
Lung cancer is one of the most common cancers and the leading cause of cancer-related death 
worldwide, with 1.6 million deaths per year [1]. The main types of lung cancer are non-small-
cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) (Figure 1). NSCLC accounts 
for most cases of lung cancer with about 85% and SCLC follows with 15%. The three types 
of NSCLC are (I) adenocarcinoma (acinar, papillar, bronchioalveolar, and solid), which 
mainly develops from the peripheral airway compartment from secreting cells of bronchioles 
or alveoli with a glandular shape (Biomarkers: TTF1; KRT7). (II) Squamous cell carcinoma 
develops from the epithelial cells of the bronchi and is diagnosed by the squamous 
differentiation (Biomarkers: KRT6/7; SOX2; p63). (III) Large cell lung cancer can be 
diagnosed if glandular or squamous histology as well as biomarkers can be excluded. The 
small cell lung carcinoma, conversely, develops from the epithelial cells of the main bronchi 
[2-4]. 
 
 
 
Figure 1 Main types of lung cancer. Lung cancer is generally divided into small-cell lung cancer (SCLC) 
(green) and non-small cell lung cancer (NSCLC) (blue). NSCLC is further subdivided into adenocarcinoma, 
squamous cell carcinoma and large cell carcinoma. This graphic is adapted and modified from Bender [5]. 
 
 
Lung cancer patients are diagnosed according to the international TNM staging system [6]. At 
the time of diagnosis, lung cancer is most often found at a locally advanced stage and has 
already spread to distant sites. Survival rates are low (13% at stage IV). The detection of 
NSCLC at early stages and the subsequent surgical resection increases the 5-year survival rate 
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(about 30-70% at stage I-II) [6]. However, 20-40% of patients at an early stage (I-IIIa) 
encounter a recurrence after surgery. Depending on the stage of the disease, different 
approaches such as surgery, radiotherapy, or chemotherapy are applied [7]. The identification 
of NSCLC subsets is critical for further patient care. For example, low-dose computed 
tomographic (CT) screening was shown to reduce lung cancer mortality by 20% [8]. Lung 
cancer patients at high-risk, such as smokers, were the main target group to be screened [9]. 
However, false positive results, radiation-induced cancers and over-diagnosis cannot be 
excluded [10]. Therefore, the identification of NSCLC subsets requires innovative cancer-
related biomarker signatures with high sensitivity and specificity that use state-of-the-art 
technologies [11].  
1.2 Aberrant signaling pathways in NSCLC 
Smoking is the primary risk factor for lung cancer [12]. Lung tumors from never-smokers 
show a markedly different tumor genomic landscape in comparison to those developed in 
smokers. Smokers have a 10-fold higher mutation frequency than never-smokers, in which 
C:G > A:T transversions are more common in smokers. On the other hand, C:G > T:A 
transitions are predominant in never-smokers. Molecular profiling from 230 lung 
adenocarcinomas using a comprehensive multiplatform analysis (mRNA, microRNA 
(miRNA), DNA sequencing, copy number analysis, methylation and proteomic analysis) 
revealed a mean of 8.9 somatic mutations per megabase. TP53 was the most commonly 
mutated gene. Various critical pathways were affected in lung adenocarcinoma, for instance, 
the activation of receptor tyrosine kinase (RTK)/RAS/RAF pathway, or alternatively, the 
activation of the PI(3)K-MTOR pathway (Figure 2). Oncogenes such as KRAS, EGFR, BRAF, 
PIK3CA, MET, and RIT1 were found to be frequently mutated. On the other hand, tumor 
suppressors such as STK11 as well as KEAP1, NF1, RB1, CDKN2A in the cell cycle 
regulation and oxidative stress pathway were found to be mutated. Moreover, chromatin 
modifying genes such as SETD2, ARID1A, and SMARCA4, the RNA slicing genes RBM10 
and U2AF1 and as well as the MGA gene that regulates the MYC pathway were commonly 
mutated [13].  
KRAS mutations have been frequently described to be involved in the pathogenesis of lung 
cancer and are associated with poor prognosis [14]. KRAS mutations and epidermal growth 
factor receptor (EGFR) mutations have been found to be mutually exclusive of one another 
[15]. Mutations in the EGFR and anaplastic lymphoma kinase (ALK) fusions were 
predominantly found in patients that were never-smokers rather than smokers. On the other 
hand, KRAS and TP53 mutations were mainly found in smokers [16]. An inversion of the 
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short arm of chromosome 2, where the genes ALK and EML4 are located, has been shown to 
result in a fusion protein. This protein has been identified in a NSCLC subset to confer 
constitutive tyrosine kinase activity [17]. 
 
 
 
Figure 2 Receptor tyrosine kinase (RTK) signaling in lung adenocarcinomas. Molecular alterations of key 
pathways such as RTK/RAS/RAF pathway and PI(3)K-MTOR pathway including the percent of cases with 
activating and inhibiting mutations. The graphic has been adapted and modified from Cancer Genome Atlas 
Research Network [13]. 
 
 
 
1.3 The EGFR family  
The EGFR belongs to the ERBB family of proteins, which includes four type 1 
transmembrane tyrosine kinase receptors: EGFR (ERBB1), ERBB2 (HER2), ERBB3 (HER3), 
and ERBB4 (HER4). The pairing between the receptors that form homo- or heterodimers 
enables the activation of a variety of different downstream signaling pathways [18]. The 
EGFR protein is composed of an extracellular domain for ligand binding, a transmembrane 
domain, and a cytoplasmic domain. The receptors occur as inactive monomers, i.e. they are 
folded in a closed conformation. EGF can bind to the extracellular region of EGFR and 
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thereby rearranges the conformation and thus induces dimerization [19]. Several ligands can 
bind to EGFR including EGF, transforming growth factor α (TGF α), amphiregulin (AR), 
epithelial mitogen (EPGN), betacellulin (BTC), HB-EGF, and epiregulin (EPR) [20]. Ligand 
binding stabilizes the dimerization of EGFR, which results in the transactivation through the 
phosphorylation of key tyrosine residues in the activation loop of the catalytic tyrosine kinase 
domain [21-23]. Molecules such as growth-factor-receptor bound-2 (GRB2) and Src-
homology-2-containing (Shc) can bind to the phosphorylated tyrosine residues, recruit RAS 
and subsequently activate the downstream RAS/RAF/MAPK signaling pathway cascade. 
Phosphoinositide 3-kinase (PI3K) is indirectly recruited to the phosphorylated tyrosine 
residue and can induce the PI3K-AKT signaling (Figure 2). Moreover, the calcium signaling 
pathway via the phospholipase C pathway leads to the activation of protein kinase C (PKC) 
[24].  
1.3.1 EGFR-targeted therapy for NSCLC 
Clinical benefits in subsets of NSCLC tumors with EGFR activating mutations were observed 
after treatment with reversible tyrosine kinase inhibitors (TKI) such as gefitinib (Iressa; Astra 
Zeneca) or erlotinib (Tarceva; Roche) and irreversible TKI such as afatinib (Giotrif; 
Boehringer-Ingelheim) [25-29]. Gefitinib is a 4-anilinoquinazoline compound that targets the 
intracellular tyrosine kinase domain of EGFR. It competes with ATP for the ATP binding site 
within the tyrosine kinase domain of EGFR, and thereby prevents the receptor 
autophosphorylation [30].  
The overexpression of EGFR has been reported and associated with poor prognosis in 
NSCLC [31]. About 10% of NSCLC cases in North America and Western Europe and about 
30-50% of cases in patients in East Asia have shown EGFR mutations. Female patients with 
adenocarcinomas and bronchioalveolar morphology were identified as a subset that clinically 
benefit from targeted therapy with the EGFR-TKI gefitinib or erlotinib [32, 33]. EGFR 
mutations are found in four exons (18-21) of the tyrosine kinase domain. The most common 
mutations were found in exon 19 (45%) with the E746-A750 in-frame deletion and in exon 21 
(40-45%) with the L858R point mutation. These mutations are commonly clustered around 
the active site of kinase and denoted as activating mutations since they lead to increased 
ligand-independent kinase activity of the receptor [28, 34]. KRAS mutations have been 
suggested as predictive markers for EGFR-TKI insensitivity [35]. Up until now, however, 
there exists no FDA-approved drug to target KRAS mutated NSCLC subsets.  
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1.3.2 EGFR-TKI resistance in NSCLC 
Although 70-75% of patients with activating mutations of EGFR respond well to the EGFR-
TKI treatment, 25-30% have intrinsic resistance to EGFR-TKI, and almost all NSCLC 
patients ultimately develop resistance to these agents of 8 to 16 months on average [25, 36, 
37]. Most patients (~ 60%) acquire a secondary mutation (T790M) leading to the resistance to 
EGFR-TKI [38-40]. Furthermore, a small subset of patients developed acquired resistance by 
transforming from NSCLC into SCLC histology [41, 42]. In about 20% of resistance cases, 
amplification of the MET oncogene has been observed [43, 44]. In addition to this 
amplification and the secondary T790M mutation, hepatocyte growth factor (HGF) conferred 
short-term EGFR-TKI resistance in two EGFR-mutant lung cancer cell lines (PC-9 and 
HCC827) [45, 46]. HGF was first described as a mitogenic protein for hepatocytes [47]. Its 
receptor is MET, a tyrosine kinase that is overexpressed in various types of cancer cells. The 
binding of HGF to MET induces pleiotropic biological effects in many cell types such as 
mitogenic, morphogenic, and antiapoptotic characteristics [48]. It has been found that HGF-
activated MET restored the phosphoinositide 3-kinase (PI3K)/AKT pathway [44]. Tumor-
stroma interaction between tumor cells and fibroblasts is widely accepted to influence tumor 
progression after therapy and known to compensate for blocked pathways targeted by specific 
inhibitors [49]. For example, HGF has been described as a mediator of tumor-stroma 
interactions that mediate invasiveness and metastasis by activating the MET pathway [45, 46].  
 
1.4 Transcriptional regulation by miRNAs 
Mammalian miRNAs are small non-coding RNA molecules (~ 22 nt) (Figure 3). They play 
important roles in physiological processes such as development and the pathogenesis of 
cancer. miRNA genes in the human genome are located in intronic or exonic regions of 
protein- or non-protein-coding transcripts [50-52]. Nearly half of the human miRNAs appear 
in clusters and are expressed polycistronically [53]. According to the miRBase21 database, a 
total of 1881 precursor and 2588 mature human miRNA sequences are known to date [54]. 
The transcription of miRNA genes by RNA polymerase II (Pol II) results in capped, 
polyadenylated primary miRNAs (pri-miRNA) that can be as large as several kilobases (kb), 
comprised of hairpin-stems and a terminal loop [55, 56]. A microprocessor complex, 
composed of the RNase III endonuclease DROSHA and the ds-RNA binding protein DGCR8 
(DiGeorge critical region 8) cleaves the pri-miRNAs in the nucleus [57-59]. The resulting 
precursor miRNA (pre-miRNA), which contains a 2 nucleotide (nt) overhang at the 3’-end, 
Introduction  17 
comprises a stem with a size of about 22 nt and a terminal loop [59]. The transport of the pre-
miRNA is then mediated by exportin-5, a Ran-GTP dependent ds-RNA-binding protein, into 
the cytoplasm [60, 61]. A ternary complex composed of the RNase endonuclease III DICER, 
the ds-RNA binding proteins TRBP (Tar RNA binding protein) and PACT (protein activator 
of PKR) cleaves the terminal loop of the pre-miRNA. This process results in a miRNA duplex 
with a size of about 22 nt and a 2 nt overhang at the 3’-end [62-64]. After DICER cleavage, 
the ternary complex dissociates and the duplex miRNA unwinds into a functional guide 
strand, which is loaded into the RNA-inducing silencing complex (RISC) [65], whereas the 
passenger strand is degraded [66]. RISC is a multi-protein complex composed of the ternary 
complex described above and the Argonaute-2 (AGO2), which mediates its effector functions 
on mRNA targets [67]. Although there are different AGO proteins, only the human AGO2 has 
been described to guide RNA cleavage [68]. The functionally active RISC complex can 
mediate independent mechanisms to silence mRNAs, such as through mRNA target cleavage, 
translational repression, and mRNA deadenylation [69-73]. The target recognition and perfect 
matching of the ‘seed sequence’ at the 5’ region of miRNAs to the 3’-untranslated region 
(UTR) of mRNAs has been described [74, 75]. Apart from perfect matching, miRNAs also 
imperfectly base pair to their mRNA targets. Moreover, a single miRNA can target several 
sites at the 3’-UTR of mRNAs. Vice versa, research has also shown that the 3’-UTR of 
mRNAs contain several target sites for different miRNAs [76].  
1.4.1 miRNA deregulation in cancer 
miRNAs have emerged as important players in many cellular processes including cell 
division, differentiation and apoptosis [77]. They have been suggested as promising cancer 
biomarkers, as they appear to be cell-type and tissue specific [78]. miRNAs have been shown 
to be more accurate in the classification of human cancers in comparison to mRNA [79]. 
Several important factors have been associated with the deregulation of miRNAs, such as 
aberrant methylation of promoter regions [80], the rearrangement of chromosomal regions 
[81], and changes in the expression of transcription factors [82, 83]. Moreover, the aberrant 
expression of different factors at posttranscriptional levels in the miRNA processing pathway 
has also been shown in cancer [84].  
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Figure 3 miRNA biogenesis and function. This graphic has been adapted and modified from Schwarzenbach et 
al. [85]. 
 
 
 
1.4.2 Deregulation of miRNAs in lung cancer pathogenesis 
Several miRNAs have been described as aberrantly expressed in lung cancer tissues. 
Members of the let-7 cluster are frequently reported as tumor suppressors, whereas members 
of the miR-17-92 cluster are reported as oncogenes. The let-7 family of miRNAs suppresses 
the expression of RAS and also inversely correlates with the RAS protein. Moreover, it is 
lower expressed in lung tumors compared to normal samples, and thus has a tumor 
suppressive role [86]. Early-stage NSCLC patients were classified into two clusters, 
depending on the expression of the let-7 cluster, while the cluster with reduced expression of 
the let-7 members significantly correlates with a shorter survival time after tumor resection 
[87]. Moreover, low levels of let-7a-2 have also been shown to correlate with poor prognosis 
in lung cancer [88].  
In contrast, members of miR-17-92 cluster are frequently overexpressed in lung cancer. The 
cluster is located within the C13orf25 gene, which has been found to be amplified in SCLC. 
Interestingly, the overexpression of the miR-17-92 cluster, rather than the overexpression of 
the C13orf25 transcript, resulted in increased cell growth [89]. The oncogene MYC encodes a 
transcription factor that binds E-box sequences about 1.5 kb upstream of the miR-17-92 
cluster and induces its expression [90]. Moreover, the miR-17-92 cluster has been linked with 
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oncogenic potential, as its overexpression augments the perfusion of tumors with blood 
vessels in mouse models. The knockdown of the miR-17-92 cluster has been shown to restore, 
for example, the expression of the anti-angiogenic protein thrombospondin-1 (THBS1) [82].  
The analysis of miRNAs as biomarkers derived from tumor tissue can provide information 
about tumor-specific miRNAs. A study using formalin-fixed and paraffin-embedded tissues 
(FFPE) has provided evidence for a miRNA panel that is associated with the prognosis of 
early-stage NSCLC patients after surgery [91]. However, access to tumor tissues is limited 
because it requires an invasive procedure. 
1.4.3 Circulating miRNAs as biomarkers in cancer 
Blood-based biomarkers offer the ability to monitor the disease after surgery as well as a 
minimally invasive testing procedure. Biomarkers derived from blood or other body fluids 
can indirectly be associated with the disease, e.g. via secreted factors from the growing tumor 
and the tumor’s microenvironment [92]. Circulating miRNAs have been shown as valuable 
prognostic and diagnostic tools as a result of their stability in body fluids such as serum. 
miRNA levels have been robustly measured after the exposure of plasma to extreme 
conditions such storage at room temperature for 24 h, several freeze-thawing cycles, and 
RNase activity [93]. Circulating miRNAs in serum have been found to be associated with 
cancer pathogenesis [93-95] and were reported to be much more robust than serum mRNAs 
[96]. Several studies have addressed the stability of circulating miRNAs in the blood, and 
these studies have shown their association not only with exosomes [97], but also with proteins 
such as AGO2 [98]. Exosomes are small membrane vesicles (50-90 nm) of endocytic origin 
and are released from cells into the extracellular environment upon the fusion of 
multivesicular bodies (MVB) with the plasma membrane [99]. Moreover, miRNA leakage 
from cells during tissue damage or apoptosis is also known [100]. 
One of the first studies on disease-specific circulating miRNAs was conducted by Lawrie and 
colleagues, who observed that high levels of miR-21 in serum is associated with poor 
prognosis of patients with diffuse large B-cell lymphoma [95]. The concordance between 
serum miRNAs and blood cell miRNAs in cancer patients is considerably lower than in 
healthy patients that appear to have similar expression profiles. Moreover, miRNAs detected 
in serum from healthy and cancer patients also show low concordance [94]. Therefore, it has 
been suggested that specific miRNA signatures can be identified in cancer patients. However, 
the origin of these specific miRNA signatures is not clear and is still under investigation.  
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1.4.3.1 Circulating miRNAs as biomarkers in NSCLC 
Besides their cost-effective analysis, circulating miRNAs enable the risk assessment of 
operable or unresectable NSCLC tumors in a minimally invasive sampling procedure and may 
be monitored before and after surgery or therapy. However, there is a lack of robust blood-
based biomarkers for both the diagnosis and prognosis of NSCLC.  
A panel of 34 miRNAs has been able to identify asymptomatic high-risk individuals with 
early-stage lung adenocarcinoma through the categorization of the individuals into two 
groups: one with malignant and the other with benign cancer [101]. miRNA signatures have 
also been associated with aggressive lung cancer cases [102]. In a combinatorial study with 
low-dose CT, these miRNA signatures have been shown to improve the benefit of low-dose 
CT through the reduction of the false-positive rate [103]. A panel consisting of four serum 
miRNAs (miR-486, miR-1, miR-499, miR-30d) has been identified to be associated with poor 
prognosis in early stages of NSCLC [104]. Cui et al. have also reported increased levels of 
miR-125b in inoperable advanced NSCLC, which is associated with poor prognosis [105, 
106]. The high expression of miR-21 in the serum of NSCLC patients has been associated 
with poor prognosis [107]. Furthermore, a 10-miRNA signature has been used for diagnosis, 
including 400 NSCLC and 220 control cases, which resulted in a high sensitivity ROC of 0.96 
in the training or 0.97 in the validation set [108].  
As the analysis of circulating miRNAs as diagnostic and prognostic biomarkers progresses, it 
may improve patient care. The risk assessment of operable NSCLC disease is critical to 
reduce the high mortality rate. Different technologies that measure miRNA levels are 
available, whereby qRT-PCR has been shown to generate robust results in contrast to 
different microarray platforms [109, 110]. The identification of disease-relevant circulating 
miRNAs can be challenging due to their minute amounts in serum and because there is no 
consensus about the normalization of miRNAs. Moreover, pre-analytical parameters must be 
considered in order to select the best possible set of miRNAs. As hemolysis has been shown 
to affect miRNA expression levels [111], it is critical to use a hemolysis-based miRNA 
indicator to determine the degree of potential hemolysis in serum samples [111, 112]. 
1.4.4 miRNAs in EGFR-TKI-resistant lung cancer  
Recurrence of lung adenocarcinoma after surgery is commonly treated with chemotherapy, 
radiotherapy, or if an actionable driver mutation is found, targeted therapy [113]. 
Considerable progress has been made in the discovery of druggable targets in NSCLC 
patients, such as EGFR [25-29]. However, the functional relevance of miRNAs in tumor 
progression, particularly in EGFR-TKI resistant NSCLC tumors, remains poorly understood.  
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Weiss et al. reported that miR-128b downregulates EGFR expression and the loss of 
heterozygosity of this miRNA was commonly found in lung cancer [114]. Gefitinib treatment 
of NSCLC patients with loss of miR-128b showed a better overall rate of survival in 
comparison to patients with no loss of miRNA. In addition, Wang et al. demonstrated an 
upregulation of miR-214 in gefitinib resistant NSCLC cells and a depletion of this miRNA 
resulted in increased sensitivity towards gefitinib, perhaps through the upregulation of PTEN 
[115]. Through a 13-miRNA signature, Bryant et al. were able to predict the response to 
EGFR-therapy [116]. Garofalo et al. reported the regulation of miRNAs through EGF and 
MET receptors. They developed cell lines with stable knockdowns of MET and EGFR using 
shRNA lentiviral particles. The knockdown of EGFR and MET resulted in the downregulation 
of miR-30b/c and miR-221/222 expression. miR-30b/c and miR-221/222 were found to target 
the apoptotic factors BIM and APAF-1, respectively. Gefitinib treatment also resulted in the 
downregulation of these miRNAs. These miRNAs, however, were not deregulated in gefitinib 
resistant lung cancer cell lines. Their study suggested that modulating specific miRNAs in 
EGFR-TKI resistant NSCLC could enable novel treatment options [117]. 
It is widely accepted that the tumor-stroma is critical for the progression of the tumor, for 
example after treatment with inhibitors such as the EGFR-TKI gefitinib [49]. Therefore, the 
crosstalk of tumor cells with stromal fibroblasts, and their underlying miRNA signaling 
network in NSCLCs may modulate gefitinib resistance, which was investigated through an in-
vitro co-culture model [46]. The model enabled the development of “short-term” resistant 
cells towards gefitinib through the induction of paracrine factors from the tumor-stroma 
interaction, as in comparison to time-consuming stably established resistant cells. Moreover, 
the reduction of EGFR activity through gefitinib treatment mimics a more physiologic 
analysis of miRNA regulation in comparison to the use of shRNA-mediated knockdown of 
EGFR, as reported by Garofalo et al. [117]. The screening approach that uses miRNA qPCR-
based arrays has been described as very accurate and efficient and can be achieved by simple 
computational analysis [118].  
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1.5 Aim of the present study 
To investigate the role of miRNAs in the development of lung adenocarcinoma, two 
approaches were used, i.e. by studying their prognostic potential in the serum of early-stage 
tumors and their functional role in therapy resistance in-vitro.  
 
The aim of the first study was to identify circulating miRNAs that are clinically relevant for 
NSCLC prognosis. Circulating miRNAs were isolated from serum samples of patients with 
early stages of NSCLC. The miRNAs from these samples were analyzed using expression 
profiling such as qRT-PCR based arrays. Specific miRNAs with prognostic potential were 
selected to find a suitable miRNA signature that can significantly predict recurrence-free and 
the overall survival of early-stage lung adenocarcinoma patients. This study may help to 
improve the identification of clinically relevant patient subsets. Furthermore, different pre-
analytical factors, such as blood collection and hemolysis that may contribute to sample bias 
between the cohorts were analyzed. 
 
The study’s second aim was to further evaluate the role of miRNAs after therapy resistance of 
NSCLC. Therefore, the study used and evaluated a co-culture system, which enabled the 
identification of transcriptomic changes associated with therapy resistance. The study applied 
global miRNA and mRNA analysis using high-throughput expression profiling techniques to 
identify putative miRNA and mRNA candidates that are involved in resistance towards 
gefitinib. In-silico analysis using miRNA target prediction algorithms were used to search for 
interactions between miRNAs and target genes. The miRNA-mRNA interaction should be 
validated by overexpression, inhibition and luciferase assays. The knockdown of the miRNA 
targets using siRNA-mediated knockdown was used to identify relevant biological pathways 
and the underlying miRNA signaling network in NSCLCs that may modulate gefitinib 
resistance.  
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2 Materials and Methods 
2.1 Materials 
 
Table 1: Equipment 
Item  Supplier 
Agarose gel electrophoresis chamber  Renner 
Bacterial shaker/incubator, Ecotron  Infors HAT 
Camera, AxioCam MRm Carl Zeiss 
Cell counter, CASY Cell Counter & Analyzer System Model TT Innovatis/Roche 
Centrifuges  Heraeus, Eppendorf 
ChemiDoc XRS+,  Bio-Rad 
CO2 incubator, CB 150 Heraeus 
Flow cytometer, FACSCanto II  BD Biosciences 
Freezing container cell culture, Mr Frosty  Nalgene 
Heating block, Thermomixer comfort  Eppendorf 
Micropipette manual, Pipetman  Gilson 
Micropiptette electronic multichannel, Xplorer  Eppendorf 
Microplate reader, Infinite M200  Tecan 
Microscope, Axiovert 40 CFL  Carl Zeiss 
Pipettor, Pipetboy Integra  Biosciences 
Power supply, E835  Consort 
Protein electrophoresis/blotting, Mini Protean  Biorad 
Real time PCR, Light Cycler 480  Roche 
Sterile cell culture hood, HERA Safe 
Thermo Scientific, MJ 
Research 
Trans-Blot® Turbo Transfer System BioRad 
UV imager, QUANTUM  Vilber Lourmat 
Vacuum manifold, QIAvac 24 Plus  Qiagen 
Vortexer, Vortex Genie  Scientific Industries 
  
Table 2: Chemicals 
 Item  Supplier 
4IPBA (4-Iodophenylboronic acid) Sigma 
acetic acid  Riedel de Haen 
agar agar  Roth 
agarose (for gel electrophoresis)  Roth 
ampicillin  Sigma 
bovine serum albumin  PAA Laboratorien 
chloroform  Roth 
DAPI dihydrochloride  Invitrogen 
EDTA  Sigma 
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ethanol  Sigma 
ethidium bromide  Sigma 
glycine  Gerbu 
hydrochloric acide  Sigma 
hydrogen peroxide  Sigma 
isopropyl alcohol  Sigma 
luminol  Sigma 
methanol  Sigma 
non fat dry milk  Roth 
peptone  Roth 
Ponceau S Sigma 
propidium Iodide solution, 1 mg/mL in water  Sigma 
sodium chloride AnalaR NORMAPUR 
sodium deoxycholate  Sigma 
sodium dodecyl sulfate  Roth 
sodium hydroxide  Fluka 
tris base  Sigma 
TRI Reagent Sigma 
tris HCl  Sigma 
triton X‐100 Sigma 
tween 20 Sigma 
yeast extract Gerbu 
 Table 3: Molecular biology reagents 
 Item  Supplier 
Absolute qPCR Mastermix  Thermo Scientific 
AmpliTaq DNA polymerase  Applied Biosystems 
CellTiter blue cell viability assay  Promega 
cOmplete, Mini,EDTA-free Protease Inhibitor Cocktail Tablet Roche 
DNA ladder mix, Generuler  Fermentas 
dNTPs  Genaxxon 
ExiLENT SYBR Green master mix Exiqon 
CSF2 Sigma 
Gel Loading Dye, Orange (6x) New England Biolabs 
HGF human Sigma 
HotStar Taq DNA polymerase  Qiagen 
KAPA Hifi Hot Start PCR Kit Peqlab 
Lipofectamine RNAiMAX  Invitrogen 
Lipofectamine 2000 Invitrogen 
Mini Complete Protease Inhibitor Cocktail  Roche 
Nuclease free water  Ambion 
PhosSTOP Phosphatase Inhibitor Cocktail Tablets Roche 
pmirGLO plasmid vector Promega 
Precision Plus Protein Kaleidoscope Prestained Standards BioRad 
Probes 480 Master Enzyme Mastermix  Roche 
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Restriction enzymes  NEB, Roche 
RNAse A  Applichem 
SOC medium  Invitrogen 
Universal Probe Library (UPL)  Roche 
 
 Table 4: Kits 
 Item  Supplier 
BCA Protein Assay Kit  Thermo Scientific 
HU HGF ELISA Invitrogen 
microRNA Ready-to-Use PCR, Human panel I+II, V2 Exiqon 
MILLIPLEX MAP Phospho Mitogenesis RTK Magnetic Bead 7-
Plex Kit 
EMD Millipore 
MILLIPLEX® MAP AKT/MTOR Phosphoprotein Magnetic Bead 
11-Plex Kit 
EMD Millipore 
Mini-PROTEAN TGX Stain-Free Precast Gels (10%, 4-20%) BioRad 
miRCURY LNA™ Universal cDNA synthesis Kit II  Exiqon 
miRNeasy Kit  Qiagen 
Plasmid Midi Kit  Qiagen 
Plasmid Mini Kit  Qiagen 
QIAquick Gel extraction Kit  Qiagen 
RevertAid H‐Minus First Strand cDNA Synthesis Kit  Fermentas 
RNeasy Mini Kit  Qiagen 
Taqman MicroRNA Reverse Transcription Kit  Applied Biosystems 
TOPO TA Cloning Kit  Invitrogen 
Trans-Blot Turbo RTA Mini LF PVDF Transfer Kit BioRad 
  
Table 5: Cell culture item 
 Item  Supplier 
0.25% Trypsin‐EDTA  Gibco 
CASYton Innovatis/Roche 
DMSO, cell culture grade AppliChem 
DPBS (‐ CaCl2, ‐ MgCl2) Gibco 
EMEM ATCC 
F‐12K with glutamine ATCC 
FBS Gibco 
Opti‐MEM I  Gibco 
RPMI Medium 1640  Gibco 
 
 Table 6: Consumables 
 Item Supplier 
0.5 ml, 1.5 ml, 2 ml microcentrifuge tubes  Eppendorf 
384-well plate, white, for Light Cycler 480 Roche 
6-well, 96-well plates, flat bottom, transparent   BD Falcon 
adhesive optically clear plate seal  Thermo Scientific 
bacterial culture tube, 12mL Greiner  
CASY cups Innovatis/Roche  
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cell culture flasks, T‐25, T‐75, T‐150  TPP  
cell culture plate, flat bottom, transparent, 96‐, 48‐, 12‐ and 6‐well BD Falcon  
cell culture plate, flat bottom, white, black, 96 well Perkin Elmer  
cell scraper Corning 
cell spatula TPP  
conical tubes, 15mL, 50mL  BD Falcon  
cryovials 1.8 ml Nunc 
FACS tube, 5mL Polystyren Round Bottom Tube BD Falcon  
filter tips, 10μL, 20μL, 100μL, 200μL, 1000μL  Neptune  
LightCycler 480 PCR plate, white, 384 well Roche  
LightCycler 480 Sealing Foil Roche  
pasteur pipettes WU 
PCR strips 0.2mL Steinbrenner  
Petri dish, 10cm TPP  
Petri dish, 6cm Greiner  Bio one  
reagent reservoirs Roth 
scalpels PFM medical AG 
serological pipettes 2.5 ml, 5 ml, 10 ml, 25 ml BD Falcon 
Thincert 24 well cell culture insert, 1 µM pore size Greiner Bio one  
 
 
Table 7: Drugs 
 Item Supplier 
Bafilomycin A1 Sigma  
Erlotinib NEB  
Gefitinib Biocat 
  
  
Table 8: Software and Online tools 
 
Item Supplier 
AxioVision 
Carl Zeiss 
MicroImaging  
Bio-Plex Manager 6.1 Bio-Rad 
Excel 2010 Mircrosoft  
DAVID v6.7 NIAID, NIH 
FACSDiva 6.1.2 BD Biosciences  
GraphPad Prism 5.01 
GraphPad Software, 
Inc  
Image Lab Software Version 5.2.1 Bio-Rad 
Ingenuity pathway analysis Ingenuity systems  
LightCycler 480 Software release 1.5.0 Roche  
TargetScan 6.2 Whitehead Institute 
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Table 9: Cell lines (TM Name) 
Item Subtype Supplier 
A549 (CCL-185) Lung cancer ATCC 
CCD-19Lu (CCL-210) Normal lung fibroblast ATCC 
HCC827 (CRL-2868) Lung adenocarcinoma ATCC 
MRC-5 (CCL-171) Normal lung fibroblast ATCC 
PC-9 Lung adenocarcinoma PHE 
H1650 Lung adenocarcinoma ATCC 
H1975 Lung adenocarcinoma ATCC 
H2030 Lung adenocarcinoma ATCC 
   
Table 10: Antibodies 
  
Item Catalog-No Supplier 
anti-c-MET sc-161 Santa Cruz 
anti-EGFR sc-03 Santa Cruz 
anti-ERBB2 #2165 Cell Signaling 
anti-ERBB3 #4754 Cell signaling 
anti-GABARAPL1 ab86497 Abcam 
anti-GAPDH #2118 Cell Signaling 
anti-LC3B #3868 Cell signaling 
anti-mouse-HRP #7076 Cell Signaling 
anti- SQSTM1 (p62) 610832 BD Bioscience 
anti-rabbit HRP #7074 Cell Signaling 
anti-ß-ACTIN #13E5 Cell Signaling 
    
Table 11: siRNAs 
  Item Sequence Supplier 
AllStars Proprietary information Qiagen  
siRNA-GABARAPL1_#6 cagctgctagttagaaaggtt Qiagen  
siRNA-GABARAPL1_#7 cagctgcaagttcttgtataa Qiagen  
siRNA-GABARAPL1_#8 tacagtgatgagagtgtctat Qiagen  
siRNA-GABARAPL1_#9 gcggtgcatcatgaagttcca Qiagen  
   
Table 12: Primer 
  Item Sequence Supplier 
GABARAPL1-NheI fw ggtaagctagcattgtggcctacagtgatgagagtg Sigma 
GABARAPL1-SalI rev agcttgtcgactcgatttatttccttggcctgatgg Sigma 
GABARAPL1-trc_UTR-
NheI 
agcttgtcgactcgatggccatcatgtagcattcct Sigma 
    
miRNA primers 
TaqMan-based real-time quantification of miRNAs was done according to Chen et al. [109] 
in the serum study. SYBR Green real-time quantification of miRNA was done according to 
[119] in the co-culture study. All PCR reactions included a“–RT” control without cDNA to 
detect genomic DNA contamination. If not otherwise stated, all miRNAs in this study are 
human miRNAs, usually denoted with a hsa for human (Homo sapiens).  
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Table 13: miRNA TaqMan Primers 
miRNA-ID Mature miRNA sequence Supplier 
miR-20b-5p caaagugcucauagugcagguag Life Technologies 
miR-21-5p uagcuuaucagacugauguuga Life Technologies 
miR-23a-3p aucacauugccagggauuucc Life Technologies 
miR-29b-3p uagcaccauuugaaaucaguguu Life Technologies 
miR-30d-5p uguaaacauccccgacuggaag Life Technologies 
miR-125b-5p ucccugagacccuaacuuguga Life Technologies 
miR-142-3p uguaguguuuccuacuuuaugga Life Technologies 
miR-331-3p gccccugggccuauccuagaa Life Technologies 
miR-451a aaaccguuaccauuacugaguu Life Technologies 
miR-486-5p uccuguacugagcugccccgag Life Technologies 
 
Table 14: miRNA mimics & inhibitors 
 
miRNA-Name Catalogue number Supplier 
miRIDIAN microRNA Hairpin 
Inhibitor Negative Control #1  
IN-001005-01 Dharmacon, GE 
miRIDIAN microRNA miR-503-
5p hairpin inhibitor 
IH-300841-07-0005 5 Dharmacon, GE 
miRIDIAN microRNA miR-503-
5p mimic 
C-300841-05-0005 5 Dharmacon, GE 
miRIDIAN microRNA Mimic 
Housekeeping Positive Control #2 
(GAPDH)  
CP-001000-02 Dharmacon, GE 
mIRIDIAN microRNA Mimic 
Negative Control #2  
CN-002000-01 Dharmacon, GE 
miRIDIAN microRNA Mimic 
Transfection Control with Dy547  
CP-004500-01 Dharmacon, GE 
  
 
 
 
Table 15: miRNA primers 
  
miRNA-ID Sequence Supplier 
let-7a-2-3p cuguacagccuccuagcuuucc Exiqon 
miR-103-3p agcagcauuguacagggcuauga Exiqon 
miR-1296-5p uuagggcccuggcuccaucucc Exiqon 
miR-181a-2-3p accacugaccguugacuguacc Exiqon 
miR-181a-3p accaucgaccguugauuguacc Exiqon 
miR-181a-5p aacauucaacgcugucggugagu Exiqon 
miR-181b-5p aacauucauugcugucggugggu Exiqon 
miR-191 caacggaaucccaaaagcagcug Exiqon 
miR-205-5p uccuucauuccaccggagucug Exiqon 
miR-222-5p cucaguagccaguguagauccu Exiqon 
miR-29b-1-5p gcugguuucauauggugguuuaga Exiqon 
miR-423-5p ugaggggcagagagcgagacuuu Exiqon 
miR-503-5p uagcagcgggaacaguucugcag Exiqon 
miR-941 cacccggcugugugcacaugugc Exiqon 
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mRNA primer design 
Primer pairs for mRNA real time PCR were designed using the Roche UPL assay design 
center software (http://qpcr.probefinder.com/organism.jsp). Primer pairs were designed with 
the Taqman or MGB-Probe module. Primer pairs spanned exon-intron boundaries whenever 
possible. Primer pairs were assessed for secondary structure. Total amplicon length was 
checked via agarose gel electrophoresis. Assay efficiency was tested by measuring cDNA 
dilution curves. Only specific assays with efficiencies of > 1.70 were used.  
 
 
Table 16: UPL primers  
UPL (#probe) Primers forward Primers reverse Supplier 
ACTB (#64) ccaaccgcgagaagatga ccagaggcgtacagggatag Roche 
c-MET (#31) tgaaattcatccaaccaaatctt aatagaaaactgacaatgttgagagg Roche 
DCKL1 (#34) caaccaggaatgtattggataaga cctggttgcgtcttcgtc Roche 
FLT-1 (#85) ccactcccttgaacacgag gtcgccttacggaagctct Roche 
GABARAPL1 (#3) tgggccaactgtatgagga ctacccccaagtccaggtg Roche 
GMCSFR (#12) agtctccgagagaagaaaagca cggattttcctgctgtaaacc Roche 
HGF (#49) gattggatcaggaccatgtga ccattctcattttatgttgctca Roche 
KDR (#18) ccccaaattccattatgacaa cggctctttcgcttactgtt Roche 
OSBPL7 (#77) gaggcttccgcttcatca catggcaggccgagatag Roche 
ZMAT3 (#2) ccaggaaagaagggaatgagt gcggggattgaagtaaggac Roche 
 
Buffers 
TAE buffer: 
40mM Tris base 
40mM acetic acid 
1mM EDTA0.05%  
 LB medium: 
10g peptone 
5g yeast extract  
10g/L NaCl 
fill to 1L with water 
adjust pH to 7, autoclave 
 
RIPA protein lysis buffer:  
150 mM sodium chloride  
1.0% Triton X‐100  
0.5% sodium deoxycholate  
0.1% SDS  
50 mM Tris base, pH 8.0 
 ECL solution:  
100mM Tris‐HCl pH 8.8  
1.25mM luminol  
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2mM 4IPBA  
store dark at 4 °C  
add 5 µL hydrogen peroxide per 15mL ECL solution 
freshly 
 
 
LB agar:  
1L LB medium  
15g agar 
autoclave, cool to 50 °C  
add ampicillin (100 µg/mL)  
 PBS-T:  
DPBS  
0.05% Tween-20 
 Transfer Buffer: 
200ml 5x Transfer Buffer (BioRad) 
200ml Ethanol (100%) 
fill to 1l with water 
 
SDS running buffer:  
25mM Tris base  
192mM glycine  
0.1% SDS 
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Serum samples and patient characteristics 
Collection and use of serum samples from different patient cohorts was done at the 
Thoraxklinik at Heidelberg University following written patient consent and the approval by 
the local ethics committee (27/2001). 
Serum samples were obtained from 275 lung adenocarcinoma patients (stage I-III, Union for 
International Cancer Control (UICC) 7th edition) on the day of surgery. Patients were only 
included that had a complete tumor resection (local R0 status). This cohort is independent of a 
previous study [120]. Detailed patient cohort description and follow-up data are listed in 
Table 18. Additional thirteen serum samples were obtained from patients by three sequential 
blood-sampling methods as described by Kahn et al. [121]. 
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2.2 Methods 
2.2.1 Molecular biology methods 
RNA and miRNA isolation from serum  
All following steps described in this section were carried out at room temperature (RT). A 
combination of phenol-guanidine-based lysis and silicamembrane- based purification was 
used for the isolation of cell-free RNA from serum samples. A total volume of 100 µL of 
human serum was thawed on ice and mixed with 300 µl Tri Reagent BD (Sigma). To ensure 
complete dissociation of nucleoprotein complexes, the mixtures were incubated for 5 min at 
RT. For serum samples there is no consensus about the normalization and a lack of robust 
endogenous miRNA, therefore synthetic miRNAs from C.elegans were used for 
normalization of sample-to-sample variation in RNA isolation [93]. A pool of miRNA mimics 
from C.elegans (cel-miR-39, cel-miR-54) (Qiagen) with a concentration of 20 nM in a volume 
of 5 µL were added as spike-in control. Additionally, 3 µg of glycogen from a 20 µg/µL 
glycogen stock was added to enhance the recovery of RNA. A total of 80 µl pure chloroform 
was added; the mix was shaken vigorously and allowed to stand for 5 min at RT. After 15 min 
of centrifugation (12,000 x g; 4 °C), the upper aqueous phase was transferred to a fresh tube. 
Purification of extracted total RNA was performed with the RNeasy kit (Qiagen) according to 
the manufacturer’s instructions. Briefly, the aqueous phase was mixed with 1.5 x volume 
100% ethanol to enable small RNA binding to the silica-membrane-based spin-columns. All 
following centrifugation steps were performed at 8,000 x g if not otherwise stated. The mix 
was immediately transferred on an RNA spin-column and centrifuged for 15 sec. Then, 700 
µL RWT buffer was added, mixed, and subsequently centrifuged for 15 sec. Next, 500 µl 
RPE buffer was added and centrifuged for 15 sec. The step was repeated but the 
centrifugation lasted for 1 min and finally the RNA was eluted in a final volume of 35 µl 
nuclease-free water at 8,000 x g. Hemolysis grade of each serum was visually rated. miR-23a-
3p/ miR-451a ratios were used as hemolysis indicator as previously reported [112]. 
 
RNA and miRNA isolation from cells  
All steps described in this section were carried out at RT. 700 µl of Qiazol (Qiagen) was 
added for up to 1 x 107 cells, mixed and incubated for 5 min. A total of 140 µl pure 
chloroform was added; the mix was shaken vigorously and allowed to stand for 5 min at RT. 
After 15 min of centrifugation (12,000 x g; 4 °C), all of the upper aqueous phase was 
transferred to a fresh tube. Purification of extracted total RNA was performed with the 
RNeasy kit (Qiagen) according to the manufacturer’s instructions as described earlier.  
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Quantification of nucleic acids 
Nanodrop spectrophotometry 
Nucleic acid concentration was measured by UV/VIS spectrophotometry using the Nanodrop 
ND-1000. The absorption maximum of nucleic acids is 260 nm and proteins have the 
maximum absorption at 280 nm. The purity of the nucleic acids was determined by 
calculating the ratio of the absorption values at 260 nm/280 nm and 260 nm/230 nm. H2O or 
TE buffer was used as the blank reference measurement for unknown sample measurements. 
 
Bioanalyzer 
The RNA integrity number (RIN) is a metric for the quality of RNA by the Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, US). In this study, RNA integrity was 
assessed using the Agilent RNA 6000 Pico Kit for the screening of miRNAs and mRNA from 
the HCC827 co-culture according to the manufacturer’s instructions (Agilent Technologies). 
The RNA in all samples was observed to have good quality (RIN > 9). 
 
Reverse transcription and quantitative real-time PCR of serum miRNA using TaqMan 
technology 
For the measurement of single miRNA assays in the serum study, the following components 
were mixed for each well of a 96-well plate: A volume of 1.5 µL total RNA including miRNA 
was reverse transcribed with 0.038 µL dNTP’s (100 mM), 0.38 µL 10 x RT Buffer, 0.75 µL 5 
x RT primers, 0.048 µL RNase Inhibitor (20 U/µL), 0.25 µL Multiscribe Reverse 
Transcriptase (50 U/µL), and 0.54 µL nuclease-free water. The reaction mix was incubated on 
ice for 5 min. Finally, RNA was reverse transcribed in three sequential steps. The first 
incubation was performed at 16 °C for 30 min followed by the strand synthesis at 42 °C for 
30 min and the inactivation of the enzyme at 85 °C for 5 min. 
For each reaction mix, a volume of 2.5 µL of cDNA was mixed with 0.25 µL TaqMan 
miRNA assay (20 x) and 2.75 µL ABsolute PCR Mix that comprises a Thermo-Start DNA 
Polymerase and a proprietary reaction buffer, and quantified using a LightCycler 480 
(Roche). The cycle started with an initial temperature of 95 °C for 15 min to denature DNA 
and activate the enzyme and was followed by a total number of 40 cycles including 95 °C 
incubation for 15 sec and a 60 °C step for 1 min. Three technical replicates were measured for 
each sample.  
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Reverse transcription and quantitative real-time PCR of miRNA from cell culture 
samples using low density based arrays  
In order to determine differentially regulated miRNAs in resistant cells, a qRT-PCR miRNA 
expression profiling was performed. Here, more than 700 miRNAs were analyzed following 
the recommended protocol (Exiqon miRCURY LNA Universal RT microRNA PCR, A and 
B- Human microRNA PCR panels V2). Amplification reactions were performed in a 384-well 
plate containing lyophilized primers.  
Reverse transcription for panel I+II was done by mixing 5 x reaction buffer (8 µl), nuclease-
free water (18 µl), 10 x enzyme mix (4 µl), synthetic UniSp6RNA spike ins (2 µl) and total 
RNA (8 µl) (5 ng/µl), equivalent to 40 ng, for each sample. The reaction mix was centrifuged 
and incubated on ice for 5 min, reverse transcribed by incubating for 60 min at 42 °C and heat 
inactivated at RT for 5 min at 95 °C. Afterwards, the cDNA was diluted by combining cDNA 
(20 µl) with nuclease-free water (1,980 µl) and 2 x ExiLENT SYBR Green master mix (2000 
µl) for each panel. For each reaction, 10 µl of the cDNA:PCR Master mix was added to each 
well, centrifuged, and measured on the LightCycler480. Thermal cycling was performed in 
the LightCycler480 (Roche) according to the recommended conditions by the supplier of the 
enzyme mix. 
 
Reverse transcription and quantitative real-time PCR of miRNA using SYBR Green 
For the measurement of single miRNA assays, total RNA isolated from cells were mixed with 
the following components for each well of a 96-well plate: A volume of 2 µL (5 ng/µl) total 
RNA including miRNA (equivalent to 10ng) was reverse transcribed with 5 x reaction buffer 
(2 µl), nuclease-free water (4.5 µl), 10x enzyme mix (1 µl), and synthetic UniSp6RNA spike 
ins (0.5 µl). The reaction mix was reverse transcribed as described in the previous section.  
Each cDNA sample was diluted 1:80 in water and 4 µl of diluted cDNA was mixed with 5 µl 
2 x ExiLENT SYBR Green master mix and 1 µl PCR primer mix and measured on a 
LightCycler480. To exclude variability between plates, an assay (UniSp3) was premixed in 
three wells of each plate to evaluate qPCR performance. The UniSP3 showed low SD 
(SD = 0.14) between all plates suggesting good overall quality for comparing samples 
between each other. 
 
Reverse transcription and quantitative real-time PCR of mRNA using UPL from cell 
culture samples 
To amplify mRNAs by PCR or measure mRNA levels by quantitative RT-PCR, mRNA was 
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reverse transcribed to cDNA. For this, the RevertAid H-Minus First Strand cDNA Synthesis 
Kit (Fermentas) was used. The following components were mixed in a PCR tube on ice: total 
RNA (0.5 μg-3 μg), random hexamer primer (1 μL), water (ad 11.5 μL), 5 x reaction buffer (4 
μL), RiboLock RNase Inhibitor (0.5 μL), 10 mM dNTP mix (2 μL), 200 U/μL RevertAid H 
Minus M-MuLV Reverse Transcriptase (1 μL). The reaction was mixed and incubated for 
5 min at 25 °C followed by 60 min at 42 °C in a thermal cycler. Enzymes were inactivated by 
heating at 70 °C for 5 min. cDNA was either frozen at -80 °C or kept on ice for use on the 
same day. 
The mRNA levels were quantified by quantitative RT-PCR using the LightCycler480 (Roche) 
and Universal Probe Library (UPL) (Roche). For UPL assays, the following components were 
mixed per well of a 384 well qPCR plate: cDNA equivalent of 5-10 ng total RNA (5 µL), 
probes 480 Master Enzyme Mastermix (Roche) (5.5 µL), forward and reverse primer mix 
(each 20 µM) (0.11 µL), UPL probe (0.11 µL), nuclease free water (0.28 µL). Cycling 
conditions were used as recommended by the manufacturers. Three technical replicates were 
measured for each sample. 
 
Microarray 
Total RNA (50 ng/µl) was analyzed using HumanHT-12 v4 Expression BeadChip Kit from 
Illumina comprising 31,000 annotated genes and 48,107 probe IDs derived from the NCBI 
RefSeq Release 38 (Nov 7, 2009). The labeling and hybridization were performed by the 
Expression Profiling Service of the DKFZ Microarray Core Facility.  
 
Bacterial cultures  
For amplification of vector DNA, the bacterial E.coli strain TOPO Top10 was used and 
cultured in LB-medium. Bacterial cells were grown under selection pressure using ampicillin 
(100 μg/mL). 
 
3’-UTR-cloning PCR 
To isolate the 3’UTR of GABARAPL1, primers (listed in Table 12) were designed for the 
specific region of interest and a PCR was performed as described in the following: For each 
reaction the following reagents were added to a PCR tube on ice as described from the 
manufacturer’s recommendation (Protocol: KAPA Hifi protocol): DNA (max. 40 ng), 5 x 
Buffer (5 µl), 10 mM dNTPs (0.75 µl), 10 μM GABARAPL1-NheI fw and GABARAPL1-
SalI rev (for full length 3’UTR of GABARAPL1) or GABARAPL1-trc_UTR-NheI (for 
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truncated version without binding site for miR-503-5p) (0.75 μL each), water (ad 25 μL) and 
0.5 µl KAPA Hifi DNA Polymerase (0.02 U/µl). The following temperature cycling was 
performed in a thermal cycler: initial denaturation (5 min at 95 °C), denaturation (20 sec at 
98 °C), annealing (15 sec at Tm +/- 10 °C), and extension (1 min/kb expected PCR product 
size at 72 °C). Steps from denaturation to extension were repeated 40 times followed by a 
final extension step for 10 min at 72 °C and cooling to 4 °C.  
 
Restriction digest and manipulation of DNA  
Restriction digests were conducted with enzymes from New England Biolabs (NEB) 
following the manufacturer’s instructions. 
 
Agarose gel electrophoresis and isolation of PCR fragments 
After amplification of DNA fragments by PCR, the PCR products were run with 6 x Gel 
Loading Dye, Orange (NEB) and separated by agarose gel electrophoresis. Agarose was 
mixed with 1 x TAE buffer to 1.0% concentration and boiled until the agarose dissolved. Gels 
were poured with the liquid agarose after cooling down to about 50 °C. For visualization of 
DNA bands, 10 µl of 0.5 mg/L ethidium bromide solution was added to 100 ml agarose 
solution, solidified and run in 1 x TAE buffer at 10 V/cm length of the gel until the loading 
dye had migrated for the desired distance. Bands were visualized using a UV transilluminator 
and the desired bands were cut from the gel and purified with the Qiaquick PCR purification 
kit (Qiagen) according to manufacturer’s protocol. 
 
T4 DNA ligation 
The double digested PCR fragment and the double digested pmirGLO (7350 bp) were ligated 
according to the protocol from NEB. DNA was extracted from 1% agarose gel. 10 x T4 DNA 
Ligase Buffer (2 µl), PCR insert fragment and the plasmid vector were used in a molecular 
ratio of 3:1 and 5:1. T4 DNA Ligase (1 µl) was incubated with the reaction at 16 °C, 
overnight. 5 µl of the ligation were used for the transformation of TOP10 chemically 
competent bacteria (see below). After incubation of the plated bacteria, a colony PCR was 
performed using the KAPA Hifi protocol. Six clones per plate were analyzed. 
 
Transformation of bacteria 
To transform chemically competent TOP10 E. coli cells (Invitrogen) with plasmids, the heat 
shock method was used. For this purpose, a bacterial suspension of 50 µl competent cells was 
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thawed on ice and mixed with 5-15 µl of DNA and incubated for 20 min on ice. Then, the 
cells were heat shocked for 30 sec at 42 °C in a water bath and immediately incubated once 
for 2 min. For the growth of the bacteria, 800 µl of SOC medium (Invitrogen) was added and 
incubated for at least 45 min at 37 °C by gentle mixing. Thereafter, cells were transferred to a 
selective agar plate and incubated at 37 °C bottom-up in an incubator overnight. 
 
Colony PCR 
Colony PCR was used to screen for successfully recombined vectors with the target of 
interest. For this purpose, only single bacterial colonies were used. A sterile pipet was used to 
pick up one single colony from the agar plates. Each pipet was transferred to PCR tubes 
containing 25 µl of the prepared PCR mixture. The remaining bacterial colony at the sterile 
pipet was transferred into 2 ml LB medium for later bacterial growth and plasmid DNA 
extraction after the correct recombinant plasmid had been identified by PCR. The KAPA Hifi 
protocol was performed as previously described to identify the insertion of 3’UTR of 
GABARAPL1 in the pmirGLO vector. PCR products were analyzed by agarose gel 
electrophoresis. 
 
DNA extraction from bacterial lysates 
To obtain vector constructs from transformed bacteria, the bacteria were prepared using the 
QIAprep Miniprep protocol (Qiagen), which is based on alkaline lysis. In brief, bacteria on a 
selective media were transferred into 2 ml of LB medium containing a selection pressure and 
incubated for at least 8 h or overnight. Afterwards, the bacteria were transferred into a 1.5ml 
microcentrifuge tube and centrifuged at 800 x g for 3 min. The cells were harvested, 
resuspended and lysed under NaOH/SDS conditions and in the presence of RNase A. The 
lysate was neutralized with a buffer containing guanidine hydrochloride and acetic acid 
thereby adjusting the lysate to high-salt binding conditions. The suspension was centrifuged in 
the following always at 17,900 x g. First, the suspension was centrifuged for 10 min at RT. 
The supernatant was transferred on a QIAprep spin column, whereby DNA is adsorped onto a 
silica membrane, washed with 70% EtOH and centrifuged twice for 1 min. The DNA 
adsorped on the silica membrane was eluted by low-salt liquids such as Tris-Chloride (10 mM 
Tris-Cl, pH 8.5) or water. A fresh 1.5 ml microcentrifuge tube was used and low-salt liquids 
were added to the center of the QIAprep column and incubated for 1 min. To obtain the DNA, 
the microcentrifuge tube was spun for 1 min. 
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DNA gel extraction 
Analytical agarose gels (1%) were used to identify and purify DNA fragments such as PCR 
products for cloning. The QIAquick Gel Extraction Kit (Qiagen) was used for purification of 
excised gel following the manufacturer’s instructions. 
 
Sanger Sequencing 
For verification of the inserted PCR fragment (for example GABARAPL1) inside the 
pmirGLO vector, Sanger sequencing was used. The sequencing reactions were performed 
using DNA and primers, which were submitted at GATC Biotech (Konstanz).  
 
2.2.2 Cell culture 
The human lung cancer cell lines HCC827, PC-9, H1650, H1975, and H2030 were 
maintained in RPMI 1640, MRC-5 and CCD-19LU (CCL-210) in EMEM medium, and A549 
in F-12K medium supplemented with 10% fetal calf serum (FCS).  
Cells were passaged every 2 to 3 days during their exponential phase in a ratio of 1:3 or 1:5, 
whereas the confluence of cells was lower than 80%. In order to split cells, the medium was 
completely aspirated and cells were washed in 10 mL DPBS. To remove cells from the 
bottom of the plate, cells were incubated with 2.5 mL 0.25% Trypsin-EDTA at 37 °C. After 
3-5 min, 10 mL complete medium was added in order to inhibit the function of trypsin. 
Subsequently, cells were transferred into a new culture flask and maintained in an incubator at 
37 C, 5% CO2 and 95% humidity.  
 
Testing for Mycoplasma contamination and cell line authentication 
Cells were regularly tested for mycoplasma following the manufacturer’s instructions 
(Multiplexion). Cell lines were authenticated before use, once every year and after completion 
of the project. DNA was extracted following the manufacturer’s instructions (Multiplexion). 
 
Cell counting 
The CASY Cell Counter & Analyzer System Model TT (Innovatis) is a cell counting system 
based on the electric recording of cells as they pass a measuring capillary. Cells with intact 
cell membrane act as electric insulators. The electric current cannot go through the membrane 
of intact cells (electric current exclusion). A signal is generated depending on the volume of 
the cells. Dead cells cannot act as electric insulators as their membrane is porous and are 
recorded by the volume of their nucleus. Cells were counted after trypsinization from the cell 
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culture dish. After resuspension of detached cells, 50 μl of the cell suspension was diluted in 
10 mL of isotonic salt solution (CASY-Ton). Only cells with viability > 85% and an 
aggregation rate lower than 1.5 were used in the experiments. 
 
Cryopreservation of cell lines 
Freshly obtained cells were propagated and frozen to establish cell banks for each cell line. At 
least 20 aliquots of each cell line at an early passage were frozen in the vapour phase of liquid 
nitrogen. A minimum of 1 x 106 cells in 1.5 mL “freezing medium” were frozen. The freezing 
medium contains the appropriate complete cell culture medium supplemented with 5% (v/v) 
DMSO. For freezing cells, the cells were first counted and a desired cell number was 
centrifuged at 300 x g for 5 min. The pellet was resuspended in freezing medium, and the 
appropriate cell number was transferred in freezing medium to 1.8 mL CryoTubes (Nunc). 
CryoTubes were transferred into an isopropyl alcohol isolated freezing container (Nalgene) 
and frozen at -80 °C. On the next day, the cells were transferred to the vapor phase of liquid 
nitrogen. 
 
Co-culture  
In each well of a 24 well plate, 2 x 104 HCC827 or PC-9 cells were seeded overnight. In 
parallel 6 x 104 MRC-5 or CCD-19LU cells were seeded in each transwell insert of a 24-well 
plate. On the next day, the medium was aspirated and the cells were treated with gefitinib 
(0.5 µM) in EMEM medium supplemented with 10% FCS for at least 1 h in the incubator. 
After 1 h incubation, the medium was aspirated and fresh medium was added to the NSCLC 
cells. For each well of a 24-well plate, a transwell insert containing the lung fibroblasts was 
placed inside and incubated for 48 h. As a result, “short-term” resistant HCC827 and PC-9 
towards gefitinib were generated. In the following text, the term “resistance” instead of 
“short-term resistance” for HCC827 and PC-9 was used. 
 
Cell viability assay 
Cell viability assays were performed using CellTiter-Blue cell viability assay (Promega). The 
CellTiter-Blue solution contains Resazurin, which gives the blue color in the solution. If cells 
are metabolically active, they can convert Resazurin into Resofurin, which is observed by a 
color change from blue to pink. For fluorescence measurements, black 96-well plates were 
used. Since cell culture medium evaporates over time at the outer wells of the plate, they were 
filled with 100 µl DPBS. This reduces the loss of cell culture medium from the inner wells. 
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3000 HCC827 and PC-9 cells were seeded in 150 μL of the appropriate medium. Wells 
containing only medium served as blank controls. The first cell viability measurement was 
carried out immediately after the treatment. One fifth medium volume of CellTiter-Blue 
reagent was added to the cells. The solution was then incubated for three hours after addition 
of CellTiter-Blue. The fluorescence intensity (excitation 579 nm, emission 584 nm) was 
measured in each well using the Infinite M200 plate reader (Tecan). 
All reagents such as the volume of medium, treatment solution and CellTiter-Blue reagent and 
the number of cells were upscaled when culture dishes other than 96-well plates were used. At 
least three technical replicate measurements were performed for each measurement. 
 
Impedance measurement  
For quantifying cell impedance of HCC827 cells after gefitinib treatment, the real-time 
electrical impedance based cell based assay system xCELLigence RTCA DP with E-plates 16 
(Roche) [122] was used. 100 µl media containing 10% FCS was added into each well of an E-
plate and incubated at RT for 30 min to ensure equilibration of media and E-plate. Thereafter, 
the E-plate was placed into the RTCA-DP in an incubator for background measurement. After 
background measurement, 3000 HCC827 cells were placed into each well of an E-plate and 
the measurements were started. Impedance was measured every 15 min for 72 h. After 24 h 
the E-plate was taken out and the medium was aspirated without touching the bottom of the 
well. Medium containing HGF (20 ng/µl) or only media containing 10% FCS was added to 
each well. The changes in impedance were measured as raw cell index, which was normalized 
to the 24 h value.  
 
Transient transfection of cell lines with miRNAs or siRNAs 
Transfection of synthetic miRNA mimics or siRNA into cells provides a technique to 
elucidate the functional role of miRNAs in cells. Overexpression of siRNAs or miRNAs can 
reduce the levels of specific mRNAs in cell lines. All siRNAs and miRNAs mimics were 
purchased from Dharmacon. Lyophilized siRNAs and miRNAs were spun down, dissolved in 
nuclease-free water and vortexed. After an incubation of 30 min at RT, the siRNAs and 
miRNAs were resuspended. All siRNAs and miRNAs were initially diluted to 10 μM or 20 
µM, respectively, and stored at -20 °C. 
In this study, the HCC827 lung cancer cell line was transfected using RNAiMAX 
Transfection Reagent (Invitrogen). Cells were initially seeded at a density of 1.5 x 105 cells in 
a volume of 2 ml per well of a 6-well plate and incubated for two days to achieve a cell 
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confluence of 60-80%. When culture dishes other than 6-well plates were used, numbers of 
cells, volumes of medium, RNAiMax were scaled accordingly. The medium was replaced 
after 24 h. First, separate tubes containing Opti-MEM serum free medium (Gibco) were used 
for the siRNAs or miRNAs and RNAiMAX reagent. All diluted reagents were incubated for 
5 min at RT. To enable the formation of transfection complexes, the solution of both tubes 
were mixed and incubated for 20 min at RT. The siRNA/miRNA:RNAiMAX transfection 
solution was then added to the cell culture medium in a dropwise manner. After the 
transfection for 24 h, the old medium was aspirated and fresh medium was added. For each 
reaction, a concentration of 0.16% (v/v) of RNAiMAX in the medium was used. siRNAs were 
used at a final concentration of 10 nM. miRNAs were used at a final concentration of 5 nM to 
40 nM. 
 
Transient co-transfection of cell lines with plasmid DNA and miRNA 
To verify direct interaction of miRNA with the 3’UTR sequence of the miRNA target, a 
luciferase assay was performed.  
1.5 x 104 HCC827 cells were seeded in each well of a white 96 well plate (Perkin-Elmer) and 
incubated overnight in a volume of 75 µl. On the next day, empty pmirGLO 
(pmirGLO_empty vector) (12.5 ng) was co-transfected with mimic miR-503-5p or negative 
mimic ctrl#2 (40 nM). In parallel, the 3’UTR GABARAPL1 cloned into pmirGLO 
(pmirGLO_GABARAPL1 vector) (12.5 ng) and a truncated 3’UTR GABARAPL1 (without the 
binding site for miR-503-5p) were co-transfected with mimic miR-503-5p or negative mimic 
ctrl#2 (40 nM) using Lipofectamine 2000 (0.5 µl) following the manufacturer’s instructions 
(Invitrogen). 
 
Cell cycle analysis 
Propidium iodide (PI), a fluorescent agent intercalates with DNA, and can be used to stain 
cells to analyze the cell cycle. This was done by measuring the DNA content of single cells by 
staining with the DNA intercalating fluorophore and subsequent FACS analysis. 
1 x 105 HCC827 or PC-9 cells were seeded in each well of a 6-well plate and cultured 
overnight. In parallel, 6 x 104 fibroblast cells (MRC-5 or CCD-19LU) cells were cultured in 
transwell inserts. On the next day, the tumor cells were treated with gefitinib (0.5 µM) and 
incubated for 48 h. Cells were detached from the dish by trypsinization. After centrifugation 
at 300 x g for 5 min, the pellet was resuspended in 1 mL of ice-cold PBS. For fixation of cells, 
ethanol was used. Cells were fixed by adding 2.5 mL ice-cold 100% ethanol dropwise to the 
cell suspension while vortexing. Fixed cells were stored at -20 °C until analysis. On the day of 
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measurement, the cells were centrifuged at 300 x g rpm for 5 min, the supernatant was 
decanted. Cells were stained and permeabilized when the pellet was resuspended in 0.5 mL PI 
staining solution (PBS containing 50 μg/ml PI, 0.1 mg/ml RNase A, 0.05% (v/v) Triton X-
100) and incubated for 40 min at 37 °C. RNase A was used to prevent background staining by 
degrading cellular RNA. The staining solution was diluted by adding 4 mL of PBS was added. 
The cells were centrifuged at 300 x g for 5 min and resuspended in 0.4 mL of PBS and 
transferred to a FACS tube. All samples were stored on ice until analysis. A FACSCanto II 
flow cytometer (BD) in the PE channel was used for PI stained cells. Data were analyzed 
using the software FACS DIVA.  
 
Luciferase assay 
All reagents were thawed to RT using a water-bath. Cells were equilibrated to room 
temperature in the cell culture hood. Medium was aspirated from cells so that a 50 µl volume 
remained. Cells were lysed by addition of 50 µl of luciferase substrate buffer and incubated at 
room temperature for at least 10 min. Firefly luciferase activities were measured by 
luminescence using Tecan M200. Following the firefly measurement 50 µl of Stop & Glo 
solution was added and incubated for 10 min. Luminescence was measured after 10 min. 
Firefly luciferase activities were normalized against the subsequently measured Renilla 
luciferase activity (Promega Dual Luciferase Reporter Assay System). Here, six replicates 
were performed for each transfection condition. For statistical analysis, the firefly luciferase 
activity of pmirGlo_GABARAPL1/pmirGLO_empty vector co-transfected with negative 
mimic ctrl#2 was defined at 100% and compared to the co-transfection with mimic miR-503-
5p. 
 
2.2.3 Immunochemical methods 
Protein isolation 
RIPA lysis buffer was used to harvest proteins from cells. The final RIPA buffer (10 ml) was 
prepared by mixing 1 tablet cOmplete, Mini, EDTA-free (Roche), 1 tablet PhosSTOP (Roche) 
and 100 µl 0.5 M EDTA (5 mM), which were always added freshly before use. During the 
protein isolation the cells were always placed on ice after washing the cells once with ice-cold 
PBS. For a confluent well of a 6-well plate 100 μL RIPA lysis buffer was added. The lysate 
was collected with a cell spatula and transferred to a 1.5 mL tube. The lysates were incubated 
on ice at 4 °C for 30 min by slowly shaking on a Thermomixer. Then, the tubes were 
centrifuged at 12,000 x g at 4 °C for 30 min. The protein lysate was then isolated by 
Methods  43 
transferring the supernatant to an ice-cold microcentrifuge tube. All protein samples were 
stored at -80 °C. 
 
BCA assay 
To determine the concentration of protein lysates, the BCA Protein Assay Kit (Thermo 
Scientific) was used. Samples were diluted 1:10 in appropriate lysis buffer. 10 μL of sample 
and standards were added to a 96-well plate in duplicate. After addition of 200 μL BCA 
working reagent, the plate was incubated for 30 min at 37 °C. In the presence of proteins, the 
BCA reagent form complexes with proteins resulting in a color change, from light blue to 
violet. The Infinite M200 plate reader (Tecan) was used to measure absorbance at 562 nM 
using. Using a dilution curve with dose-dependent concentrations of BSA, the protein 
concentrations were calculated. 
 
SDS polyacrylamide gel electrophoresis and Western Blot 
Proteins in the cell lysates were quantified by Western blotting. To detect specific proteins in 
the cell lysate, SDS-PAGE was used to separate proteins based on their molecular weight. 
This is achieved due to their differential rates of migration through a gel under an electric 
current. SDS-PAGE was carried out using a 4-20% gradient gel (BioRad), SDS running 
buffers and protein ladders (BioRad). The samples were mixed with appropriate volumes of 
lysis buffer and the proteins were reduced and their tertiary structure was denatured by 4 x 
Roti-Load (Roth). The samples were vortexed, shortly centrifuged and incubated at 95 C for 
5 min on a Thermomixer. Finally, the samples were loaded onto the gels (20 μl, 30 μg per 
lane) and the gels were run using the Mini Protean gel chamber system (BioRad) for about 45 
min at 120 V, 60 mA. Due to their negative charge, the proteins move from the negative 
cathode to the positive anode. 
Transfer of separated proteins from the gel onto a PVDF membrane was carried out using the 
Trans-Blot Turbo Transfer System (BioRad). The PVDF membrane was activated in 
methanol for 5 min then equilibrated with transfer stacks in 1 x transfer buffer (BioRad). 
Low-molecular weight proteins (< 30kDa) were transferred for 5 min, mixed-molecular 
weight proteins (5-150) for 7 min, and high-molecular weight proteins for 10 min at 1.3 A for 
up to 25 V. After the transfer, the membrane was blocked with either 5% non-fat dry milk or 
5% BSA in 1 x PBS-T buffer depending on the primary antibody used. Transfer of proteins 
was checked by PonceauS solution by incubating the membrane for 5 min at RT. The 
membrane was cleared by rinsing the membrane for 5 min in water and destained by washing 
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with PBS-T (0.05%) for 5 min. Then, the blocking solution was exchanged for the primary 
antibody solution which was prepared in the respective blocking buffer recommended for the 
antibody. The membrane was incubated with the primary antibody solution over night at 4 °C 
while shaking slightly. On the next day, the membrane was washed 3 times for 5 min with 
PBS-T before incubation with the secondary, horseradish peroxidase (HRP)-conjugated 
antibody in PBS-T for 1 h at RT. After another 3 washes for 5 min in PBS-T, bands were 
recorded using a non-commercial ECL solution [123] and the ChemiDoc XRS+ system 
(BioRad). 
 
Luminex-based protein quantification  
The Luminex xMAP technology allows to analyze total and phosphoproteins based on 
fluorescently labeled beads. Proteins were quantified using the BCA protein assay kit after 
lysing the cellular samples in Milliplex lysis buffer. After the lysis, the samples were 
incubated with the fluorescently labeled beads coated with specific primary antibodies. For 
detection of the primary antibodies certain secondary antibodies, Streptavidin PE conjugates 
and Biotin detection antibodies were used. Signal detection was done by exciting the 
fluorescent dye of the primary (635 nm) and Streptavidin PE coupled to the secondary (532 
nm) antibodies. The signals were detected by a Bio-Plex 200 System. Quantification of 
signals was reported in mean fluorescent intensities (MFI). This was achieved by detecting 
the signal of each individual microsphere by digital-signal processors and quantifying the 
fluorescent reporter signals [124]. The protocol was performed according to the 
manufacturer’s instructions. The Luminex analysis was carried out in two independent 
experiments. In this study, the MILLIPLEX MAP Phospho Mitogenesis RTK Magnetic Bead 
7-Plex Kit (20 µg protein per well) or the MILLIPLEX MAP 11-Plex AKT/MTOR Panel-
Phosphoprotein kit (20 μg protein per well) were used. Luminex analysis was done using a 
Bio-Plex 200 system (BioRad) and data were exported from the Bio-Plex Manager software 
6.1. 
 
Luminex-based cytokine quantification 
For cytokine measurement, the supernatant of cells was taken and directly placed on ice. A 
total of 41 analytes was tested. A standard curve and quality control samples were included 
for the screening. 25 µl supernatant of each sample was used for analysis according to 
manufacturer’s instructions (Millipore). After equilibrating the 96-well plate with 200 µl 
washing buffer, 25 µl standard or control, and 25 µl matrix solution was added. For the 
Methods  45 
samples of interest, 25 µl of samples and 25 µl assay buffer were added to each well. Next, 25 
µl beads were added and incubated overnight at 4°C under constant agitation (350 rpm). On 
the next day, and after a 1x washing step, 25 µl PE-conjugated streptavidin was added, which 
can bind to biotinylated detection antibodies and bound to the protein of interest. Incubation 
was for 1h at room temperature. Here, the human cytokine/chemokine magnetic bead panel 
(HCYTMAG-60K-PX41) was used. Standard curves were performed using the 5-PL method. 
Luminex analysis was done using a Bio-Plex 200 system (BioRad) and data were exported 
from the Bio-Plex Manager software 6.1. 
 
ELISA 
Extracellular levels of human hepatocyte growth factor (Hu HGF) were quantitatively 
determined in cell culture supernatant of HCC827/MRC-5 co-culture cells or single cultures. 
Here, the ELISA kit measuring Hu HGF (Invitrogen) was applied. For this, 2 x 104 HCC827 
cells were seeded in a well of a 24-well plate and 6 x 104 MRC-5 cells into a transwell insert 
of a 24-well plate and treated with gefitinib and co-cultured as described earlier. The cells 
were treated with gefitinib (0.5 µM) and co-cultured for 48 h. The supernatant of the cells was 
thereafter taken from each well, centrifuged at 300 x g and the remaining supernatant was 
transferred into a fresh 1.5 ml microcentrifuge and directly stored at -80 °C. The extracellular 
concentration of Hu HGF in the supernatant of the co-culture was measured at an absorbance 
wavelength at 450 nm (Tecan) according to the manufacturer’s instructions using a diluted 
standard curve of Hu HGF with predefined concentrations. 
 
 
2.2.4 Computational analysis 
Statistical data analysis 
Statistical analysis for the serum study was performed using R. The raw data were read in and 
normalized against the mean of two spike-ins (cel-miR-39 and cel-miR-54). The following 
formula was used in the serum study for calculating delta-delta (ΔΔ) Cp values: 
 
Recurrence-free and overall survival were used as clinical endpoint. Second tumors were 
censored. Univariable and multivariable Cox models were used to assess hazard-ratio and p-
value for each miRNA or altogether. In the univariable case, only one miRNA entered the 
model at a time. In the multivariable case, all miRNAs were used as predictors. Maximization 
of the concordance index was used to test different miRNA combinations in a prognostic 
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model. Analysis was done using 5-time repeated 10-fold cross-validation to prevent over-
fitting. The additional value of a miRNA marker panel to standard clinical parameters was 
tested in a likelihood-ratio test. The hazard ratio (HR) indicates the risk to relapse. For 
example, an HR with a fold change of 2 is calculated by the change of a miRNA by 1 Cp 
value. 
Statistical analysis for the co-culture study was performed using GraphPad Prism 5.01 or 
Qlucore Omics software 3.0 (Two-group comparison). P-values if not derived from a two-
tailed test (inequality) are described in each figure legend. P-values are depicted as asterisks 
where * p < 0.05, ** p < 0.01 and *** p < 0.001. 
The Cp values from the quantitative real-time PCR in the miRNA screening of the co-culture 
study were calculated and normalized by overall median. Relative expression fold changes 
were calculated using the 2(-ΔΔCp) method [125, 126]. To determine appropriate miRNA 
normalizing genes, the stability of expression was calculated by the overall average 
expression of all genes in all samples and compared with the individual gene using the 
NormFinder software [127]. Here, miRNAs from one plate (n = 384) were used to assess 
potential housekeeping genes. 
 
Assessment of hemolysis 
In order to evaluate the impact of hemolysis in this patient cohort, a miRNA-based hemolysis 
indicator measuring miR-23a-3p/miR-451a ratios was used [111, 112]. The ratio between 
miR-451a, which is known to be affected by hemolysis and miR-23a-3p, which is known to be 
unaffected by hemolysis, was calculated. Samples with a ΔCp value (miR-23a-3p-miR-451a) 
lower than seven were categorized as not hemolytic and samples that had a higher ΔCp value 
of seven as affected by hemolysis. 
 
Pathway analysis using DAVID  
To find canonical pathways enriched in genes differentially regulated between co-cultured 
treated and only treated cells, a pathway analysis was performed using the online software 
tool Database for Annotation, Visualization and Integrated Discovery (DAVID) [128]. Genes 
were determined for upregulation and downregulated in co-cultured treated in comparison to 
single treated NSCLC tumor cells through microarray expression profiling by Qlucore Omics 
software 3.0 analysis using p-value < 0.05 and linear fold change (FC) ≥ 1.5. The data was 
uploaded on to the DAVID server and a functional analysis was performed with default 
settings. 
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Ingenuity pathway analysis 
To find miRNA/mRNA interactions within co-cultured treated and only treated cells, a 
microRNA Target Filter analysis was performed using the online software tool Ingenuity 
Pathway Analysis (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity). The data 
from the microarray experiment was uploaded to the IPA server and correlated using the 
Ingenuity microRNA target filter with putative targets of miR-503-5p with default settings.  
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3 Results 
3.1 Serum miRNAs of early-stage lung adenocarcinoma patients 
Circulating miRNAs have been found to be promising biomarkers for prognosis and diagnosis 
in a plethora of cancer diseases [85]. In an initial work, serum miRNAs were screened in 
early-stage (I-IIIa) lung adenocarcinoma patients with early recurrence after surgery within 
24 months (n = 20) against patients that did not develop a recurrence within 24 months 
(n = 20). Serum miRNAs including miR-142-3p and miR-29b-3p were validated in a cohort of 
114 patients. Combinatorial analysis of miR-142-3p expression levels with tumor stage 
information improved stratification of patients with high and low-risk to develop a recurrence 
(AUC: 0.78) [120].  
3.1.1 miRNA selection  
In this study, the prognostic potential of eight selected miRNAs was evaluated (Table 17). 
The eight miRNAs were included here as they were reported as prognostic marker candidates 
in previous studies. Five of them were found to be promising candidates in the study by 
Kaduthanam et al. [120]. The miRNAs miR-21-5p, miR-142-3p, miR-331-3p and miR-486-5p 
were also included in miRNA signatures as prognostic or diagnostic markers [101, 102]. To 
search for the best miRNA panel that can significantly predict progression-free and overall 
survival in early-stage lung adenocarcinoma patients the prognostic potential of the selected 
miRNAs was evaluated.  
 
 
Table 17: Promising prognostic or diagnostic circulating miRNAs in lung cancer 
miRNA-ID References 
miR-20b-5p [120, 129] 
miR-21-5p [102, 107, 130, 131] 
miR-29b-3p [120] 
miR-30d-5p [104] 
miR-125b-5p [105, 106]  
miR-142-3p [101, 102, 120] 
miR-331-3p [101, 120] 
miR-486-5p [101, 102, 104, 120, 132] 
 
 
3.1.2 Pre-analytical consideration of blood-sampling collection  
In a previous study, increased levels of circulating miR-142-3p were identified and validated 
in early relapsed lung adenocarcinoma patients in comparison to patients with no relapse 
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within 24 months [120]. To further validate these results in a new cohort of NSCLC patients, 
a total of 275 serum samples were collected. Of these, 65 samples (in the following defined as 
cohort 1) were collected after induction of anesthesia via an arterial catheter. Samples from 
cohort 1 were collected in the same manner as in the previous study [120]. The remaining 210 
samples were collected before anesthesia via venipuncture, which is the routine sampling 
procedure in the clinics (internal discussion) and in the following defined as cohort 2. 
Samples from cohort 1 (n = 65) and the previous study (n = 154) were studied in a 
retrospective manner. Patient samples from cohort 2 (n = 210) were studied in a prospective 
manner by updating patient data each year. The follow-up time of the patients from cohort 1 
was longer (about 10 months) in comparison to samples from cohort 2 (Table 18). Patients 
with stage Ib tumors in cohort 1 were not observed. Moreover, a significantly higher fraction 
of patients was observed to have stage IIa tumors in cohort 1 in comparison to cohort 2. All 
tumors in cohort 1 were initially classified according to UICC TNM 6th edition. In contrast to 
tumors from cohort 2, which were already classified according to TNM 7th edition. The main 
changes from the revision of TNM 6th ed. to TNM 7th ed. included the staging classification 
(T staging) [6]. Upon revision to TNM 7th ed. most tumors with T 2b N0 M0 were re-
classified from stage Ib (TNM 6th ed.) to stage IIa (TNM 7th ed.). 
After extracting RNA from the serum samples, the spike-in miRNAs (cel-miR-39 and cel-
miR-54) were measured among all serum samples (Figure 4). Since none of the measurements 
showed a drop-out, all samples were included in this study. cel-miR-39 showed slightly lower 
variance (0.36) among the samples than cel-miR-54 (0.47). The two miRNAs were highly 
correlating to each other (Pearson: 0.9) indicating that both external spike-in miRNA controls 
were suitable for normalization.  
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Table 18: Patient characteristics of lung adenocarcinoma patients  
Patient characteristics Cohort 1 n=65 Cohort 2 n=210 
Test statistic  
(p-value) 
 
Primary tumors UICC TNM 7th   
 
  
IA 9 (14%) 42 (20%) 0.2438  
Ib 0 (0%) 43 (20%) NA  
IIa 33 (51%) 25 (12%) < 0.0001  
IIb 6 (9%) 35 (17%) 0.1425  
IIIa 17 (26%) 65 (31%) 0.4614  
Adjuvant therapy  
 
  
Chemotherapy 14 (22%) 74 (35%) 0.0390  
Radiotherapy 9 (14%) 30 (14%) 0.9306  
Median time DFS, m (n=81; n=27) 10.8 14.3 0.1709  
Median time RFS, m (n=66; n=22) 7.3 13.4 0.1231  
Metastatic site  
 
  
Local recurrence 4 (6%) 9 (4%) 0.5375  
Distant metastasis 18 (28%) 57 (27%) 0.9318  
Second tumor 5 (8%) 15 (7%) 0.8833  
Unknown 0 1 NA  
Disease-free (no second tumor) 38 (58%) 128 (61%) 0.6898  
Deaths 18 (28%) 50 (24%) 0.5276  
Time to death, m (n=50; n=18) 18 19 0.9059  
Follow-Up, m  46.9 36.3 < 0.0001  
Epidemiology  
 
  
Age, y 63 65 0.8632  
Sex  
 
  
M 37 (57%) 122 (58%) 0.8683  
F 28 (43%) 88 (42%) 0.9689  
Smoking, pack year  30 35 0.6350  
Numbers are presented as median; abbreviations: m, months; y, years; DFS (Disease-free survival, including second tumor); RFS 
(recurrence-free survival, without second tumor); Test statistic (p-value): Mann-Whitney 
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Figure 4 cel-miR-39 and cel-miR-54 expression among cohort 1 (n = 65) and cohort 2 (n = 210). 
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3.1.2.1 Increased miRNA levels detected in serum samples from venipuncture in 
comparison to serum samples from arterial catheter 
First, the miRNA levels between the two cohorts were compared. Each of the selected 
miRNA was compared between the cohort 1 and the cohort 2 to identify if the different blood 
drawings have an impact on the miRNA expression level. All eight miRNAs measured from 
cohort 1 samples drawn from arterial catheter were significantly downregulated (p < 0.001) 
with a median fold change (FC) of 0.6 in comparison to cohort 2 (Figure 5).  
 
 
 
Figure 5 miRNA expression between cohort 1 vs cohort 2. n = 275 serum samples were collected from early-
stage lung adenocarcinoma patients. A fraction of patients n = 210 (cohort 2) was collected via venipuncture 
without anesthesia and n = 65 (cohort 1) were collected via an arterial catheter after induction of anesthesia. The 
miRNA values were normalized using the mean of cel-miR39/54. Box and Whiskers: 2.5-97.5% percentile. p-
values were tested using Mann-Whitney test. 
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In order to test whether the differences between cohort 1 and cohort 2 can be traced back to 
the blood drawings, three different blood samples from each patient (n = 13) were collected. 
The three blood samples were sequentially drawn  
a) via venipuncture one to two days before surgery,  
b) via venipuncture on the same day but prior to surgery with a sedative and  
c) via arterial catheter including induction with anesthetics prior to surgery.  
For each sample, ten miRNAs were tested. Here, miRNAs in serum drawn via venipuncture 
(a) (FC = 1.3) or venipuncture with sedative (b) (FC = 1.4) showed a tendency to be increased 
in comparison to blood drawn from arterial catheter (c) (Figure 6). In particular, miR-20b-5p 
(p = 0.011) and miR-29b-3p (p = 0.025) showed significant differences between the sampling 
methods a/b in comparison to c (Table 19). The sampling methods (a) and (b) were 
comparable (FC = 0.98). Only miR-125b-5p did not show the same tendency, which might be 
due to its low expression. Whether the reduction of miRNAs in serum drawn via arterial 
catheter is derived from the anesthetics or from the blood drawing from the artery could not 
be determined. In conclusion, pre-analytical consideration must take place at the stage when 
blood is drawn from the patients as this has an impact on serum miRNA expression levels.  
 
 
 
Figure 6 miRNA expression from sequentially drawn blood samples. Three serum samples were drawn from 
each of the 13 patients via (a) venipuncture (n = 13), 2) via (b) venipuncture with sedative (n = 13), and via (c) 
an arterial catheter (n = 13). The miRNA values were normalized using cel-miR39. p-values were determined 
using Wilcoxon matched pairs test. 
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Table 19 miRNA expression from different blood drawings in comparison to miRNAs derived from serum 
via venipuncture  
 miRNA-ID Venous (FC) Venous sedative (FC) Arterial (FC)  
miR-20b-5p 1.00 0.88 0.69* 
miR-21-5p 1.00 0.99 0.95 
miR-29b-3p 1.00 1.15 0.51* 
miR-30d-5p 1.00 1.27 0.90 
miR-125b-5p 1.00 1.79 1.26 
miR-142-3p 1.00 0.97 0.66 
miR-331-3p 1.00 1.04 0.72 
miR-486-5p 1.00 1.01 0.79 
miR-23a-3p 1.00 0.94 0.83 
miR-451a 1.00 1.04 0.81 
*pVal < 0.05; FC: fold change 
 
 
3.1.3 miR-142-3p levels associated with early relapse in cohort 1 
After having shown that miRNA expression levels differ in serum samples when derived from 
venous or arterial blood, miRNA expression levels derived via venipuncture or via arterial 
catheter were separately analyzed. For example, the miR-142-3p expression level was 
analyzed using a binary endpoint such as relapse within 24 months (n = 11) in comparison to 
no relapse within 24 months (n = 19) within cohort 1 (serum samples via arterial catheter 
(data not shown) The remaining 35 samples either did not meet the inclusion criteria, or were 
excluded due to a miRNA-hemolysis indicator above seven Cp. miR-142-3p was found to be 
elevated (FC = 1.74) in the early relapse group, which is in line with the previously published 
study [120]. However, the difference was not significant (p = 0.62), which may be due to the 
fact that the numbers of patient samples were low.  
 
 
 
3.2 Identification of circulating miRNAs as prognostic markers in NSCLC patients 
3.2.1 Clinical characteristics of cohort 2  
This study focused on serum samples collected via venipuncture from 210 early-stage lung 
adenocarcinoma patients (cohort 2) (Table 18). Within this cohort, there was a slightly higher 
fraction of patients (31%) with stage IIIa tumors. Patients with stage Ia (20%) and Ib (20%) 
tumors were more common than those with stages IIa (12%) and IIb (17%). Patients received 
adjuvant chemotherapy (35%) more often than adjuvant radiotherapy (14%). Within a follow-
up time of 36.3 ± 10 months, most of the disease events (n = 81) were located at distant sites 
(27%) and nine out of 88 occurred locally. Fifteen out of 81 patients developed a second 
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tumor. To analyze recurrence-free survival (RFS) the second tumor relapse events were 
censored. Fifty patients died within 19 ± 9 months.  
3.2.2 Distribution and correlation of miRNA expression data sets  
The normalized expression values (ΔCp values) of each selected miRNA were assessed by 
analyzing the distribution of each miRNA expression dataset. miR-21-5p, miR-142-3p, and 
miR-486-5p were found to have high miRNA levels (0 to -5 ΔCp) (Figure 7). The miRNA 
levels of miR-30d-5p, miR-125b-5p, miR-331-3p, and miR-20b-5p were in a medium range (-5 
to -10 ΔCp) and miR-29b-3p (-5 to -15 ΔCp) was observed to have a biphasic curve with 
miRNA levels at medium ranges (-5 to -10 ΔCp) and relatively low levels (-10 to -15 ΔCp). 
Monophasic curves were seen for seven out of eight miRNAs. miR-29b-3p was observed to 
have the highest number of patient samples with absent calls.  
Interestingly, patients with stage IIIa had significantly lower miR-29b-3p expression levels in 
comparison to stage I (p = 0.002) or II (p = 0.053), respectively (Figure 8).  
All miRNAs were positively correlated with one another, albeit different strengths (Figure 9). 
miR-142-3p and miR-331-3p showed a high correlation (0.96) to each other. Moreover, miR-
20b-5p and miR-486-5p showed high correlation to each other (0.92) as well as miR-30d-5p to 
miR-20b-5p (0.87), miR-486-5p (0.89) and to miR-21-5p (0.91).  
These data suggested that the miRNA expression data sets of miR-486-5p, miR-20b-5p, and 
miR-30d-5p were related with each other, however, most miRNA expression data sets were 
distinct from each other. miR-29b-3p showed the lowest correlation with all other miRNAs, 
which might be explained due to its biphasic nature. 
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Figure 7 Kernel density plot of miRNAs. Kernel density estimate from different miRNA expression levels 
(ΔCp).  
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Figure 8 miR-29b-3p expression in serum samples of lung adenocarcinoma at different stages. The miR-
29b-3p expression levels were determined in cohort 2 at stage III (n = 65), stage II (n = 60), and stage I (n = 85). 
The miRNA values were normalized using the mean of cel-miR39/54. Box and Whiskers: 2.5-97.5% percentile. 
p-values were tested using Mann-Whitney test. 
 
 
 
Figure 9 miRNA correlation plot. The miRNAs selected for analysis in serum samples of cohort 1 (n = 210) 
were analyzed in a pairwise correlation matrix plot. 
 
 
3.2.3 miR-20b-5p and miR-486-5p identified to be affected by hemolysis  
Hemolysis during blood collection has an impact on the content of miRNAs in serum or 
plasma [111]. In order to evaluate the impact of hemolysis in this patient cohort, a miRNA-
based hemolysis indicator measuring miR-23a/miR-451a ratio was used. If the ΔCp is higher 
than seven the risk of hemolysis is high (n = 129). On the other hand, if the ΔCp is lower than 
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seven the indication is no hemolysis (n = 81) (Figure 10). These results were corroborated by 
visually rating red colored serum samples (indicating hemolysis, data not shown). All samples 
that showed ΔCp higher than seven value derived from the miR-23a-3p/miR-451a ratio were 
visually rated as red. Each of the eight analyzed miRNAs was tested to be affected by 
hemolysis. Therefore, samples that were indicated as hemolytic (n = 47) (excluding samples 
that have a ΔCp above eight, Figure 10) were compared to those samples that were not 
indicated as hemolytic samples (n = 129) (Table 20). Hereby, a high correlation of miR-486-
5p and miR-20b-5p with the hemolytic samples was identified, which had fold changes above 
1.5 and therefore regarded as potentially hemolytic. Although miR-30d-5p also showed a 
significant p-value it had a low fold change (FC = 1.32). Hence, this miRNA was regarded as 
potentially not hemolytic due to its low fold change. Since miR-20b-5p and miR-486-5p were 
affected by hemolysis, the following analyses in this study were performed without these two 
miRNAs.  
To exclude recurrence-free survival (RFS) or overall survival (OS) to be biased by hemolysis, 
survival-rates were analyzed using Kaplan-Meier plots (Figure 11): No significant difference 
could be observed for RFS (p = 0.72) or OS (p = 0.93). In conclusion, hemolysis in this cohort 
did not play a role in these two outcomes. 
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Figure 10 Hemolysis in serum samples. Hemolysis in serum samples was indicated if the expression level was 
above seven (red). Samples with a ΔCp value below seven (blue) were considered as potentially not hemolytic. 
The miRNA values were normalized using the mean of cel-miR-39/54. 
In Table 20 the fold changes and p-values of the eight selected miRNAs were analyzed within cohort 2 
(excluding samples that have a ΔCp > eight). p-values were calculated by Mann-Whitney test. 
 
Table 20: Differential miRNA expression between 
hemolytic (n = 47) vs non-hemolytic samples (n = 
129) 
miRNA-ID FC p-value 
miR-20b-5p 1.92 <1.00E-04 
miR-21-5p 1.13 2.85E-01 
miR-23a-3p 0.86 3.76E-01 
miR-29b-3p 1.30 3.66E-01 
miR-30d-5p 1.32 1.40E-02 
miR-125b-5p 1.19 9.69E-02 
miR-142-3p 0.86 1.01E-01 
miR-331-3p 0.93 3.25E-01 
miR-451a 2.33 <1.00E-04 
miR-486-5p 1.91 <1.00E-04 
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Figure 11 Influence of hemolysis on RFS and OS. Patient samples indicated as potentially hemolytic (n = 81; 
red line) were compared to those, which were not (n = 129; blue line). Clinical endpoints such as recurrence-free 
survival (RFS) (left side) and overall-survival OS (right side) were plotted. p-values were tested using log-rank 
test. 
 
 
3.2.4 Analysis of prognostic potential of circulating miRNAs  
As each of the eight selected miRNAs were shown to have prognostic potential, a combined 
analysis using a miRNA panel was evaluated in serum of patients with early-stage lung 
adenocarcinoma. Table 21 shows the results of univariable Cox models (only one miRNA in 
the model: Single) as well as the hazard-ratios and p-values from one multivariable model (all 
miRNAs entered the model: Combined). The hazard ratio (HR) indicates the risk to relapse. 
Using univariable analysis, no miRNA was associated with overall survival. Using the 
multivariable approach, only miR-29b-3p showed a p = 0.05 and therefore could be associated 
with overall survival. 
 
 
Table 21: Univariable and multivariable Cox-models for the assessment of miRNAs with overall survival 
  Single Combined 
miRNA-ID HR  
95% 
lower 
95% 
upper P HR 
95% 
lower 
95% 
upper P 
miR-21-5p  1.04 0.79 1.39 0.77 1.68 0.82 3.43 0.16 
miR-29b-3p  0.89 0.79 1.01 0.06 0.88 0.78 1.00 0.05 
miR-30d-5p  1.03 0.79 1.33 0.84 0.95 0.44 2.08 0.90 
miR-125b-5p  1.05 0.79 1.39 0.75 1.11 0.74 1.65 0.61 
miR-142-3p  0.85 0.65 1.11 0.22 1.16 0.49 2.73 0.74 
miR-331-3p  0.82 0.62 1.08 0.16 0.56 0.22 1.41 0.22 
miR-486-5p 1.06 0.86 1.31 0.59 1.17 0.60 2.27 0.64 
miR-20b-5p  1.01 0.82 1.25 0.93 0.78 0.45 1.36 0.38 
HR: hazard ratio; Single: Univariable analysis; Combined: Multivariable analysis; 95% upper/lower: 
95% upper/lower confidence interval; P: p-value 
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Multivariable analysis with all miRNAs as in Table 21 shows the potential of miRNAs that 
could predict overall survival. The best miRNA candidates in a panel calculated by the 
concordance index (C-index) were miR-331-3p, miR125b-5p, and miR-29b-3p (Table 22). 
However, the selected panel could not significantly discriminate patients with high and low 
risk overall survival. 
 
Table 22: Assessing miRNAs with overall survival and improvement in combination with staging 
 Panel  Likelihood-ratio test 
  HR 95% lower 95% upper P P (Stage I/II vs IIIa) 
miR-29b-3p 0.89 0.79 1.01 0.07 
0.06 miR-125b-5p  1.28 0.92 1.77 0.14 
miR-331-3p  0.77 0.56 1.05 0.10 
HR: hazard ratio; Panel: miRNA panel calculated by C-index; 95% upper/lower: 95% upper/lower 
confidence interval; P: p-value 
 
 
Staging is one of the strongest prognostic factors for survival. Therefore, the additional value 
of the marker panel to staging was determined. A likelihood-ratio test was used to test if the 
miRNA panel could contribute to an additional value. Stage I and II were grouped together 
and compared against stage IIIa. The additional value of the miRNA panel against staging 
"Stage I/II vs IIIa" revealed a p = 0.06 (Table 22). This suggested that the miRNA-panel 
(miR-331-3p, miR125b-5p, miR-29b-3p) together with staging information indicated a trend to 
predict survival, but could not significantly differentiate patients from high-risk and low-risk 
groups.  
Finally, a miRNA panel was assessed as a suitable marker panel for recurrence-free survival 
(RFS). However, again no stable panel of miRNAs could be identified to predict RFS within 
the patient cohort 2, which indicated weak associations of the measured miRNAs with RFS 
(data not shown).  
 
In summary, the potential of circulating miRNAs to stratify patients into high and low-risk 
patients according to the recurrence of the tumor or the overall survival was analyzed. To 
identify relevant miRNAs associated with prognosis in early stages of patients with lung 
adenocarcinoma, circulating miRNAs were screened within a cohort of n = 40 patients. miR-
142-3p was validated in an independent cohort (n = 114) to be associated with prognosis 
[120]. Based on this study, further serum samples were collected (n = 275). The samples were 
divided in two cohorts due to different blood collection techniques. Eight circulating miRNAs 
were selected and studied in both cohorts. Circulating miRNAs isolated from venipuncture 
were higher abundant than those isolated from arterial blood. Sequential blood samples taken 
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from venous and arterial blood (n = 13) supported this finding. Therefore, the eight selected 
miRNAs were analyzed only from one cohort (n = 210). In this study, two commonly 
reported miRNA biomarker candidates (miR-20b-5p, miR-486-5p) were observed to be 
affected by hemolysis. Univariable and multivariable Cox models were generated based on 
the miRNA expression values and tested with overall and relapse-free survival. A panel of 
miRNAs (miR-29b-3p, miR-125b-5p, and miR-331-3p) was analyzed, which, however, could 
neither be associated with overall survival nor the relapse-free survival. A benefit of the 
miRNA panel beyond staging could not be determined. 
 
 
 
3.3 EGFR-TKI resistance in NSCLC cells using a co-culture model  
3.3.1 Gefitinib treatment results in reduced cell viability of HCC827 and PC-9 NSCLC 
cells in a dose-dependent manner  
Since miRNAs are involved in the progression of NSCLC tumors and in therapy resistance to 
EGFR-TKI [117], the transcriptional regulation by small non-coding RNAs and mRNAs in 
EGFR-TKI resistant NSCLC was analyzed.  
To investigate miRNAs contributing to an aggressive phenotype, a co-culture model using 
gefitinib sensitive lung adenocarcinoma cells with lung fibroblasts was used to generate 
resistance. NSCLC cell lines harboring the activating inframe deletion (del E746-A750) of 
EGFR have been reported to respond to inhibitors such as gefitinib or erlotinib [133]. To test 
this finding, HCC827 and PC-9 cells harboring this deletion and the lung cancer cell line 
A549 that did not harbor this deletion were tested for their response to gefitinib and erlotinib. 
The cell viability was reduced in a dose-dependent manner in gefitinib-hypersensitive 
HCC827 (IC50: 0.0008 µM) and sensitive PC-9 (IC50: 0.1250 µM) after 72 h. Treatment 
with erlotinib resulted in a slightly reduced IC50 values in comparison to gefitinib for 
HCC827 (IC50: 0.0989 µM) and PC-9 cells (0.4626 µM) after 72 h. After treatment, there 
were still 40% viable cells even at high concentrations (10 µM). This may be due to the pre-
existence of MET amplification, i.e. before gefitinib treatment [134]. As expected, treatment 
of A549 cells with gefitinib did not result in a reduction of cell viability even at a 
concentration of 10 µM (Figure 12). 
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Figure 12 Cell viability of HCC827 and PC-9 cells after dose-dependent titration of EGFR-TKIs. HCC827 
and PC-9 cells were treated with A) gefitinib or B) erlotinib and incubated for 72 h until measurement. A549 
cells were included as a resistant cell line against gefitinib. Values were calculated as mean. The standard 
deviation was calculated from six replicates for each concentration. 
 
 
3.3.2 Co-culture with lung fibroblasts induces resistance of NSCLC cell lines towards 
gefitinib 
To drive cells into resistance towards EGFR-TKI, a co-culture model was used according to 
Wang et al. [46]. A cell viability assay was employed in order to determine the optimal 
medium for the tumor cell line HCC827 and the fibroblast cell lines MRC-5 and CCD-19LU 
(CCL-210), respectively. EMEM medium showed slightly increased cell viability in 
comparison to culturing cells with RPMI 1640. Therefore, if cells were cultured together, 
EMEM was used (Figure 13).  
 
 
Figure 13 Cell viability of HCC827 tumor cells and fibroblast cells in different culture media. HCC827, 
MRC-5, and CCL-210 were cultured for 96 h in RPMI1640 or EMEM culture medium.  
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HCC827 cells were cultivated in bottom chambers of a transwell insert (1 µm) and treated 
with increasing concentrations of gefitinib (0.05 µM – 0.5 µM). The inhibitor was washed 
after 1 h of treatment and then combined with the lung fibroblasts CCD-19LU (CCL-210) 
(Figure 14 A) or MRC-5 (Figure 14 B) and co-cultured for 72 h. Reduced cell viability of the 
lung tumor cell line HCC827 after gefitinib treatment was observed (0.05 µM to 0.5 µM) 
ranging from approximately 57% residual viability (0.5 µM) to 49% (0.05 µM) (Figure 14 B). 
After co-culturing with MRC-5 or CCD-19LU, the treated HCC827 cells became less 
sensitive towards gefitinib within 72 h. The most effective restoration of cell viability was 
achieved at 0.5 µM gefitinib treatment and co-culture with 6 x 104 fibroblasts. Therefore, in 
the following experiments, a TKI concentration of 0.5 µM was used. A similar finding was 
observed for PC-9 cells after co-culturing with MRC-5 cells within 72 h (Figure 15 B). 
Furthermore, co-culture conditions with lower than 10% FCS resulted in lower resistance of 
HCC827 cells after gefitinib treatment (data not shown). Therefore, co-culture conditions with 
10% FCS were chosen. 
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Figure 14 Determination of the co-culture condition. Cell viability of HCC827 cells after co-culture with 
fibroblast cells A) CCL-210 or B) MRC-5 cells was tested. Each co-culture after gefitinib treatment (red bars) 
was tested for the increase of cell viability after comparing to co-culture alone (gray bars) and gefitinib treatment 
alone (blue bars). Measurements were taken after 72 h. Samples were normalized to a DMSO control (black 
bars). Standard deviations were calculated from three replicates. 
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Figure 15 Co-culturing HCC827 or PC-9 NSCLC cells with MRC-5 fibroblasts results in reduced 
sensitivity towards gefitinib. A) HCC827 or B) PC-9 cells were cultured with or without gefitinib (0.5 µM) in 
the presence or absence of MRC-5 cells for 72 h. Standard deviations were calculated from two independent 
experiments. 
 
 
3.3.3 Cell cycle analysis of co-cultured NSCLC cells  
To characterize the cell cycle of co-cultured cells, the cells were stained with propidium 
iodide. The population of dying cells was 1.8 x and 2.7 x increased in treated HCC827 and 
PC-9 cells, respectively, in comparison to co-cultured cells, as indicated by the sub-G1 phase 
fraction. Co-cultured gefitinib treated HCC827 (1.8 x fold change) (Figure 16 A) and PC-9 
(2.7 x fold change) (Figure 16 B) cells showed a trend for increased DNA synthesis (S)-phase 
after 48 h compared to only gefitinib treated cells.  
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Figure 16 Cell cycle analysis of co-cultured HCC827 or PC-9 cells with fibroblast cells MRC-5. Propidium 
iodide staining was employed to determine cell cycle changes of A) HCC827 or B) PC-9 cells after co-culture. 
Standard deviations were calculated from at least two replicates. 
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3.3.4 EGFR and MET activity in resistant HCC827 cells  
To demonstrate the reduction of EGFR activity after gefitinib treatment, the phosphorylation 
status of the EGFR family after drug exposure with gefitinib in HCC827 cells was analyzed. 
Since the NSCLC cell line HCC827 harbors an activating mutation (del E746-A750), it 
triggers downstream pathways of EGFR. At first, the total protein expression of different 
receptors (EGFR, MET, ERBB2, ERBB3) in untreated HCC827, MRC-5, and CCD-19LU 
(CCL-210) cells was determined (Figure 17 A). The lung tumor cells had a strong EGFR and 
MET expression, whereas both receptor proteins were expressed markedly lower in the lung 
fibroblast cells MRC-5 and CCD-19LU. The other receptor proteins ERBB2 and ERBB3 
were not or poorly expressed in the tumor and fibroblast cells.  
In order to determine the activation of EGFR in the co-culture model, a multiplex bead-based 
phosphorylation assay (Luminex) using a pan-specific antibody against the phospho-tyrosine 
residues of EGFR, MET, ERBB2, ERBB3, ERBB4, IGF and IR after gefitinib treatment and 
co-culture was applied (IGF and IR could not be measured in neither the co-culture nor the 
HGF culture).  
As expected, the phosphorylation levels of EGFR showed high MFI (Mean fluorescent 
intensity) signals in DMSO treated cells (Control) (15,353 MFI). Almost no difference was 
observed and the MFI levels remained at high levels after co-culture alone (14,463 MFI). 
However, the signal was reduced 29-fold after 24 h in gefitinib treated (0.5 µM) HCC827 
cells (529 MFI) (Figure 17 C). Yet, after co-culture with MRC-5 cells, the phosphorylation of 
EGFR was slightly increased by1.9-fold (982 MFI).  
MET was found to show high MFI signals in DMSO treated cells (Control) (13,855 MFI) and 
remained at high MFI levels after co-culture (8,805 MFI). MET phosphorylation was 
observed to be downregulated after gefitinib treatment (107 MFI), but increased 14-fold after 
subsequent co-culture (982 MFI). Phosphorylation signals of ERBB2 and ERBB3 were 
markedly reduced after gefitinib treatment. However, the signal was not rescued anymore 
after co-culture. ERBB4 phosphorylation was not detected. The results were corroborated 
using hepatocyte growth factor (HGF) induction (Figure 17 D), which is a prominent inducer 
of EGFR-TKI resistance [45]. EGFR phosphorylation signal was reduced after gefitinib 
treatment (1,497 MFI) and did not show any differences after resistance induction (1,499 
MFI) as in the co-culture. As expected the phosphorylation signal of MET was increased  
(1.3-fold) after HGF induction, however, it was not as effective as after co-culture (14-fold). 
Maybe different signals secreted by the fibroblast cells have a greater effect on the 
phosphorylation signal of MET than HGF induction alone.  
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As a negative control for the phosphorylation status (MFI signal), lysates from unstimulated 
HeLa cells were used and lysates from Hek293 cells stimulated with fetal calf serum (FCS) 
were used as positive control and measured (Figure 17 B). Stimulation with FCS in Hek293 
cells clearly induced signals in all analyzed proteins ranging from 10,000 to 25,000 MFI. 
Unstimulated HeLa cells showed signals ranging from 70 MFI to 408 MFI. To compare the 
phosphorylation signals of each protein between samples, equal amounts of protein input were 
used.  
In conclusion, these data shoed that gefitinib treatment reduced the phosphorylation of EGFR 
and MET. Co-culture with MRC-5 cells after gefitinib treatment rescued the phosphorylation 
of MET, which is known to induce resistance after gefitinib treatment [46]. 
 
 
 
Figure 17 Total and active EGFR family and MET status. A) Total protein status of single cultivated 
HCC827 tumor cells, fibroblasts cell lines CCD-19LU (CCL-210) and MRC-5 is shown. Protein lysates were 
isolated after 24 h co-culture, quantified by BCA and equal amounts (20 µg) were analyzed. Molecular weight: 
EGFR:170 kDa; MET precursor: 170 kDa; ERBB2: 185 kDa; ERRB3: 185 kDa, ß-ACTIN: 42 kDa. B-D) 
Luminex analysis of EGFR family and MET. B) Phosphorylation of proteins from stimulated Hek293 (positive 
control) and unstimulated HeLa lysates (negative control). Phosphorylation signals of proteins from C) co-
cultured or D) HGF induced HCC827. MFI: Mean fluorescent intensity. Multiplex-Luminex analysis was used 
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to assess phosphorylation signals of MET, EGFR, ERBB2, ERBB3, and ERBB4 by a pan-tyrosine antibody. 
Standard deviations were calculated from two experiments with three technical replicates.  
 
 
3.3.5 MTOR/AKT signaling pathway in resistant HCC827 cells 
HGF activates the PI3K/AKT signaling pathway and MTOR is a downstream target of both 
EGFR and MET. Therefore, the MTOR/AKT signaling pathway was analyzed in the co-
culture [134]. The phosphorylation signals of AKT, GSK3A, GSK3B, IGF1R, IR, IRS1, 
MTOR, p70S6K, PTEN, RPS6, and TSC2 were measured using the multiplex bead-based 
immunoassay system (Luminex). 
Consistent with the previously shown data (Figure 17 B), in which the phosphorylation signal 
of MET was increased in resistant cells after gefitinib treatment, the phospho-signals of most 
proteins were downregulated after reduction of EGFR activity using gefitinib (Figure 18 B). 
Co-culture or HGF (Figure 18 C) induction alone did not dramatically change MFI signals in 
comparison to the DMSO control. Activation of AKT (4.8-fold), GSK3A (5.3-fold), IRS1 
(4.4-fold), MTOR (1.1-fold), RPS6KB1 (p70S6K) (12.5-fold), RPS6 (7.9-fold), and TSC2 
(2.2-fold) were observed in resistant HCC827 cells after gefitinib treatment. Data from Figure 
18 C (HGF induction of HCC827 cells) corroborate these results. Phosphorylation of GSK3B 
after gefitinib treatment did not result in a clear reduction because it was not observed to be 
reduced after gefitinib treatment in Figure 18 B.  
The internal control (GAPDH) was not observed to change MFI signals between the different 
samples. In this assay, three controls were used to assess the phosphorylation signal of the 
different proteins (Figure 18 A). As a negative control, cell lysates from phosphatase treated 
HeLa cells were used. As a positive control, cell lysates from insulin stimulated HepG2 cells 
and IGF-1 stimulated MCF-7 cells were used. The negative control showed signals near 
background level. Equal amounts of protein were used to analyze between different samples.  
These data indicated that activation of MET through the co-culture or HGF may lead to the 
activation of the MTOR/AKT signaling pathway resulting in reduced sensitivity towards 
gefitinib.  
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Figure 18 Phospho-signals of MTOR/AKT pathway. Luminex analysis was performed for the MTOR/AKT 
signaling pathway. A) Phosphorylation of stimulated HepG2 stimulated with Insulin (positive control), MCF7 
stimulated with IGF-1 (positive control), and unstimulated HeLa lysates (negative control). B) HCC827 cells 
were cultured with or without gefitinib (0.5 µM) in the presence or absence of MRC-5 cells for 48 h. 
Phosphorylation signals of proteins of C) HGF induced HCC827. Protein lysates were quantified by BCA assay. 
Equal amounts of protein (20 µg) were loaded. MFI: Mean fluorescent intensity. Standard deviations were 
calculated from two experiments with three technical replicates.  
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3.4 Identification of paracrine factors in co-culture medium  
3.4.1 Paracrine factors secreted by fibroblasts induce resistance of HCC827 towards 
gefitinib 
To further identify factors that might induce resistance towards gefitinib in HCC827 cells, the 
cell culture medium from fibroblasts was tested (Figure 19 B). Therefore, cell culture medium 
from MRC-5 lung fibroblasts was centrifuged and the supernatant was applied on gefitinib 
treated HCC827 cells. Thereby, the HCC827 tumor cells responded as in the co-culture 
setting. This suggested that fibroblast-derived analytes in the culture medium were necessary 
to induce resistance in the NSCLC cells towards gefitinib. In order to avoid gefitinib uptake 
by fibroblast cells, lung tumor cells were washed after treatment. To test whether cell survival 
after treatment was specific for fibroblasts, the MRC-5 cells were replaced with lung tumor 
cells A549 (Figure 19 A). Thereby, the resistance of the EGFR-mutant HCC827 cells was 
markedly reduced suggesting that the co-culture with fibroblast cells is required to overcome 
gefitinib mediated cell toxicity. 
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Figure 19 Factors secreted by lung fibroblast cells results in resistance of HCC827 cells to gefitinib. A) 
HCC827 cells were cultured with (0.5 µM) or without gefitinib in the presence or absence of A549 cells for 72 h. 
B) HCC827 cells were cultured with (0.5 µM) or without gefitinib in the presence or absence of undiluted cell 
culture medium from MRC-5 fibroblast cells. Standard deviations were calculated from three replicates. 
 
 
3.4.2 HGF is secreted by fibroblasts into the co-culture medium 
As HGF is a known inducer of resistance, the quantity of HGF in the co-culture medium was 
assessed by ELISA with the cell culture media of the co-culture model (HCC827/MRC-5) and 
of the separate cultivations (HCC827 or MRC-5) (Figure 20). Human HGF was not 
measurable in only growth media with or without 10% FCS. The lung tumor cell line 
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HCC827 alone also did not secrete HGF into the medium, irrespective of treatment with 
gefitinib. However, after co-culture with MRC-5, 4 ng/ml HGF was detected in the medium. 
When MRC-5 cells were incubated alone, an even higher concentration of HGF (5 ng/ml) was 
observed.  
 
 
 
Figure 20 HGF ELISA of cell culture medium from HCC827 co-culture. HCC827 cells were cultured with 
or without gefitinib (0.5 µM) in the presence or absence of MRC-5 cells for 48 h. Cells were incubated for 48 h 
in co-culture with cell culture medium 10% FCS or without. Cell culture medium from HCC827 cells alone, in 
co-culture, as well as medium from MRC-5 cells was analyzed using ELISA kit (Invitrogen) for human HGF 
levels. The amount of HGF was measured using a standard curve. Standard deviations were calculated from two 
experiments. 
 
 
To identify other cytokines involved in the co-culture system, a bead-based multiplex system 
was used. Therefore, HGF levels were technically validated in the supernatant of HCC827 co-
culture (Figure 21 A) and PC-9 co-culture (Figure 21 B) with MRC-5 cells using the Luminex 
system. Similar to the ELISA analysis, HGF from the supernatants of HCC827 or PC-9 single 
cultures were present at background levels. Media from co-culture with MRC-5 showed 
markedly increased levels of HGF. The single culture medium of MRC-5 cells showed the 
highest levels (1852 MFI) of HGF. The HGF levels were within the linear portion of the 
standard curve, which was measured using the 5-parameter logistics curve (5-PL) (data not 
shown). The measurements were within tolerable %coefficients of variation (CV < 25%). 
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Figure 21 Luminex analysis of HGF in cell culture media of HCC827 and PC-9 co-cultures. A) HCC827 or 
B) PC-9 cells were cultured with or without gefitinib (0.5 µM) in the presence or absence of MRC-5 cells. After 
48 h co-culture, the cell culture medium of HCC827 and PC-9 cells was taken and 25 µl cell culture medium was 
analyzed for HGF (bead region: 62) expression using a bead-based immunoassay (BioRad). Standard deviations 
were calculated from three experiments. MFI, mean fluorescent intensity. 
 
 
3.4.3 Screening of cytokines involved in gefitinib resistance  
Further cytokines that might be involved in the induction of resistance to gefitinib were 
searched. Therefore, cytokines in the supernatant of HCC827 (Figure 22 A) and PC-9 (Figure 
22 B) co-cultured cells were screened. In total, 41 cytokines were measured using the 
multiplex bead-based immunoassay (Supplemental Figure 1; Supplemental Table 1). 
Subsequently, six analytes (GRO, IL6, IL8, MCP1, CXCR3 (IP10) and VEGF) were selected 
because the abundances of these cytokines were within measurable ranges. Although CSF2 
was slightly below the range of the quality control samples (data not shown), this analyte was 
also included.  
No analyte was observed in both cell lines HCC827 and PC-9 to be at low levels in the single 
culture medium and increased in the culture medium of co-cultured NSCLC tumor cells as it 
was observed with HGF. 
IL6 and IL8 showed similar patterns between the two cell lines (HCC827 and PC-9), i.e. the 
MFI of the analytes were increased after co-culture (Figure 22 A/B). However, the MFI of 
IL6 and IL8 in the single culture medium of HCC827 cells already had a high background 
level above 1,500 MFI for IL6 and above 6,000 MFI for IL8 cells and was therefore not 
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considered for further analysis. Moreover, CSF2, CXCR3, and VEGF were increased within 
the HCC827 and PC-9 co-culture medium. The MFI of CXCR3 in comparison to the other 
analytes was markedly reduced in the culture media of MRC-5 cells. On the other hand, 
within the co-cultured PC-9 cells, CXCL1, CXCR3, VEGF and CCL2 showed increased MFI 
levels in comparison to the single cultures (Figure 22 B). The changes of CXCR3 and CCL2 
in the cell culture medium from single to co-culture were nearly 100-fold and more than 
20,000-fold, respectively.  
Human cytokine standards containing all analytes of interests in the assay were used as 
controls (data not shown). A dilution curve for each analyte was determined. In addition, two 
human cytokine quality control samples were included, which contained all analytes at 
predefined concentrations, whereby one quality control sample showed increased MFI values 
over all analytes in comparison to the second control sample.  
In conclusion, the analytes VEGF and CSF2 showed the same pattern as HGF in the cell 
culture medium of HCC827/MRC-5 co-culture levels.  
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Figure 22 Multiplex bead based analysis of cytokines and chemokines in the cell culture medium of 
HCC827 and PC-9 cells. HCC827 and PC-9 cells were cultured with or without gefitinib (0.5 µM) in the 
presence or absence of MRC-5 cells. After 48 h co-culture, the cell culture medium of A) HCC827 and B) PC-9 
cells was harvested, and the human cytokine/chemokine magnetic bead panel was analyzed from 25 µl cell 
culture medium. Seven out of 41 measured analytes (CSF2 (GM-CSF) (20), CXCL1 (GRO) (26), IL6 (57), IL8 
(63), CCL2 (CCL2) (67), VEGF (78), CXCR3 (IP-10) (65)) are presented. Standard deviations were calculated 
from three experiments with three technical replicates. MFI, mean fluorescent intensity. 
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3.4.4 Upregulation of MET and GM-CSFR in HCC827 cells in comparison to MRC-5 
cells 
The receptors corresponding to the selected analytes in section 3.4.3 were analyzed by qPCR 
using cell lysates from HCC827 and MRC-5 cells in order to determine in which cell type 
they were more abundant. To determine the abundance of the receptor for HGF, the mRNA 
levels of MET; for CSF2: CSF2RA; and for VEGFA: VEGFR1 (KDR) and VEGFR2 (Flt1) 
were analyzed. MET levels were decreased after gefitinib treatment (FC = 0.63). CSF2RA 
showed increased levels (FC = 5.3) after gefitinib exposure in comparison to DMSO. 
However, differential mRNA expression between the different culture conditions was only 
minor in comparison to the more striking results if mRNA levels of the fibroblast cell line 
MRC5 were compared to the tumor cell line HCC827. The mRNA levels of MET were higher 
(FC = 37.4) in comparison to MRC-5 cells (Figure 23 A). In line with the results from MET, 
CSF2RA was also higher (FC = 40.4) in HCC827 cells in comparison to in MRC-5 cells 
(Figure 23 B). In contrast, KDR (FC = 305.9) (Figure 23 C) and Flt1 (FC = 1.6) (Figure 23 D) 
were more abundant in the fibroblast cell line MRC-5 than in HCC827. In summary, these 
results suggested that ligands such as HGF and CSF2 were more abundant in the cell culture 
medium of fibroblast cells and/or in the co-culture medium. MET and CSF2RA were found to 
be more abundant in HCC827 cells than in fibroblasts.  
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Figure 23 mRNA expression of selected receptors in HCC827/MRC-5 co-culture. HCC827 cells were 
cultured with or without gefitinib (0.5 µM) in the presence or absence of MRC-5 cells for 48 h. mRNA levels of 
A) MET (cMET), B) CSF2RA (GM-CSFR), C) FLT1, and D) KDR were normalized with the housekeeping gene 
ACTB. mRNAs levels were normalized to HCC827 control. Standard deviations were calculated from three 
experiments. 
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3.4.5 Administration of HGF induces resistance to gefitinib in HCC827 and PC-9 cells  
Since the genes MET and CSF2RA were found to be more abundant in tumor cells, HGF and 
CSF2 ligands were selected for further analysis on their influence after gefitinib treatment by 
measuring cell viability. These factors are known to target MET or CSF2 receptors, 
respectively. To evaluate whether HGF or CSF2 could induce resistance in HCC827 after 
gefitinib treatment, different concentrations of HGF (5-80 ng/ml) or CSF2 (20-40 ng/ml) were 
administered. 
The cell index, reflecting cell adherence, number, viability, and morphology in real-time 
[122], was shown to be reduced for HCC827 after gefitinib treatment in comparison to 
gefitinib and subsequent HGF induction (Figure 24 A). Similar results were observed for PC-
9 cells (data not shown). HGF was also observed to be markedly higher expressed (566-fold) 
by fibroblast cells than by HCC827 cells using qPCR (Figure 24 B). Administration of CSF2 
with different concentration to HCC827 did not result in reduced sensitivity towards gefitinib 
(data not shown). 
These results suggested that HGF could overcome gefitinib-mediated toxicity in EGFR-
mutant NSCLC cells. 
 
 
 
Figure 24 HGF reduces sensitivity towards gefitinib. A) Impedance measurement of HCC827 cells after 
treatment with gefitinib and/or HGF (20 ng/ml) induction. HCC827 were seeded in E-plates and incubated for 
24 h using an xCELLigence (Roche). Standard deviations were calculated from quadruplicates. The cell index 
was normalized after 24 h. B) Relative HGF expression was normalized to ACTB. HCC827 cells were cultured 
alone or in co-culture with MRC-5 cells for 48 h. The mRNAs from the different culture conditions were 
compared to HCC827 control. Standard deviations were calculated from three experiments. 
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3.5 miRNA profiling of co-cultured NSCLC cells 
To analyze miRNAs involved in EGFR-TKI resistant HCC827 cells, 731 miRNAs were 
profiled using qRT-PCR arrays with three biological replicates (n = 12). Those miRNAs with 
a median Cp value > 35 in equal to or more than 75% (9/12) of samples (n = 453) were 
excluded from the analysis (Figure 25 A). All other miRNAs (n = 278) were included. To 
compare the miRNAs between the samples, the miRNA data was median normalized. The 
median of n = 278 miRNAs was Cp = 32.1 (Figure 25 B).  
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Figure 25 miRNA profiling of HCC827 co-culture. HCC827 cells were cultured with or without gefitinib (0.5 
µM) in the presence or absence of MRC-5 cells for 48 h. For each sample, n = 731 human miRNAs were 
measured. A) Penalized miRNAs. B) Median normalization of not penalized miRNAs. 
 
 
3.5.1 Selection of miRNA candidates from the screening experiment  
For miRNA analysis, the HCC827 tumor cells were grown under four different conditions for 
48 h, i.e.:  
- Separately cultured (HCC -/-),  
- Treated with gefitinib but separately cultivated (HCC +/-),  
- Not treated but cultivated in co-culture (HCC -/+), 
- Treated and cultivated in co-culture (HCC +/+).  
To select and narrow down the number of miRNAs, a linear fold change (FC) ≥ 1.5 and an 
unpaired two-tailed Student t-Test p < 0.05 was applied. Subsequently, all miRNAs were 
ranked according to their FC. The miRNAs were also tested using a false discovery rate (q-
value). All of the selected miRNAs had a q-value < 0.2. MRC-5 cells were also screened and 
analyzed for differential expression after treatment and subsequent co-culture. However, no 
differentially expressed miRNA could be validated by comparing +/+ vs +/- (data not shown). 
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The comparison: HCC +/+ vs HCC +/- was the main comparison to select potential miRNAs 
that may be involved in the resistance to gefitinib. In total, 31 miRNAs were found to be 
deregulated if a FC ≥ 1.5 and a p < 0.05 was applied and miRNAs had a median Cp ≤ 35 
(Figure 26 A; Supplemental Table 2). From these 31 miRNA, 19 were found to be 
downregulated while twelve were upregulated. To further narrow down the number of 
miRNAs for validation, the selection was done using a FC ≥ 2. miR-205, miR-181a-2-3p, 
miR-181a-3p, miR-181a-5p, miR-181b-5p were found to be downregulated while miR-503-5p, 
1296-5p, miR-222-5p, let-7a-2-3p, miR-941, miR-29b-1-5p were upregulated in the resistant 
lung tumor cells (Table 23). Although miR-181a-5p and miR-181a-3p showed slightly lower 
than FC = 2, these miRNAs were taken into account because they belong to the miR-181 
cluster with miR-181b-5p. Here, miR-29b-3p, which is the major form of the mir-29b-1 
precursor was also observed to be differentially regulated. However, miR-29b-1-5p was 
selected because it showed a higher FC, and although it was earlier denoted as the miRNA* 
strand or the minor form of the mir-29b-1 precursor, reports have shown potential functional 
miRNA* species [135].  
 
 
Table 23: Selected deregulated miRNAs from miRNA array profiling and analysis of HCC +/+ vs HCC +/- 
miRNA ID p-value q-value Fold change Median Cp 
miR-205 2.50E-02 1.63E-01 0.42 32.50 
miR-181a-2-3p 2.56E-02 1.63E-01 0.46 31.67 
miR-181b-5p 6.01E-04 4.61E-02 0.47 29.44 
miR-181a-5p 2.91E-03 6.53E-02 0.52 27.03 
miR-181a-3p 6.63E-04 4.61E-02 0.60 33.04 
miR-503-5p 9.19E-03 8.97E-02 2.02 28.56 
miR-1296 1.72E-02 1.39E-01 2.05 34.60 
miR-222-5p 9.03E-03 8.97E-02 2.34 33.86 
let-7a-2-3p 6.39E-03 7.52E-02 2.46 32.07 
miR-941 1.75E-02 1.39E-01 2.51 33.20 
miR-29b-1-5p 2.79E-03 6.53E-02 2.66 30.98 
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Figure 26 HeatMap of deregulated miRNAs involved in resistance of HCC827 cells towards gefitinib. A) 
Co-culture & gefitinib treated HCC827 (HCC +/+) cells compared to HCC827 cells treated with gefitinib in 
single culture (HCC +/-). B) HCC827 cells treated with gefitinib in single culture (HCC +/-) compared against 
untreated cells in single culture (HCC -/-). miRNAs were selected if FC was above 1.5 and p < 0.05. Each group 
consists of three experiments. Red: Upregulation; Green: Downregulation. 
 
 
3.5.1.1 Deregulated miRNAs in HCC827 under different culture conditions  
To identify miRNAs directly regulated by downregulation of EGFR activity, HCC +/- vs 
HCC -/- was compared (Figure 26 B; Supplemental Table 3). In this analysis, 42 miRNAs 
were differentially expressed if the same filter criteria were used as mentioned above. All 
miRNAs that were selected in the main test (HCC +/+ vs HCC +/-) were inversely regulated. 
From the 42 miRNAs, 15 were downregulated while 27 were upregulated. For example, miR-
205, miR-181a-2-3p, miR-181a-3p, miR-181a-5p, miR-181b-5p were found to be upregulated, 
while miR-503-5p, miR-222-5p, let-7a-2-3p, miR-29b-1-5p were downregulated in the 
gefitinib treated HCC827 cells in comparison to not treated HCC827 cells.  
To identify differentially expressed miRNAs after treatment in co-cultured HCC827 cells, a 
test that compares HCC +/+ vs HCC -/+ was done. Here, eleven miRNAs were found to be 
differentially expressed. miR-181-5p and -3p were observed to be upregulated in HCC +/+ in 
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comparison to HCC -/+. This suggested that regulation of miR-181a-5p and -3p is markedly 
influenced by downregulation of EGFR activity even in co-cultured cells, i.e. when other 
signaling pathways were activated (Supplemental Table 4). 
To identify differentially regulated miRNAs due to the co-culture with MRC-5, HCC -/+ vs 
HCC -/- were compared. Here, only three miRNAs (miR-30c-1-3p, miR-490-3p, and miR-
891b) were observed to be deregulated (Supplemental Table 5). 
An appropriate set of reference genes was selected such as miR-103, miR-423-5p, miR-191, 
SNORD49A, SNORD38B, and U6, which were designated as potential housekeeping genes 
and tested using Normfinder [127], where for each gene a stability value was estimated, 
which is reflected by the standard deviation (SD). Using this method, SNORD49A was found 
to have the best stability value (SD = 0.004), miR-191 and miR-103 showed a stability value 
at SD = 0.005 and U6 showed the lowest stability at SD = 0.021 (data not shown). Since 
normalization using miRNAs as housekeepers is more appropriate for miRNAs as target 
molecules, miR-191 was used in validation experiments as normalizing gene [136]. 
3.5.2 Validation of selected miRNAs in HCC827 and PC-9 cells 
In a validation study, the selected miRNAs from the profiling were analyzed using three 
biological replicates of HCC827 cells. Here, miR-1296-5p, miR-941, and miR-222-5p showed 
a median Cp above 35 across all 12 samples and were, therefore, were excluded. The 
remaining eight miRNA candidates from the miRNA profiling were validated in HCC827 
cells (Table 24; Figure 27). Consistent with the screening data, five miRNAs (miR-181a-3p, 
miR-205-5p, miR-181a-2-3p, miR-181b-5p, miR-181a-5p) were downregulated, while three 
miRNAs (miR-503-5p, miR-29b-1-5p, and let-7a-2-3p) were upregulated by comparing 
HCC+/+ vs HCC+/-. Among the eight miRNAs, miR-181a-2-3p did not show significant 
deregulation.  
 
Table 24: Validation of selected miRNAs in gefitinib-treated co-cultured HCC827 cells 
miRNA ID pVal Fold change Median Cp 
miR-181a-3p 1.69E-03 0.51 34.17 
miR-205-5p 1.17E-02 0.52 33.47 
miR-181a-2-3p 1.13E-01 0.56 34.04 
mir-181b-5p 3.89E-02 0.58 30.20 
miR-181a-5p 4.36E-03 0.61 27.13 
miR-1296 6.78E-01 0.89 36.26 
miR-941 9.17E-01 0.96 35.35 
miR-222-5p 3.85E-01 1.63 37.13 
miR-503-5p 1.90E-02 1.81 29.05 
miR-29b-1-5p 3.68E-02 1.83 33.68 
let-7a-2-3p 1.80E-03 3.71 35.00 
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Figure 27 Validation of selected miRNAs in HCC827 co-culture. HCC827 cells were cultured with or without 
gefitinib (0.5 µM) in the presence or absence of MRC-5 cells for 48 h. miRNAs were measured and normalized 
against miR-191. Relative expression was calculated by comparing to HCC827 control. A log2 base scale was 
used for y-axis. Values above or below the dotted line indicate an up- or downregulation, respectively, of the 
miRNA in comparison to control HCC827 cells. Standard deviations were calculated from three experiments. 
 
 
In addition to the technical validation in the same cell line, the differential expression of the 
eight selected miRNAs was tested not only in HCC827 (Figure 28 A) but also in the second 
gefitinib-sensitive cell line PC-9 (Figure 28 B) comparing +/+ vs +/- at different time points 
(24 h, 48 h, and 72 h). In the HCC827 cell line, all miRNAs were observed to show the same 
direction of regulation as observed in the profiling study and in the first validation. However, 
in PC-9 cells, the expression of let-7a-2-3p, miR-181a-3p, miR-181a-5p, miR-205-5p, miR-
181b-5p, miR-181a-2-3p were not the same at each time-point as in the HCC827 cell line. 
These miRNAs were therefore also excluded from further analysis. Only miR-503-5p and 
miR-29b-1-5p were upregulated in PC-9 and HCC827 by comparing +/+ vs +/- at different 
time points. 
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Figure 28 Validation of selected miRNAs in HCC827 and PC-9 cells after co-culture and gefitinib 
treatment against gefitinib treatment only at different time points. A) HCC827 or B) PC-9 cells were 
cultured alone and treated with gefitinib (0.5 µM) or co-cultured with MRC-5 cells and treated with gefitinib for 
24 h, 48 h, and 72 h. miRNAs were measured and normalized against miR-191. A log2 base scale was used for 
y-axis. Values above or below the dotted line indicate an up- or downregulation, respectively, of the miRNA in 
comparison to gefitinib treatment. Standard deviations were calculated from three experiments. 
 
 
To identify miRNAs to be influenced by HGF, which was shown to be the major factor to 
induce resistance, the most interesting miRNAs (including miR-503-5p and miR-29b-1-5p) 
were then tested for differential expression after gefitinib treatment and subsequent HGF 
induction. To assess miRNA regulation in HGF-triggered EGFR-TKI resistant lung tumor 
cells, soluble HGF was administered to treated cells. The same regulation pattern of miR-29b-
1-5p and miR-503-5p as in co-cultured cells was observed (Figure 29). Since miR-29b-1-5p 
and miR-29a-3p derive from the same precursor and are clustered together within a proximal 
distance of 10kb they are believed to be co-expressed [137]. Interestingly, Garofalo et al. 
already described miR-29a-3p to be downregulated in HCC827 and PC-9 cells after gefitinib 
treatment. Ectopic overexpression of miR-29a-3p in gefitinib exposed HCC827 and PC-9 
cells resulted in reduced apoptosis and increased cell viability [117]. Therefore, miR-503-5p 
was considered as the most interesting candidate as nothing was known about the regulation 
of this miRNA in EGFR-TKI resistant cells. The main focus of this study was to assess the 
impact of the deregulation of this miRNA. 
In summary, the data from the screening and validation study suggested that miR-503-5p was 
upregulated in resistant HCC827 and PC-9 cells. Moreover, the selected miRNAs, in 
particular miR-503-5p, could compensate their expression after co-culture or HGF induction if 
the EGFR activity was reduced upon gefitinib treatment.  
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Figure 29 Regulation of selected miRNAs in HGF induced HCC827 cells after gefitinib treatment. 
HCC827 cells were cultured with or without gefitinib (0.5 µM) in the presence or absence of HGF (20 ng/ml) 
cells for 48 h. miRNAs were measured and normalized against miR-191. Relative expression was calculated by 
comparing to HCC827 control. A base-10 log scale was used for y-axis. Values above or below the dotted line 
indicate an up- or downregulation, respectively, of the miRNA in comparison to control HCC827 cells. Standard 
deviations were calculated from three experiments. 
 
 
3.5.3 miR-503-5p expression in different lung cancer cell lines after treatment with 
gefitinib 
To further elucidate the role of miR-503-5p in conferring resistance, its expression was 
analyzed for differential expression after gefitinib treatment in different lung cancer cell lines 
containing wild-type (wt) EGFR. Here, significant differential expression of miR-503-5p was 
observed in HCC827 cells after gefitinib treatment in comparison to DMSO control (FC = 
0.50). PC-9 cells showed also a slight downregulation (FC = 0.81; p = 0.3). Other lung cancer 
cell lines such as A549 (wt) (FC = 0.84), H2030 (wt) (FC = 1.28), H1650 (FC = 0.87), and 
H1975 (FC = 1.07) did not show significant downregulation (Figure 30). Interestingly, H1650 
has the same deletion of EGFR (delE746-A750) but no deregulation of miR-503-5p was 
observed. EGFR-TKI resistance in H1650 cells has been suggested to be due to loss of PTEN 
[138] since IC50 of H1650 was found at 1.9 µM. Moreover, H1975 was described to be less 
sensitive towards gefitinib due to T907M gatekeeper mutation [40]. Stably resistant HCC827 
(HCC827GR2 and GR4) also showed no significant differential expression of miR-503-5p 
(FC = 1.15 and 1.16). HCC827GR2 and GR4 showed lower IC50 than the HCC827 cells. The 
resistant HCC827 were also identified as HCC827 cells using SNP based multiplex human 
cell line authentication test [139], which was performed at the DKFZ Core Facility (data not 
shown).  
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These results suggested that miR-503-5p levels were reduced after treatment in gefitinib 
hypersensitive cells but not in gefitinib-resistant cells.  
 
 
 
Figure 30 Expression of miR-503-5p in different lung cancer cell lines after gefitinib treatment. Relative 
expression of miR-503-5p normalized to miR-191 in different lung cancer cell lines after treatment with 0.5 µM 
gefitinib. Relative expression was calculated by comparing to DMSO control. Values above or below the dotted 
line indicate an up- or downregulation, respectively, of the miRNA in comparison to control cells (DMSO). 
Standard deviations were calculated from three experiments. IC50 and EGFR mutation status (from COSMIC 
database: http://cancer.sanger.ac.uk\cell_lines) are listed for each of the cell lines on the right panel. 
 
 
 
3.6 Gene expression profiling of co-cultured HCC827 and PC-9 cells  
To further explore the molecular mechanism of EGFR-TKI resistant NSCLC cells, the 
genome-wide transcriptome of HCC827 and PC-9 cells was analyzed. Profiling was done 
using Illumina microarrays to identify common mRNAs associated with gefitinib resistance. 
The data was quantile normalized and hierarchical clustering of mRNAs showed expected 
group clusters of HCC827 (Figure 31 A) and PC-9 (Figure 31 B). 
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Figure 31 Dendrogram of HCC827 and PC-9 co-cultured cells. A) HCC827 and B) PC-9 were cultured with 
or without gefitinib (0.5 µM) in the presence or absence of MRC-5 cells for 48 h. Hierarchical clustering of 
quantile normalized data of all Illumina (ILMN) probes from microarray data is shown. 
 
 
The differential expression of mRNAs was analyzed with the following comparison: (+/+) vs 
(+/-). Illumina probes were defined as differentially expressed if they showed a FC ≥ 1.5 and 
p < 0.05 (t-Test). In total, 1017 probes were upregulated in HCC827 cells and 238 in PC-9 
cells (Figure 32 A). Between both cell lines, 145 probes overlapped. On the other hand, 1018 
of them were found to be downregulated in HCC827 cells and 211 in PC-9 cells. In both cell 
lines, 92 probes were downregulated (Figure 32 B). A total of 237 were identified to be 
differentially regulated (10 Illumina probes were excluded (initially n = 247) because they 
showed discrepancies in the regulation between HCC827 and PC-9 cells). To check overlap 
between the other comparisons, all probes from both cell lines were analyzed using a Venn-
Diagram (Figure 32 C). Most of them from the main test overlapped with those from the 
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comparison (+/-) vs (-/-). Interestingly, most of the probes showed inverse regulation to the 
main test.  
 
 
 
Figure 32 Venn-Diagram of ILMN probe IDs between different analyzed groups within co-cultured 
HCC827 and PC-9 cells. ILMN probe IDs with FC > 1.5 and a pVal < 0.05 were selected and identified to be 
A) upregulated or B) downregulated in both the HCC827 and PC-9 cells. c) Differentially expressed Illumina 
probe Ids from both HCC827 and PC-9 cells between different analyzed groups.  
 
 
Some Illumina probe Ids were designed to target a specific splice isoform for which multiple 
isoforms are known or the probes were designed such as that they target all splice isoforms of 
a gene. Therefore, the 237 Illumina probes corresponded to 211 single transcripts for HCC827 
and PC-9 cells. From the 211 mRNAs, 84 were downregulated and 127 were upregulated in 
the comparison (+/+) vs (+/-) (Supplemental Table 6). The data from the microarray was 
technically validated using 40 selected mRNAs out of 211 genes (19%) using qRT-PCR. A 
high correlation between array data and PCR data was found indicating that the microarray 
data were reliable (R² = 0.78; Pearson: 0.89; Figure 33). 
Using Gene Ontology analysis, an enrichment of genes coding for proteins involved in cell 
death and vesicle mediated transport upon treatment with gefitinib was identified to be 
upregulated (Table 25). Enrichment of cell cycle genes, DNA replication and cellular 
response to stress were downregulated. After treatment and co-culture, genes associated with 
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cell cycle genes were upregulated while enrichment of genes associated with vesicle-mediated 
transport was downregulated (Table 26). 
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Figure 33 Correlation analysis of microarray and qPCR. Pearson correlation of 40 genes between microarray 
and qPCR comparing the fold changes of co-culture treated against only treated samples. 
 
Table 25: GO analysis of ILMN microarray data +/- vs -/-  
Category Term Count % PValue List Total Pop Hits Pop Total Benjamini Regulation
GOTERM_BP_FAT GO:0008219~cell death 32 9.38 1.66E-05 258 719 13528 9.73E-03 Up
GOTERM_BP_FAT GO:0006915~apoptosis 24 7.04 1.16E-03 258 602 13528 1.14E-01 Up
GOTERM_BP_FAT GO:0016192~vesicle-mediated transport 25 7.33 2.66E-04 258 576 13528 6.51E-02 Up
GOTERM_BP_FAT GO:0007049~cell cycle 127 32.40 9.87E-75 317 776 13528 1.68E-71 Down
GOTERM_BP_FAT GO:0000279~M phase 88 22.45 7.92E-69 317 329 13528 6.76E-66 Down
GOTERM_BP_FAT GO:0006260~DNA replication 48 12.24 3.28E-35 317 190 13528 5.10E-33 Down
GOTERM_BP_FAT GO:0006259~DNA metabolic process 74 18.88 8.99E-38 317 506 13528 1.53E-35 Down
GOTERM_BP_FAT GO:0033554~cellular response to stress 50 12.76 1.18E-15 317 566 13528 9.48E-14 Down  
 
Table 26: GO analysis of ILMN microarray data +/+ vs +/-  
Category Term Count % PValue List Total Pop Hits Pop Total Benjamini Regulation
GOTERM_BP_FAT GO:0007049~cell cycle 37 31.36 2.27E-20 99 776 13528 7.21E-18 Up
GOTERM_BP_FAT GO:0000279~M phase 23 19.49 1.30E-15 99 329 13528 3.17E-13 Up
GOTERM_BP_FAT GO:0006974~response to DNA damage stimulus 21 17.80 1.86E-12 99 373 13528 2.22E-10 Up
GOTERM_BP_FAT GO:0048015~phosphoinositide-mediated signaling 10 8.47 1.35E-08 99 88 13528 8.02E-07 Up
KEGG_PATHWAY hsa03030:DNA replication 11 9.32 8.49E-13 52 36 5085 4.42E-11 Up
GOTERM_BP_FAT GO:0006323~DNA packaging 5 6.17 1.78E-03 61 117 13528 1.98E-01 Down
GOTERM_BP_FAT GO:0016192~vesicle-mediated transport 7 8.64 4.17E-02 61 576 13528 6.51E-01 Down
GOTERM_BP_FAT GO:0030182~neuron differentiation 8 9.88 3.12E-03 61 438 13528 2.42E-01 Down
GOTERM_BP_FAT GO:0000904~cell morphogenesis involved in differentiation 6 7.41 4.47E-03 61 244 13528 2.93E-01 Down  
 
 
 
3.7 Identification of GABARAPL1 as a target of miR-503-5p 
3.7.1 Selection of mRNAs from microarray experiments using miRNA prediction  
To predict putative targets of miR-503-5p, miRNA prediction algorithms such as TargetScan 
6.2 are commonly used. This data prediction algorithm predicts 385 transcripts with 
conserved sites for miR-503-5p (if using one transcript per gene having the highest aggregate 
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PCT [140]). However, several target prediction databases enable to select putative miRNA 
targets from different algorithms. In order to determine putative miR-503-5p mRNA targets, 
an overlap of the Ingenuity pathway analysis (IPA), including experimentally validated 
interactions from TarBase, miRecords, the prediction algorithm TargetScan, and manual 
search of miRNA-related findings from the peer-reviewed literature was employed. Ingenuity 
listed a total of 770 putative targets of miR-503-5p. In combination, the in-silico data with 770 
putative targets and the microarray data analysis with 211 selected mRNAs revealed an 
overlap of eight putative genes, four out of which showed expression inversely correlated to 
miR-503-5p expression, i.e. all four selected genes (ZMAT3, GABARAPL1, DCLK1, and 
OSBPL7) were inversely regulated to the miRNA in the main test (+/+ vs +/-) (Figure 34 A). 
In a next step, the selected mRNAs were validated in HCC827 co-culture (Figure 34 B). 
DCLK1 had Cp values above 35 and were therefore excluded. Here, only Gamma-
aminobutyric acid receptor-associated protein-like 1 (GABARAPL1) was identified to be 
significantly upregulated upon gefitinib treatment (FC = 3.4). However, its expression was 
downregulated in HCC +/+ vs +/- (FC = 0.46). According to TargetScan 6.2, GABARAPL1 is 
a predicted conserved target of miR-503-5p with a 7mer-1A seed match, which stands for an 
exact match comprising the seed from positions 2-7 of the mature miRNA followed by an ‘A’ 
at target position 1 [75] (Figure 35). The probability of conserved targeting (PCT), a metric 
used to assess the predicted miRNA-mRNA pairing, revealed a PCT = 0.73. High aggregate 
PCT indicates a high confidence with low false-discovery rate for biologically conserved target 
sites [140].  
In summary, the selection of mRNAs from the screening list using a miRNA-target filter 
suggested a miRNA/mRNA pairing (miR-503-5p/GABARAPL1) in gefitinib resistant cells.  
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Figure 34 Validation of mRNAs in HCC827 co-culture. A) Differentially expressed genes in HCC +/+ vs 
HCC +/- from Illumina Bead Chip analysis were overlapped with putative miR-503-5p target genes from 
Ingenuity database. B) HCC827 cells were cultured with or without gefitinib (0.5 µM) in the presence or absence 
of MRC-5 cells for 48 h. mRNA levels of ZMAT3, GABARAPL1 and OSBPL7 were assessed. Values are 
presented from two independent experiments each with three replicates. Relative expression was calculated by 
comparing to HCC827 control. Values above or below the dotted line indicate an up- or downregulation, 
respectively, of the miRNA in comparison to control cells (DMSO treated). Red arrow: Upregulated; Green 
arrow: Downregulated. 
 
 
Figure 35 3’UTR of GABARAPL1. Predicted pairing of 7mer-1A seed region for miR-503-5p at the 
GABARAPL1 3’UTR site. miR-503-5p was predicted as a conserved miRNA by TargetScan 6.2. 
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3.7.2 Validation of GABARAPL1 as target of miR-503-5p 
To test the miRNA-target interaction, exogenous double-stranded miRNA mimics were 
transiently transfected into HCC827 cells and the expression of the miRNA and known 
mRNA target sequence was analyzed.  
Transfecting HCC827 cells using RNAiMAX (FC < 0.1) was more efficient than using the 
transfection reagent HiPerfect (FC > 0.45) (Supplemental Figure 2).  
In order to find an interaction between miR-503-5p and GABARAPL1 regulation, the miRNA 
was overexpressed by transiently transfecting double-stranded RNA molecules at 40 nM for 
48 h and 72 h (Figure 36 A). Significant reduction of endogenous mRNA levels of 
GABARAPL1 after ectopic overexpression of miR-503-5p was observed after 48 h (p = 0.001; 
FC = 0.78) and 72 h (p < 0.001; FC = 0.59). To further elucidate the regulation of endogenous 
protein levels of GABARAPL1 after ectopic overexpression of miR-503-5p, a Western Blot 
of the small molecular weight protein (15 kDa) was performed. The protein level of 
GABARAPL1 was decreased upon miR-503-5p overexpression (Figure 36 B). 
Inhibiting the expression of miR-503-5p should lead to the derepression of GABARAPL1. As 
expected, no reduction of GABARAPL1 but a slight increased tendency was observed, which, 
however, was not significant (p = 0.22; FC = 1.2) (Figure 36 C).  
Direct targeting of GABARAPL1 by miR-503-5p was tested by a luciferase reporter assay 
containing the full length 3’UTR of GABARAPL1. The luciferase activity was significantly 
reduced (p = 0.02; FC = 0.80) in HCC827 cells when miR-503-5p was co-transfected with 
GABARAPL1 3’UTR vector in comparison to a non-targeting miRNA (ctrl#2) (Figure 37). As 
expected, co-transfection of miR-503-5p with GABARAPL1 3’UTR, in which the binding site 
for miR-503-5p was truncated did not significantly alter luciferase activity (p = 0.14; FC = 
1.03). Moreover, co-transfection of miR-503-5p with empty pmirGLO vector also did not 
significantly alter luciferase activity (p = 0.13; FC = 0.89). 
In summary, these results suggested that miR-503-5p directly targets GABARAPL1 and 
downregulated its expression on mRNA and protein level.  
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Figure 36 Expression of GABARAPL1 after miR-503-5p overexpression and inhibition. HCC827 cells were 
transiently transfected with A) miRIDIAN miR-503-5p mimics (GE) at 40 nM using RNAiMAX (Invitrogen). 
GABARAPL1 downregulation was determined at a 48 h and 72 h post-transfection time. B) Proteins were 
harvested after 48 h and assessed for GABARAPL1 expression (Molecular weight: 14 kDa). GAPDH 
(Molecular weight: 37 kDa) was used as loading control. C) HCC827 cells were transiently transfected with 
miRIDIAN miR-503-5p Hairpin inhibitor (GE) at 100 nM using RNAiMAX (Invitrogen) and assessed for the 
derepression of target mRNA levels of GABABRAL1 after 72 h. mRNA normalization was performed using 
ACTB. Linear relative fold changes are shown. Statistical analysis employed the unpaired two sided t-Test (**p 
< 0.01; ***p < 0.001). Standard deviations were calculated from three experiments.  
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Figure 37 Direct interaction of miR-503-5p and GABARAPL1 identified by 3’UTR Luciferase assay. A) 
GABARAPL1 3´UTR containing a seed region for miR-503-5p was cloned into pmirGLO luciferase vector 
containing firefly luiferase (luc) and a renilla reporter (ren) for normalization. B) HCC827 cells were transfected 
with empty pmirGLO vector, pmirGLO containing GABARAPL1 3´UTR, and pmirGLO containing truncated 
GABARAPL1 3’UTR and co-transfected with mimic miR-503-5p (40 nM) or miRNA negative mimic control#2 
(40 nM). Statistical analysis employed the unpaired two sided t-Test (*p < 0.05). The graphs show values out of 
three independent experiments each with six replicates. 
 
 
 
3.8 Autophagy regulation in HCC827 co-culture 
3.8.1 Increase of autophagy markers SQSTM1 (p62), LC3B-II after Bafilomycin A1 
treatment 
One of the most commonly used approaches to assess autophagy is to determine the 
conversion from endogenous LC3B-I to LC3B-II, whereby the LC3B-II indicates the 
lipidated form of LC3B (LC3B-II). Moreover expression of the autophagy marker SQSTM1 
(p62) is commonly assessed by Western Blot. Inhibition of late stage autophagy by 
Bafilomycin A1, a specific inhibitor of the vacuolar-type H+-ATPase [141] results in the 
increase of autophagosomes (Figure 38 A).  
Blocking the fusion resulted in the increase of SQSTM1 and LC3B-II after 24 h using 
different concentrations of Bafilomycin A1 indicating accumulation of these proteins within 
the autophagosome and thus defective autophagy (Figure 38 B). GABARAPL1 was also 
observed to be increased after Bafilomycin A1 treatment. Moreover, different time points 6 h 
- 48 h were also tested, which showed comparable results (data not shown).  
GABARAPL1 belongs to the Atg8 family and shares 29% sequence similarity with LC3 [142, 
143]. It can also be lipidated forming GABARAPL1-II. However, here it could not be 
determined whether the second lower band is the lipidated form of GABARAPL1 or the result 
of cross-reaction with GABARAP, which shows 86% similarity with GABARAPL1 (UniProt 
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Alignment, data not shown). The siRNA-mediated knockdown of GABARAPL1 resulted in 
the reduction of the upper band (Figure 40). However, the lower band did not disappear 
suggesting that cross-reaction with another protein with high sequence similarity such as 
GABARAP is the more likely reason for the lower band.  
 
 
 
Figure 38 Autophagy markers after Bafilomycin A1 treatment. A) Schematic representation of autophagic 
pathway. Bafilomycin A1 (BafA1) inhibits fusion of autophagosome and lysosomes. B) Expression of autophagy 
markers LC3B, SQSTM1 (p62) and GABARAPL1 after treatment of HCC827 cells with DMSO and different 
concentration of BafA1 (50-500 nM) for 24 h. GAPDH was used as loading control. The second lower band of 
GABARAPL1 is discussed in section 3.8.1. Molecular weight: GABARAPL1: 14 kDa; SQSTM1: 62 kDa; 
LC3B: 14; 16 kDa. 
 
 
3.8.2 Deregulation of autophagic activity after gefitinib treatment and subsequent co-
culture  
To test GABARAPL1 protein expression in co-culture, GABARAPL1 was measured on 
Western Blot. After gefitinib treatment, a known inducer of autophagy [144], GABARAPL1 
was upregulated after 48 h and 72 h (HCC+/- vs -/-: 1.4 x and 1.5 x) but decreased by 20% in 
HCC+/+ vs +/- (Figure 39 A/B) after 48 h and 72 h. These results were corroborated in cells 
cultured with HGF and gefitinib treatment, where GABARAPL1 was observed to be 
upregulated (HCC+/- vs -/-: 1.3 x – 1.4 x), while the comparison HCC+/+ vs +/- showed a 
decrease by 50% (Supplemental Figure 4). 
To identify autophagy regulation in co-cultured cells, SQSTM1 (p62) levels were measured. 
SQSTM1 is an adapter protein that can bind many different proteins to form protein 
complexes. For example, it can bind LC3 and other substrates to the inner surface during the 
maturation of the phagophore to transport it to autophagosomes for degradation. If autophagy 
is defective, SQSTM1 accumulates in the cytoplasm [145-147]. SQSTM1 levels were 
observed to be marginally reduced upon gefitinib treatment in comparison to DMSO 
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treatment after 48 h and 72 h (HCC+/- vs -/-: 0.9 x) (Figure 39 A/B). Although gefitinib is an 
inducer of autophagy, decrease of SQSTM1 was marginal maybe due its low concentration 
(0.5 µM). Upon co-culture, SQSTM1 levels were increased in comparison to treated cells 
after 48 h and 72 h (HCC+/+ vs +/-: 1.2 x and 1.3 x) (Figure 39 A/B). These results were 
corroborated from in-vitro culture after HGF administration (HCC+/+ vs +/-: 2.1 x) 
(Supplemental Figure 4).  
Moreover, conversion of LC3B-I to LC3B-II could also be clearly observed after gefitinib 
treatment for 72 h. Gefitinib treatment resulted in increased levels of LC3B-II in comparison 
to DMSO control (1.7 x). Co-culture after gefitinib treatment resulted in the reduction of 
LC3B-II (0.7 x). Increase of the lipidated form of LC3B (LC3B-II) between the different 
culture conditions is associated with deregulated autophagic activity  
In this study, slightly increased levels of SQSTM1 and decreased levels of LC3B-II were 
found in resistant HCC827 cells while GABARAPL1 showed inverse regulation indicating 
deregulation of autophagic activity. 
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Figure 39 Expression of SQSTM1 (p62) and GABARAPL1 in resistant HCC827 cells. HCC827 cells were 
cultured with or without gefitinib (0.5 µM) in the presence or absence of A) MRC-5 cells for 24-72 h. B) 
Densitometric analysis of GABARAPL1, SQSTM1, and LC3B-II. The analysis was performed using ImageLab 
5.2.1. Protein levels were normalized to internal GAPDH levels. Predicted molecular weight: SQSTM1: 62kDa, 
LC3B: 14, 16 kDA, GABARAPL1:14 kDa.  
 
 
3.8.3 Accumulation of SQSTM1 after GABARAPL1 knockdown indicates defective 
autophagy 
Since miR-503-5p has a plethora of targets, this study focused on the possible role of 
GABARAPL1 as it was found to interact with this miRNA. To assess the role of 
GABARAPL1 in autophagy, the autophagy marker SQSTM1 (p62) was measured after 
knockdown of GABARAPL1. Four different siRNAs were used to knockdown GABARAPL1. 
The siRNA-mediated knockdown of GABARAPL1 showed 5% - 19% expression depending 
on the siRNA (Supplemental Figure 3). Three out of four (siGABARAPL1#6, #8, and #9) 
Results  93 
were considered as effective siRNAs and were selected for further analysis. Upon knockdown 
of GABARAPL1, the expression of SQSTM1 was clearly increased after 48 h (#6: 2.4 x; #8: 
1.6 x; #9: 3.3 x) (Figure 40 A/C). This suggested that reduction of GABARAPL1 results in 
defective autophagy.  
The siRNA-mediated knockdown of GABARAPL1 expression resulted in slightly increased 
LC3B-II expression after 24 h and 48 h (Figure 40 B). The increase of LC3B-II expression 
may be the result of compensating the loss of GABARAPL1 and is therefore increased [148]. 
Transfection with siRNAs against GABARAPL1 reduced the GABARAPL1 protein to more 
than 95% in all siRNA-mediated transfections.  
These data suggested that siRNA-mediated knockdown of GABARAPL1 results in increased 
SQSTM1 levels indicating accumulation of this protein due to defective autophagy.  
 
 
 
Figure 40 Expression of SQSTM1 (p62) and GABARAPL1 after siRNA-mediated knockdown of 
GABARAPL1. HCC827 cells were transfected with three different siRNAs (10 nM) against GABARAPL1 and 
AllStars1 (10 nM) or Mock for A) 24 h and 48 h. B) LC3B expression was measured after treatment as described 
in A). C) Densitometric analysis of GABARAPL1, SQSTM1 and LC3B-II was performed using ImageLab 
5.2.1. Molecular weight: SQSTM1: 62kDa, LC3B: 14, 16 kDA, GABARAPL1:14 kDa. (24 h/48 h). 1: Mock, 2: 
AllStars1, 3-5: siRNA-mediated knockdown of GABARAPL1#6, #8, and #9. 
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In summary, miRNAs and mRNAs were investigated in the development of resistance using 
a gefitinib co-culture model. Gefitinib-sensitive HCC827 and PC-9 cells were co-cultured 
with lung fibroblasts (MRC-5).  
Global miRNA analysis revealed expression changes associated with EGFR-TKI resistance. 
Eleven miRNAs were selected, out of which miR-503-5p was validated in both cell lines. 
Inhibition of EGFR activity by gefitinib resulted in the reduction of miR-503-5p. The 
subsequent co-culture following treatment with gefitinib resulted in the increase of miR-503-
5p. Although the expression of miR-503-5p was reduced after gefitinib treatment in HCC827 
cells, no difference of this miRNA was found in other lung cancer cells, which had lower 
sensitivities to gefitinib.  
Subsequently, global gene expression profiling revealed 211 differentially expressed mRNAs 
in the resistant HCC827 and PC-9 cells. Based on the gene expression profile, an enrichment 
of genes that are involved in cell migration and apoptosis was found after treatment with 
gefitinib. In the resistant cells, genes associated with apoptosis were downregulated, whereas 
cell cycle genes were upregulated. To determine potential miRNA target genes of miR-503-
5p, the global gene expression profiling was compared with miRNA prediction databases. 
Several predicted target genes of miR-503-5p were identified. Among these, GABARAPL1 
was verified as a putative target. Ectopic overexpression of miR-503-5p resulted in a 
significant reduction of GABARAPL1 mRNA and protein. Moreover, direct interaction was 
shown by 3'UTR luciferase reporter assay. Deregulation of autophagy was indicated by the 
reduced protein levels of SQSTM1 and increased LC3B-II after gefitinib treatment. Resistant 
HCC827 cells showed an accumulation of SQSTM1 but lower LC3B-II protein content. Since 
GABARAPL1 has been suggested to play a role in autophagy, siRNA-mediated knockdown 
of GABARAPL1 resulted in the accumulation of SQSTM1. This indicated that autophagy was 
defective in NSCLC with reduced GABARAPL1 expression. 
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4 Discussion 
Improving the stratification of lung cancer patients through biomarkers can help clinicians to 
select the optimal strategy for patient care. Circulating miRNAs have been suggested as 
stable, non-invasive biomarkers in body fluids such as serum in cancer detection [93, 94]. The 
identification of prognostic tumor-specific circulating miRNA profiles in patients with 
operable NSCLC may provide a blueprint for better patient care and treatment. Moreover, 
circulating miRNAs can serve as cost-effective markers to enable monitoring before and after 
patients’ therapy, or furthermore, for the risk assessment of operable or not operable NSCLC 
patients. Many miRNA markers have been suggested as diagnostic and prognostic markers in 
NSCLC [85, 101, 102, 104, 120]. In this study, miRNAs were not only evaluated in the 
context of the progression of the tumor at early stages of NSCLC patients, but also after 
therapy in NSCLC cells. In order to focus on a specific signaling pathway, NSCLC cells that 
harbor the druggable target EGFR were analyzed after treatment. Moreover, miRNA 
regulation was studied in EGFR-TKI treated NSCLC cells. Although patients with activating 
mutations in EGFR respond well to EGFR-TKI treatment, almost all NSCLC patients 
ultimately develop resistance to these agents [149, 150]. Since miRNAs are known to be key 
molecules in tumor progression, this research assessed both their potential as prognostic 
markers as well as their functional relevance to contribute to a metastatic phenotype in 
NSCLC. Therefore, the aim of this PhD work was: 
 
- Firstly, to identify circulating miRNAs as prognostic markers for early-stage lung 
adenocarcinoma.  
- Secondly, to evaluate the involvement of miRNAs in NSCLC tumor progression. In 
therapy resistance, miRNAs were hypothesized to be involved in mediating the 
resistance towards gefitinib in lung cancer cells via the induction of stromal cells. 
Therefore, the crosstalk between tumor cells and stromal fibroblasts and its underlying 
miRNA signaling network in NSCLCs that may modulate gefitinib resistance was 
elucidated.  
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4.1 Circulating miRNAs as markers for early-stage lung adenocarcinoma. 
4.1.1 Pre-analytical consideration for circulating miRNA analysis 
For the analysis of circulating miRNAs, it is critical to have adequately defined pre-analytical 
parameters that are standardized for the collection of a blood sample. In particular, the 
differences between miRNA expression levels from different blood sampling, via 
venipuncture or arterial sampling, are still poorly understood. In this present study, two 
cohorts of 65 patients (blood drawn via arterial catheter) and 210 patients (blood drawn via 
venipuncture) were measured. The increased expression for all selected miRNAs in samples 
in which blood was drawn via venipuncture in comparison to samples withdrawn via an 
arterial catheter was observed. To further evaluate differences in blood drawings that 
influence miRNA expression, serum samples from the same patient were derived from venous 
blood before and on the day of surgery, as well as after the induction of anesthesia via an 
arterial catheter. Again, almost all the selected miRNAs showed an increase in samples 
isolated from venous blood. It remains elusive, however, whether the induction of anesthesia 
or the vessel puncture procedure is critical for the findings.  
Kahn et al. identified different expression levels of three biomarkers: Squamous Cell 
Carcinoma antigen (SCC), Carcinoembrionic Antigen (CEA), and CYFRA 21-1. The 
expression level of SCC was dependent on the procedure of blood withdrawal. Its expression 
was increased in samples in which blood was taken via arterial catheter through the induction 
of anesthesia in comparison to samples via venipuncture [121]. 
Thorpe et al. reported that blood collection by different blood drawing procedures resulted in 
differences in the ovarian cancer serum marker prolactin. Their study found that prolactin 
levels were markedly increased at the time of surgery in comparison to samples prior to 
surgery [151]. Differential expression of miRNAs in arterial and peripheral venous plasma 
was already observed in patients with gastric cancer. However, they observed decreased and 
increased miRNA expression in peripheral venous samples in comparison to arterial blood 
[152].  
As miRNAs are known to be deregulated under hypoxic conditions [153, 154], different 
oxygen levels in arterial and venous blood may influence miRNA regulation.  
miRNAs have been shown to be taken up by recipient cells and to be communicators between 
cells [97]. Therefore, one may also speculate that miRNA expression levels withdrawn from 
arterial blood should be higher in comparison to blood withdrawn via venipuncture, as 
miRNAs may be absorbed and taken up by cells, because blood flows first from arterial to 
venous circulation. This is, however, contradictory to the results presented here, in which 
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most of the miRNAs have been shown to be higher in venous blood than in arterial blood. 
One can assume that the increase of specific miRNAs in serum samples from blood 
withdrawn via venipuncture might derive from actively secreting tumor cells. Moreover, the 
passive leakage of miRNAs via apoptosis or necrosis might also be possible [155]. It is also 
likely that differences are caused due to the different composition of arterial and venous 
blood, which results in different PCR efficiencies, and thus, differently measured miRNA 
expression levels. Further studies must be conducted in order to clarify the differential 
expression of miRNA withdrawn from venous and arterial blood. 
From internal discussions, in this study, it is known that serum from blood drawn via arterial 
catheters is subjected to one freeze and thaw cycle to room temperature. The decreased 
miRNA expression may be due to the release of miRNAs from exosomes or AGO proteins 
and their subsequent degradation via RNases after a freeze and thaw cycle. Although the 
found differences were subtle, they were systematic.  
Although Mitchell et al. reported no difference of miRNAs after freeze and thaw cycles [93], 
Grasedieck et al. showed that the repeated freeze and thaw cycles of miRNAs at room 
temperature decreased miRNA levels [96]. The differences in miRNA expression between 
both studies may be explained by several reasons. For example, Mitchell et al. [93] performed 
studies using plasma, whereas Grasedieck et al. [96] used serum samples. Moreover, in both 
studies repeated freeze and thaw cycles were performed with low numbers of miRNAs. 
Global miRNA analysis might provide a broader picture as to whether certain miRNA 
populations are expressed differentially after repeated freeze and thaw cycles. Therefore, the 
changes in miRNA expression levels cannot only be influenced by different blood drawing 
procedures, but also by freeze and thaw cycles. 
In order to minimize variation in miRNA expression analysis, serum sample sets should be 
considered for pre-analytical variables such as blood withdrawal as well as freeze and thaw 
cycles.  
4.1.2 Evaluation of circulating miRNA candidates as prognostic markers in NSCLC 
As in a previous study, miR-142-3p was identified to be associated with the early recurrence 
of NSCLC [120], this miRNAs was again studied in another cohort of n = 65 patients, which 
were sampled via an arterial catheter. Again, the miRNA expression of miR-142-3p showed a 
tendency to be increased in patients with an early recurrence of lung adenocarcinoma.  
In this study, hemolysis was evaluated in serum samples. miR-20b-5p and miR-486-5p were 
identified as strongly correlated with hemolytic miRNA miR-451a. However, hemolysis was 
not associated with overall or recurrence-free survival. miR-486-5p has previously been 
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described as a prognostic biomarker for NSCLC [104]. Hemolysis has been shown to affect 
miRNA expression levels elsewhere [111], in particular, miR-16 and miR-451a. It remains 
elusive, however, as to whether hemolysis in this study as well as others occurs during blood 
processing or as a result of a disease. 
After excluding the hemolytic miRNAs, the prognostic potential of a miRNA panel in early-
stage (I-IIIa) lung adenocarcinoma patients was evaluated. These miRNAs were selected as 
they were described to play a role as prognostic or diagnostic markers in NSCLC in different 
studies [101, 102, 104-107, 120, 129-131]. A panel of miRNAs was calculated using Cox-
regression models as prognostic markers. As a result of the tumor heterogeneity among 
patients, the use of a biomarker panel was expected to be more sensitive and specific than 
single markers [156]. 
miR-29b-3p expression showed the strongest prognostic association. This miRNA has 
previously been described in NSCLC to promote tumor invasiveness. Patients with high-c-
MYC and low miR-29b levels were associated with poor OS and RFS [157]. miR-29b-3p, 
miR-125b-5p, and miR-331-3p were identified as a panel, but were not able to significantly 
discriminate high-risk and low-risk patients. The combining of staging information and the 
miRNA panel was not significantly beneficial to stratify high and low-risk patients.  
In conclusion, this study evaluated the prognostic potential of a miRNA panel in early-stage 
(I-IIIa) lung adenocarcinoma patients. Increased miR-142-3p levels were identified and 
associated with poor prognosis in early-stage lung adenocarcinoma.  
This study highlights the importance of pre-analytical variables for the analysis of circulating 
miRNAs from serum samples. It showed that blood-collection via venipuncture results in 
higher expression levels of selected circulating miRNAs in comparison to blood-collection via 
an arterial catheter. Moreover, the expression of miR-20b-5p and miR-486-5p in serum of 
NSCLC were found to be strongly associated with hemolysis.  
 
4.2 Role of miRNAs in therapy resistance of lung adenocarcinoma cells 
4.2.1 Acquired resistance mechanisms towards EGFR-TKI of lung adenocarcinoma  
In order to further evaluate the involvement of miRNAs in the progression of NSCLC, a 
resistance model towards gefitinib was used, which Wang et al. have described [46].  
In this study, NSCLC cells that harbor an inframe deletion of exon 19 in EGFR were used. 
The inframe deletion of exon 19 is an activating mutation [149]. Up to 10 to 20% of patients 
from Europe and 40 to 60% of Asians carry an activation mutation of EGFR [36, 158]. 
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Therapy with the first generation EGFR-TKI inhibitor gefitinib has shown remarkable tumor 
shrinkage and an improvement in progression-free survival [25]. Patients, however, do 
commonly develop a resistance towards the targeted therapy [149]. This study used a NSCLC 
resistance model towards gefitinib to identify the differential regulation of miRNAs and target 
genes. Not all cells died from the gefitinib treatment, which may be due to the presence of a 
pre-existing MET amplification, which allows these cells to survive the treatment [44]. The 
administration of gefitinib results in a kinase-dependent reduction of cell viability. The model 
from Wang et al. enables a fast-track model to analyze molecules that affect EGFR-TKI 
sensitivity. The co-culture system, in comparison to stable EGFR-TKI resistant cells, enables 
the analysis of the interaction between tumor and fibroblast cells. Moreover, the EGFR-TKI 
gefitinib allows a more physiological condition through a reduction of tyrosine kinase 
activity, whereas other studies instead use artificial approaches by shRNA-mediated EGFR 
knockdown [117], which is kinase-independent, as it identifies the deregulation of 
downstream targets.  
To further explore the paracrine factors that induce the resistance of gefitinib treated NSCLC 
cells, a panel of growth factors, cytokines and chemokines were analyzed. 
The cell culture medium of fibroblasts alone resulted in the resistance of HCC827 cells to 
gefitinib. The reduced levels of HGF in the co-culture medium, in comparison to the MRC-5 
culture medium, may be a consequence of the binding of HGF, which is produced by MRC-5 
cells, to the membrane receptor MET on the surface of HCC827 cells. In this study, HGF was 
identified to be prominently secreted and able to induce resistance in HCC827 cells. This 
finding is consistent with other reports that demonstrated an HGF-mediated resistance 
towards gefitinib [46]. Several MET inhibitors were tested using the co-culture system [159] 
and in clinical trials [160], however, no inhibitor received the FDA’s approval to be used in 
cases of lung cancer. 
In this study, VEGF was also found to be a putative target to overcome insensitivity towards 
gefitinib in HCC827 cells. In EGFR-TKI-resistant lung cancer cells, HGF may induce VEGF. 
These results were consistent with Takeuchi and his colleagues, who showed that MET 
activation in PC-9 cells by HGF resulted in increased VEGF production [161]. Increased 
VEGF production is known to induce tumor angiogenesis [162], and is a potential mechanism 
to overcome the EGFR blockade [163]. 
CSF2 was another factor that was found to be increased in the co-culture relative to the single 
tumor cell culture medium. The mRNA levels of the cell membrane receptor CSF2RA was 
increased in the tumor cell lines in comparison to the fibroblasts, which suggests that the 
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ligand may bind to the CSF2 receptor. Administration of CSF2, however, did not result in 
insensitivity towards gefitinib (data not shown). CSF2 was also found to be upregulated in 
EGFR-TKI resistant HNSCC cells [164]. 
In this study, the IL6 and IL8 signaling proved to be increased in the co-culture, but decreased 
in the single culture. Although the abundance of IL6 and IL8 was already very high in the cell 
culture medium, the activation of the IL6 receptor may require high levels of the ligand to 
induce insensitivity towards gefitinib. Reports have found the TGF-beta-IL6 axis mediates 
resistance towards erlotinib treatment in a mouse model [165]. Moreover, it has been shown 
that metformin can sensitize EGFR-TKI resistant lung cancer cells by decreasing IL6 
signaling [166]. Interestingly, the IL6R/JAK1/STAT3 signaling has been reported to induce 
resistance towards the irreversible EGFR-TKI afatinib, which is also critical to the interaction 
between fibroblast cells MRC-5 and lung cancer cells [167]. The IL8 signaling has also been 
suggested to be involved in resistance towards gefitinib. Liu et al. demonstrated that the 
suppression of IL8 in PC-9 cells resistant to gefitinib resulted in the increase of dead cells in 
combination with gefitinib through the reduction of the stemness-related genes (ALDH1A1, 
NANOG, and SOX2). Moreover, increased IL8 expression was associated with poor 
progression-free survival of EGFR-TKI treated lung adenocarcinoma patients [168].  
In breast cancer, GRO (CXCL1) has also been described to be involved and overexpressed in 
metastatic sites. It can attract CD11b+Gr1+ myeloid cells, which in turn results in increased 
cell survival [169]. 
Moreover, Zhang et al. have reported activation of the AXL kinase as one of the main reasons 
for acquired resistance to treatment to both gefitinib and erlotinib in EGFR-mutant NSCLC 
patients. HCC827 cells that were resistant to erlotinib showed increased AXL expression and 
were shown to have an aggressive phenotype (increased cell migration and associated with 
epithelial-to-mesenchymal transition properties) in-vitro and in-vivo. The siRNA-mediated 
knockdown of AXL was shown to increase sensitivity to erlotinib in EGFR-mutant HCC827 
cells, although not in erlotinib-resistant cell lines [170]. 
In summary, HGF secreted from fibroblast cells was the strongest inducer of resistance 
towards gefitinib in NSCLC cells HCC827 and PC-9.  
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4.2.2 miR-503-5p identified to be involved in gefitinib resistant lung adenocarcinoma 
cells 
To determine differentially expressed miRNAs in resistant and sensitive cells, miRNAs 
between gefitinib treated cells versus subsequently co-cultured cells were analyzed. A total of 
31 miRNAs were observed to be differentially regulated.  
miR-503-5p was found to be the most interesting candidate involved in the gefitinib-
insensitive HCC827 cells. Within this study, miR-503-5p was found to be inhibited by 
reducing EGFR activity using gefitinib in HCC827 cells. Other cell lines with wild-type 
EGFR or lung cancer cell lines with lower sensitivity towards gefitinib showed nearly no 
regulation after gefitinib treatment. The co-culture or HGF alone did not change miR-503-5p 
expression, however, in cases that cells were pre-treated with gefitinib, the co-culture or HGF 
treatment resulted in the restoration of miR-503-5p expression. This result suggests that miR-
503-5p can only compensate its expression after co-culture or HGF induction if the EGFR 
activity is reduced. Its expression may be dependent on a certain threshold. To identify the 
downstream factors of EGFR and MET responsible for miR-503-5p deregulation, 
transcription factors binding to upstream sequences of miR-503-5p must be studied. For 
example, it has been found that MET induces the activation of ELK1 transcription factor, 
which can induce the expression of the miR-23a-27a-2-2 cluster. Interestingly, miR-27a was 
able to downregulate the expression of MET and EGFR by binding to their 3’UTR and/or by 
downregulating the expression of SPRY2 [171]. Therefore, it would be of interest to identify 
transcription factors that regulate miRNAs, for example the binding of ELK1 at promoter 
regions of miR-503-5p, through the application of chromatin immunoprecipitation 
experiments. 
miR-503-5p is located on the X-chromosome and clusters with other miRNAs such as miR-
424, miR-542, and the miR-450 family. Reports have shown that miR-503-5p promotes tumor 
progression in other cancer types. Patients with esophagal cancer that have a high expression 
of miR-503-5p had poorer disease-free survival [172]. miR-503-5p was found to be 
overexpressed in adenocarcinomas in comparison to adenomas and normal mucosa [173]. 
Ectopic overexpression in colon adenocarcinoma cells resulted in increased malignant 
transformation and was shown to confer tumorigenicity in-vivo. The inhibition of miR-503-5p 
resulted in decreased cell proliferation, migration, and cell invasion, but in increased 
apoptosis, which might partly be due to the regulation of the tumor-suppressor FBXW7. 
However, it has also frequently been reported to have tumor suppressive functions in lung 
cancer. For example, it has been reported to regulate the anti-apoptotic protein BCL2 or PI3K 
p85 and IKBKB [174-176]. Li et al. showed through combined bisulfite restriction analysis 
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that the expression of miR-503-5p is inversely correlated with its methylation status, and 
moreover, that it can target FANCA [175]. 
It would be beneficial to generate a stable cell line that could constitutively express the 
miRNA or to use an inducible system. Further insight into long-term expression analysis may 
be achieved through a stable transfection of miR-503-5p, as it allows to be used in xenograft 
models to analyze tumor growth in-vivo. 
Within the screening data of this study, further miRNAs have also been identified by other 
groups to play a role in the resistance of EGFR-TKI NSCLC cells. For example, here it was 
shown that miR-34a was upregulated after gefitinib treatment, but downregulated after 
subsequent co-culture. Zhou et al. also identified miR-34a upregulation after gefitinib 
treatment. This miRNA was found to induce apoptosis in the very same cells, partially 
through the reduction of MET expression. By ectopic overexpression of miR-34a Zhou et al. 
could show that resistance towards gefitinib is reduced if it is combined with the miRNA 
[177].  
Moreover, miR-29b-3p and 5p and miR-222-5p were found to be downregulated after gefitinib 
treatment and upregulated after subsequent co-culture. Interestingly, Garofalo et al. identified 
miR-29a and miR-29c, miR-222 to be downregulated after drug exposure with gefitinib in 
HCC827 and PC-9 cells. The authors have identified these miRNA from a screen after 
developing a stable knockdown of MET and EGFR that used shRNA lentiviral particles [117]. 
The overexpression of miR-221/222 resulted in more resistant cells towards gefitinib 
treatment. Interestingly, the opposite arm of the mature miR-29b-1-5p sequence, the miR-29b-
3p, has been associated with overall survival in the serum of early stage NSCLC patients 
[120]. 
Within the screening dataset from this PhD work, miR-181a-5p was found to be upregulated 
after gefitinib treatment. This miRNA has been described to be downregulated in most tumors 
and reported to function as a tumor suppressing gene [178-180]. miR-181a-5p belongs to the 
miR-181 family, which includes the four different miRNAs miR-181a, b, c, and d. Ectopic 
overexpression of miR-181a-5p was shown to reduce cell migration in COS-1 cells. 
Moreover, the levels of miR-181a-5p were lower in the invasive front of human colonic 
mucosal cells in relative to tumor-adjacent normal epithelial cells [181].  
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4.2.3 The autophagy gene GABARAPL1 is a target of miR-503-5p  
A global transcriptomic profiling was performed to search for differentially regulated mRNAs 
involved in the co-culture model. The expression data of HCC827 and PC-9 cells were 
compared and common mRNAs were selected. 
In total, 211 mRNAs were found to be deregulated. Most of the upregulated mRNAs were 
associated with the cell cycle and the response to a DNA damage stimulus. Genes involved in 
vesicle mediated transport, neuron differentiation, and cell morphogenesis were 
downregulated.  
Early growth response 1 (EGR1) was the top upregulated mRNA in the dataset. Consistent 
with the presented data, the EGR1 gene was found to be downregulated after gefitinib 
treatment [182]. However, EGF stimulation was shown to upregulate EGR1 expression in 
EGFR-mutant NSCLC cells. Another report described that impaired nuclear translocation of 
EGR1 results in PTEN loss, and thus results in the acquisition of resistance to gefitinib [183].  
The Aurora-A kinase (AURKA) family has also been described to be upregulated under the 
same experimental conditions in the co-cultured treated cells in comparison to only treated 
cells [184]. Interestingly, the overexpression of AURKA has proven to reduce gefitinib 
sensitivity. The insensitivity towards gefitinib by AURKA could be lowered by transfecting 
EGFR mutant NSCLC cells with the shRNA mediated-knockdown of AURKA. 
When combining the mRNA data sets from the microarray and database predicting miRNA 
target genes, four mRNAs were observed to be potentially targeted by miR-503-5p. From the 
four mRNAs, GABARAPL1 was validated by qRT-PCR, Western Blot and Luciferase Assay 
System using 3'UTR-reporter constructs to be targeted by miR-503-5p. GABARAP, which 
was first described as an early estrogen-regulated gene [185], was later found to be an 
ubiquitin-like modifier and involved in intracellular trafficking of GABAAR, a type-A 
ionotropic receptor and ligand-gated chloride channel mediating inhibitory neurotransmission. 
GABARAPL1 shares 86% identity with GABARAP [186]. The GABARAP family 
(GABARAP, GABARAPL1, GABARAPL2, and GABARAPL3) belongs to the Atg8 family. 
The MAP-LC3 (Microtubule-associated protein light chain 3), which consists of MAP1A 
(LC3A), MAP1B (LC3B), and MAP1C (LC3C), also belongs to this subfamily of Atg8. 
GABARAPL1 has been reported to increase the expression of the kappa-type opioid receptor 
on the cell surface [187]. It can link the receptor GABAAR and tubulin [142]. Chakrama et al. 
associated GABARAPL1 with autophagic vesicles [188], which thereby indicates that it is not 
only involved in the trafficking of proteins, but is also involved in processes such as 
autophagy. Autophagy is a catabolic process that involves the degradation of superfluous 
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cellular components such as intracellular proteins, lipids, and organelles so that the cell 
maintains homeostasis. The degradation takes place in lysosomes and the degraded products 
are then exported into the cytoplasm for recycling. The conjugation of Atg8 to the 
phosphatidylethanolamine (PE) lipid is critical for phagophore formation [189]. Although 
both the LC3s and GABARAPs are critical during the maturation of the autophagosome for 
the autophagic process, the GABARAP, including GABARAPL1 and LC3 family members, 
have been reported to have distinct roles in the autophagic process. Through the deletion of 
each of the family members, Weidberg et al. could show that GABARAPs are essential after 
the elongation of the phagophore membrane, which the LC3s mediated [190]. 
 
4.2.4 Role of autophagy in EGFR-TKI resistant HCC827 cells 
Autophagy regulation in the co-culture model was further determined by analyzing the 
expression of GABARAPL1 and the standard autophagy markers LC3B and SQSTM1. 
GABARAPL1 and LC3B-II were increased after gefitinib treatment and decreased after 
subsequent co-culture. This dynamic suggested that autophagic activity has changed.  
To further evaluate autophagic activity, the autophagy marker Sequestome 1 (SQSTM1/p62), 
was taken into consideration. SQSTM1 is also known as an adaptor protein that can target 
specific cargo via its ubiquitin-associated (UBA) domain and LC3A and B and the 
GABARAP proteins via its LC3-interacting region (LIR) domain for autophagic processing 
[191, 192]. In this study, SQSTM1 was slightly accumulated in the resistant cells, which 
indicated further suppressed autophagy in comparison to cells that were solely treated with 
gefitinib. Cells with homeostatic metabolism have low SQSTM1 levels due to clearance by 
autophagy. In mice with deficient autophagy, SQSTM1 was observed to accumulate in the 
cytoplasm [193]. SQSTM1 is involved in a plethora of cellular functions such as cell growth, 
survival, and mitosis through the interaction with different binding partners. For example, 
SQSTM1 has been reported to activate NFKB1 (NF-κB), which leads to cell growth [194]. 
Activation of NFKB1 has been sown to rescue erlotinib-induced cell death in HCC827 cells 
in-vitro and in-vivo by reducing the expression of the inhibitor of NFKB1 (NFKBIA). 
Moreover, low NFKBIA expression, indicating high-NFKB1 activation, was measured in 
EGFR-mutant lung cancer patients treated with erlotinib with poor progression-free and 
overall-survival [195]. The accumulation of SQSTM1 was associated with a poor overall rate 
of survival in patients with NSCLC [196]. SQSTM1 releases and stabilizes nuclear factor 
erythroid 2-related factor 2 (NFE2L2/Nrf2) from KEAP1, and therefore, activates NFE2L2, 
which leads to the induction of the antioxidant defence system [197]. Yamadori et al. have 
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shown that NFE2L2 was constitutively activated in the NSCLC cell line PC-9 that harbors the 
EGFR-activation mutation, whereas treatment with EGFR-TKI resulted in the downregulation 
of NFE2L2. Moreover, their study revealed that the knockdown of KEAP1 resulted in 
increased cell growth. Interestingly, their study demonstrated EGFR-TKI resistance in a 
patient with advanced NSCLC harboring a gene mutation in KEAP1 [198]. It would, 
therefore, be interesting to determine a regulation of NFE2L2 by miR-503-5p that may 
contribute to EGFR-TKI resistance in EGFR-mutant NSCLC cells.  
SQSTM1 has been shown to be regulated by the MTOR pathway, which is critical to the 
autophagy pathway [199]. The MTOR pathway was analyzed in order to further emphasize 
the involvement of autophagic processes. Active MTOR is known to suppress autophagy 
[200]. Using the Luminex system, the phosphorylation status of several members of the 
MTOR/AKT pathway was analyzed. In this study, phosphorylation of MTOR was shown to 
be slightly downregulated upon gefitinib treatment. However, after co-culture, p-MTOR was 
slightly upregulated. RPS6KB1, a downstream target of MTOR, was also shown to be 
downregulated after gefitinib treatment. Activated RPS6KB1 has been associated with 
reduced autophagy [201, 202]. However, RPS6KB1 and its substrate RPS6 have been shown 
to promote autophagy [202, 203]. The dual role of RPS6KB1 in autophagy may be the result 
of varied experimental settings, i.e. it has a positive role under nutrient deprivation, but under 
normal conditions and if autophagy is fatal to the cell, it has a negative role on autophagy 
[204]. Activated AKT has also been shown to suppress autophagy [205]. AKT activation 
phosphorylates MTOR, which in turn suppresses the autophagic processes. In this study, p-
AKT was also shown to be downregulated after gefitinib treatment and increased from 
subsequent co-culture. Active TSC2 has also been described to repress MTOR [206]. In 
TSC2-null mouse embryonic fibroblasts (MEFs) reduced autophagy was reported in 
comparison to TSC2- positive controls [207]. In line with the study, in which phosphorylation 
of GSK3A and B were shown to be downregulated in cells with associated increased 
autophagy, Marchand et al. have shown that GSK3 inhibition was able to increase autophagic 
flux [208]. Therefore, in contrast to other reports describing treated resistant tumors with 
autophagy inhibitors, it would be interesting to identify, upon induction of autophagy, the 
impact on drug sensitivity in resistant EGFR active-mutant NSCLC cells. Specific inhibitors 
(BEZ235, PI-103), either alone or in combination with EGFR-TKIs were successfully used to 
target the PI3K/AKT/MTOR pathway in order to sensitize EGFR-TKI resistant HCC827 and 
PC-9 cells [209, 210]. Moreover, MTOR inhibitors, such as temsirolimus and everolimus, 
reduced HGF-induced resistance to gefitinib in HCC827 and PC-9 cells and in-vivo [211].  
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The role of autophagy in resistance to EGFR TKI treatment is still poorly understood, as the 
consequences of autophagy have been shown to be cytoprotective or cytotoxic in different 
studies. Wei et al. have shown evidence of a cytoprotective role of autophagy in EGFR 
mutant lung cancer cells with the inframe deletion of exon 19. In their study, they have shown 
that inactive BECN1 (Beclin 1) leads to autophagy suppression, promotes tumor growth, and 
is resistance to EGFR-TKI-driven therapy. They have shown that activated EGFR inhibits 
autophagy through its binding to BECN1, which leads to its phosphorylation and thus to 
decreased BECN1-associated VPS34 kinase activity by altering its interaction with inhibitors 
such as BCL2 and KIAA0226 (Rubicon). The phosphorylation of BECN1 by activated EGFR 
leads to autophagy suppression and promoted NSCLC growth. The disruption of the EGFR-
BECN1 complex by EGFR-TKI erlotinib in cells with active EGFR mutations resulted in the 
induction of autophagy by enabling the inhibitors to bind to BECN1 [146].  
miR-503-5p moderately reduced GABARAPL1 expression and was predicted to bind hundreds 
of targets. Therefore, siRNAs, which mimic the action of miRNAs, were used against 
GABARAPL1 to specifically silence this gene. The siRNA-mediated knockdown of 
GABARAPL1 was utilized to identify its involvement in autophagic activity. Therefore, 
standard autophagic markers such as LC3B and SQSTM1 were analyzed. As expected, the 
knockdown of GABARAPL1 resulted in the accumulation of SQSTM1, which indicated that 
SQSTM1 was not degraded by autophagy. Since the accumulation of SQSTM1 was also 
observed in resistant HCC827 cells, as GABARAPL1 was increased, these findings indicated 
that autophagic processes were suppressed in those cells. Although LC3B-II was found to be 
increased after GABARAPL1 knockdown, it is possible that LC3B compensates for the 
function of the GABARAP family [148].  
These findings were in line with another report that showed increased oncogenic activity in 
breast cancer cells with decreased GABARAPL1 expression. The knockdown of 
GABARAPL1 resulted in decreased autophagic flux [212]. Moreover, the low expression of 
GABARAPL1 was associated with poor prognosis of hepatocellular carcinoma (HCC). The 
knockdown of GABARAPL1 in HCC induced cell growth [213].  
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4.3 Conclusion and Outlook 
The aim of this study was to analyze miRNAs involved in NSCLC progression. For this, two 
approaches were defined, i.e. to identify circulating miRNAs as prognostic markers in early-
stage lung adenocarcinoma patients, and secondly, and to analyze the role of miRNAs in 
EGFR-TKI therapy resistance.  
In conclusion, circulating miRNAs were analyzed to stratify patients into high-risk and low-
risk patients, according to the progression of the tumor or their overall survival. miR-142-3p 
levels were associated with the prognosis of early-stage lung adenocarcinoma patients. By 
investigating the potential of circulating miRNAs as prognostic markers, pre-analytical 
variables such as blood withdrawal and hemolysis were identified to influence miRNA 
expression levels. Future studies using miRNAs from serum samples should consider these 
pre-analytical variables.  
Moreover, the data presented in this research identified miR-503-5p as regulated in resistant 
NSCLC cells and shown to interact with GABARAPL1. The reduction of GABARAPL1 was 
partially mediated by the overexpression of miR-503-5p. Autophagic activity was deregulated 
in resistant lung adenocarcinoma cells in comparison to cells that were sensitive to gefitinib. 
The siRNA-mediated knockdown of GABARAPL1 resulted in SQSTM1 accumulation, which 
indicated defective autophagy. Further studies on miR-503-5p expression and autophagy 
regulation in EGFR-TKI resistant lung adenocarcinoma patients might enable novel treatment 
options.  
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Supplemental Figure 1 Cytokine analysis of supernatant of PC-9 and HCC827 co-culture with MRC-5 
cells. Each number for each cytokine depicts the bead region. Note, HGF (62) was measured using a single-Plex 
assay. Red dotted line: Background. MFI: mean fluorescent intensities.  
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Supplemental Figure 2 Determination of transfection effiency after transient transfection of miRNA 
mimic molecules. miRIDIAN microRNA Mimics (GE) that targets the 3' UTR of GAPDH were transiently 
transfected at 5-100 nM using HiPerfect (Qiagen) or RNAiMAX (Invitrogen) into HCC827 and analyzed for the 
decrease of target mRNA levels of GAPDH. GAPDH downregulation was determined using UPL based method 
at 48 h post-transfection. GAPDH expression from miRNA mimic GAPDH transfected samples was normalized 
to GAPDH expression from samples transfected with miRNA mimic control#2, which is based on cel-miR-239b 
mature sequence Standard deviation were calculated from 3 experiments.  
 
Supplemental Figure 3 GABARAPL1 expression after siRNA-mediated knockdown of GABARAPL1. 
HCC827 were treated with 4 different siRNAs against GABARAPL1 #6, #7, #8, and #9 for 72 h. 
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Supplemental Figure 4 Expression of SQSTM1 (p62) and GABARAPL1 in resistant HCC827 cells. 
HCC827 cells were cultured with or without gefitinib (0.5 µM) in the presence or absence of HGF cells for 48 h. 
Densitometric analysis of GABARAPL1, SQSTM1, were performed using ImageLab 5.2.1. Protein levels were 
normalized to internal GAPDH levels. Prediceted molecular weight: SQSTM1: 62kDa, GABARAPL1:14 kDa 
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Supplemental Table 1 Cytokine data of PC-9 and HCC827 supernatant 
Cell line PC-9 HCC827  MRC-5 
Analytes 
DMSO 
Ctrl SD 
Gef 
Ctrl SD 
DMSO 
MRC-5 SD 
Gef 
MRC5 SD 
DMSO 
Ctrl SD 
Gef 
Ctrl SD 
DMSO 
MRC5 SD 
Gef 
MRC5 SD MRC-5 SD 
EGF (12) 0.96 1.53 -0.79 0.29 3.13 0.87 3.13 2.29 1.04 0.63 0.63 1.56 2.13 2.38 3.71 2.81 0.79 0.95 
FGF-2 (13) -0.17 0.76 -2.17 1.15 0.17 1.38 0.92 0.95 0.58 0.63 0.17 0.58 1.25 1.39 0.92 0.95 -0.42 0.38 
Eotaxin (14) 13.5 0.5 10.83 1.84 31.08 2.1 31.67 3.75 17.75 2.41 25.75 4.44 56.5 25.12 50.5 6.55 21.5 1.32 
TGF-alpha (15) 73.17 5.19 18.58 0.76 66.25 3.91 19.08 0.58 3.17 1.66 3.08 0.38 5.5 0.66 3.83 1.88 4.08 0.58 
G-CSF (18) 1.96 1.18 2.79 1.01 6.54 1.46 9.13 4.67 7.63 1.15 3.96 1.18 21.21 20.52 10.29 5.26 2.29 0.38 
Flt-3L (19) 0.79 0.76 1.46 1.04 3.29 0.76 3.21 1.13 3.13 1.39 4.79 1.04 8.54 1.01 7.71 1.28 4.88 1.09 
GM-CSF (20) 76.5 4.13 31.25 2.7 95.42 12.01 66.83 4.4 46.58 4.11 371.33 34.27 897.08 80.09 523.75 54.47 771.83 27.96 
Fractalkine (21) 4.21 2.08 3.54 0.29 11.04 1.15 10.46 0.63 10.63 1.15 17.46 0.88 24.38 4.09 27.21 3.51 16.79 0.38 
IFN-alpha2 (22) 3.67 1.44 2.75 0.25 8.25 1.75 8.08 2.53 5.67 1.77 9 0.9 14.25 2.63 15.08 4.16 8.42 1.66 
IFNgamma (25) 3.83 0.63 2.67 1.59 9 2.61 8.17 2.04 6.83 0.63 8.5 1.52 11 1.3 10.75 0.66 6.83 0.72 
GRO (26) 9.79 0.38 12.46 2.32 133.79 54.21 217.04 102.4 9.63 0.25 3892.54 220.26 3717.71 1319.19 4871.96 438.44 2296.71 487.33 
IL-10 (27) -0.79 0.38 -0.29 0.58 -0.54 0.95 1.04 0.14 0.21 0.95 0.71 0.72 1.04 0.29 1.46 0.52 -0.71 0.14 
MCP-3 (28) -1.67 0.76 -1.83 1.01 32.92 8.82 50 24.58 11.25 0.66 -0.5 1.15 21.75 17.03 24.42 4.14 -1 1.75 
IL-12P40 (29) 0.33 0.38 -0.5 1.32 0.42 0.14 0.42 0.63 1.42 0.52 -0.75 0.43 3 0.87 1.75 1.39 0.25 0.25 
MDC (30) 2.42 0.76 0.83 0.72 6.92 1.66 2.25 0.5 0.42 0.76 -0.67 1.13 0.08 0.29 -0.42 0.29 -1.75 1 
IL-12P70 (33) 0.25 1 -0.17 2.13 1.92 0.76 1.33 0.8 3.25 1 1 0.9 1.83 0.52 2.58 1.04 1.08 0.58 
PDGF-AA (34) 324.92 6.17 121.75 6.29 356.42 20.44 204.42 5.38 75.92 2.24 255.17 7.59 587.67 77.84 354.5 30.81 539.25 22.64 
IL-13 (35) -1.67 0.95 -1.33 0.52 0.08 1.01 1.83 1.26 0.92 0.38 0.5 1.39 0.92 0.72 1.92 1.01 -0.58 1.01 
PDGF-BB (36) 6.75 5.43 9.33 1.7 8.58 1.76 10.25 0.87 0.67 0.14 8.58 0.58 5.92 1.76 10.25 0.9 2.5 0.75 
IL-15 (37) 11.75 0.66 10.75 0.75 17.08 3.09 17.42 0.95 22.83 2.47 14.33 1.18 23.42 3.76 21.42 1.88 19.17 1.15 
sCD40L (38) 0.75 1.56 2.17 1.7 1.25 0.87 0.75 1 0.08 1.53 0.83 1.01 1.42 1.53 2.92 0.76 0.25 0.5 
IL-17A (39) -1.67 0.38 -1.58 0.29 0.25 2.18 -0.25 0.5 -1.58 0.29 -0.92 1.26 -0.42 0.76 0.83 0.52 -1.33 0.8 
IL-1RA (42) 0.54 1.01 1.13 1.56 4.96 1.01 4.88 0.9 5.38 0.87 3.96 3.19 6.79 0.88 6.13 0.66 2.46 0.14 
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IL-1alpha (44) 1.29 0.76 2.13 4.82 3.88 3.25 0.88 1.75 8.54 13.96 5.21 0.8 9.21 6.28 8.79 2.02 4.96 2.25 
IL-9 (45) -0.08 0.38 -1.67 1.23 0.33 0.72 0.17 1.23 0 0.9 0.17 0.63 1.92 1.15 0.92 0.29 0.5 0.25 
IL-1beta (46) -0.92 0.52 0.08 0.95 1.17 2.57 0.42 0.52 6.25 9.31 0.83 1.15 1 0.5 1.5 1 -0.33 1.61 
IL-2 (48) -1.13 0.75 -1.46 0.29 0.38 1.09 1.29 0.72 0.79 1.59 -0.79 0.76 0.88 1.8 0.88 0.9 -0.13 1.56 
IL-3 (51) 0 0.25 0.25 0.25 1.75 0.87 1.17 1.15 1.83 2.13 0.83 0.14 1.58 0.76 1.42 1.61 0.67 0.8 
IL-4 (53) -0.17 0.8 -0.58 0.52 -0.42 2.36 1.42 0.29 0.92 0.76 -0.92 1.26 1 1.64 0.5 1.15 -1.17 1.01 
IL-5 (55) 1.5 0.5 0.33 0.29 2.75 1.09 2.08 1.63 0.75 0.43 0.42 1.04 1.08 0.52 1.5 2 0.33 0.76 
IL6 (57) 133.83 1.66 464.08 19.84 1638.42 180.17 1747.83 252.08 1671.25 107.48 3701.83 139.95 5095.17 599.05 6784.58 367.25 1950.67 74.6 
IL-7 (61) 17.83 1.59 17.33 1.28 31.67 2.31 35.25 8.13 24.92 0.76 28.92 4.29 43.25 9.96 49.67 4.01 26.08 2.13 
IL8 (63) 4816.58 180.71 3688.58 141.47 9240.92 445.66 9612.08 1279.01 6451.83 512.58 8165.92 255.78 13287.83 2563.86 13170.33 841.89 7744.5 534.58 
CXCR3 (65) -1.25 0.87 0.83 0.38 77.58 6.53 90.33 7.48 1.58 1.18 412.67 48.05 495.17 294.17 1055.42 162.13 16.75 6.43 
CCL2 (67) 0.67 0.76 0.17 0.63 23126.75 478.25 23460.5 536.85 24377.5 73.98 5726.25 333.98 23411.58 622.29 23836.08 196.47 2145 54.06 
MIP-1alpha (72) 2.54 2.5 -2.04 1.89 1.04 4.42 2.46 3.01 3.88 3.7 1.63 0.75 6.38 10.83 -0.21 4.01 -1.88 2.5 
MIP-1beta (73) -1.08 0.76 -1 0.9 0.83 0.52 2.08 1.04 0.67 0.38 -0.08 0.58 0.58 1.44 0.58 0.76 0.25 0.5 
RANTES (74) -0.5 0.5 0.5 1.15 0.17 0.76 -0.17 1.15 -0.08 1.91 9 1.73 1.67 2.47 4.67 1.89 2.58 0.8 
TNFalpha (75) 10.75 0.9 20.67 0.76 10.83 1.15 11.08 1.38 1.42 0.58 45.83 7.78 23.75 1.15 39.5 3.5 22.33 2.02 
TNFbeta (76) 0.21 0.38 -0.63 1.75 0.13 1 0.79 1.26 0.13 0.9 0.63 0.66 0.88 0.25 1.79 0.58 -1.79 0.38 
VEGF (78) 54.17 4.4 5 0 146.58 16.55 45 6.38 6 1.52 24 0.75 664.17 135.55 107.08 15.88 473.58 27.55 
HGF (62) -68 1.8 -59.5 19.7 1048.5 92.99 1220 178.28 -25.3 23.69 -20.8 0.35 2769.8 127.63 3344.3 66.11 3830.3 58.34 
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Supplemental Table 2: miRNA comparison: HCC +/+ vs HCC +/- 
miRNA_ID p-value q-value Fold change Median Cp 
hsa-miR-205 2.50E-02 3.63E-01 0.42 32.50 
hsa-miR-181a-2* 2.56E-02 3.63E-01 0.46 31.67 
hsa-miR-181b 6.01E-04 9.69E-02 0.47 29.44 
hsa-miR-24-1* 4.474E-02 4.57E-01 0.50 35.23 
hsa-miR-26a 1.94E-03 1.49E-01 0.50 28.37 
hsa-miR-181a 2.91E-03 1.50E-01 0.52 27.03 
hsa-miR-196a 4.40E-03 1.70E-01 0.56 30.78 
hsa-miR-125a-3p 4.23E-02 4.57E-01 0.56 33.37 
hsa-miR-30e 1.93E-03 1.49E-01 0.58 31.39 
hsa-miR-181a* 6.63E-04 9.69E-02 0.60 33.04 
hsa-miR-27b 1.13E-03 1.25E-01 0.62 26.98 
hsa-miR-215 4.40E-02 4.57E-01 0.63 34.31 
hsa-miR-181c 3.67E-02 4.13E-01 0.63 35.04 
hsa-miR-34c-5p 2.88E-02 3.77E-01 0.63 29.27 
hsa-miR-34a 2.55E-02 3.63E-01 0.63 27.84 
hsa-let-7b 4.66E-03 1.70E-01 0.64 27.56 
hsa-miR-200b 2.04E-03 1.49E-01 0.64 28.83 
hsa-miR-720 1.49E-02 3.07E-01 0.66 24.50 
hsa-let-7f 6.49E-03 1.82E-01 0.66 27.61 
hsa-miR-29b 6.39E-03 1.82E-01 1.53 28.19 
hsa-miR-18a 3.27E-03 1.50E-01 1.60 28.91 
hsa-miR-130b 3.76E-02 4.17E-01 1.67 33.03 
hsa-miR-877 9.35E-03 2.21E-01 1.69 33.19 
hsa-miR-886-5p 3.29E-03 1.50E-01 1.74 29.31 
hsa-miR-503 9.19E-03 2.21E-01 2.02 28.56 
hsa-miR-1296 1.72E-02 3.24E-01 2.05 34.60 
hsa-miR-222* 9.03E-03 2.21E-01 2.34 33.86 
hsa-let-7a-2* 6.39E-03 1.82E-01 2.46 32.07 
hsa-miR-1979 4.67E-04 9.69E-02 2.49 23.36 
hsa-miR-941 1.75E-02 3.24E-01 2.51 33.20 
hsa-miR-29b-1* 2.79E-03 1.50E-01 2.66 30.98 
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Supplemental Table 3: miRNA comparison: HCC +/- vs HCC -/- 
miRNA_ID p-value q-value Fold change Median Cp 
hsa-miR-490-3p 1.43E-02 1.68E-01 0.23 35.72 
hsa-miR-100* 1.40E-04 2.54E-02 0.30 35.97 
hsa-let-7a-2* 4.87E-04 3.90E-02 0.32 32.07 
hsa-miR-222* 1.47E-02 1.68E-01 0.34 33.86 
hsa-miR-1539 3.19E-02 2.85E-01 0.43 34.04 
hsa-miR-30b* 1.95E-02 2.09E-01 0.43 33.90 
hsa-miR-1979 1.44E-03 6.60E-02 0.45 23.36 
hsa-miR-503 1.11E-02 1.45E-01 0.49 28.56 
hsa-miR-886-5p 1.22E-02 1.54E-01 0.51 29.31 
hsa-miR-542-5p 4.11E-02 3.26E-01 0.51 33.03 
hsa-miR-29b-1* 3.38E-02 2.90E-01 0.54 30.98 
hsa-miR-450b-3p 5.79E-03 1.03E-01 0.54 35.04 
hsa-miR-210 4.49E-03 1.02E-01 0.60 28.08 
hsa-miR-130b 1.54E-02 1.73E-01 0.61 33.03 
hsa-miR-18a 4.27E-03 1.02E-01 0.61 28.91 
hsa-miR-141 5.74E-04 3.90E-02 1.53 25.43 
hsa-miR-182 1.88E-03 6.60E-02 1.55 28.46 
hsa-miR-125a-3p 1.27E-02 1.55E-01 1.59 33.37 
hsa-miR-200b 2.31E-03 7.34E-02 1.59 28.83 
hsa-miR-720 5.78E-03 1.03E-01 1.63 24.50 
hsa-miR-93* 4.21E-02 3.31E-01 1.66 31.42 
hsa-miR-34b* 5.62E-03 1.03E-01 1.68 30.38 
hsa-miR-34a 1.67E-02 1.85E-01 1.70 27.84 
hsa-miR-34c-3p 1.14E-03 5.96E-02 1.84 32.41 
hsa-miR-28-3p 9.80E-03 1.30E-01 1.88 30.45 
hsa-miR-940 5.91E-03 1.03E-01 1.92 28.64 
hsa-miR-10a 1.45E-03 6.60E-02 1.95 33.75 
hsa-miR-147b 5.27E-03 1.03E-01 2.06 33.18 
hsa-miR-431 7.91E-03 1.20E-01 2.17 33.99 
hsa-miR-26a 5.87E-04 3.90E-02 2.19 28.37 
hsa-miR-181a* 5.28E-03 1.03E-01 2.23 33.04 
hsa-miR-146a 7.46E-03 1.19E-01 2.52 34.32 
hsa-miR-181a 2.82E-04 2.95E-02 2.55 27.03 
hsa-miR-181b 1.97E-05 1.44E-02 2.56 29.44 
hsa-miR-663 4.12E-03 1.02E-01 2.57 31.66 
hsa-miR-34a* 1.40E-02 1.68E-01 2.88 32.94 
hsa-miR-328 3.70E-03 1.00E-01 3.03 34.71 
hsa-miR-181a-2* 2.66E-02 2.61E-01 3.53 31.67 
hsa-miR-24-1* 6.81E-03 1.13E-01 3.86 35.23 
hsa-miR-205 2.55E-02 2.58E-01 4.06 32.50 
hsa-miR-665 9.39E-03 1.27E-01 4.13 31.60 
hsa-miR-373* 3.24E-02 2.85E-01 5.95 35.40 
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Supplemental Table 4: miRNA comparison: HCC +/+ vs HCC -/+ 
miRNA ID p-value q-value Fold change Median Cp 
hsa-miR-126 3.88E-03 2.70E-01 0.41 33.57 
hsa-miR-25* 4.22E-02 5.10E-01 0.61 34.04 
hsa-miR-181a 1.30E-02 3.30E-01 1.51 27.03 
hsa-miR-361-3p 2.61E-02 4.18E-01 1.59 33.51 
hsa-miR-34a 1.75E-02 3.82E-01 1.59 27.84 
hsa-miR-495 1.17E-02 3.26E-01 1.61 34.55 
hsa-miR-181a* 1.38E-03 1.87E-01 1.70 33.04 
hsa-miR-663 4.58E-02 5.22E-01 1.89 31.66 
hsa-miR-200b* 7.57E-03 3.00E-01 2.12 33.65 
hsa-miR-1237 2.89E-02 4.23E-01 2.14 34.26 
hsa-miR-940 2.01E-03 1.87E-01 2.32 28.64 
 
Supplemental Table 5: miRNA comparison: HCC -/+ vs HCC -/- 
miRNA ID p-value q-value Fold change Median Cp 
hsa-miR-490-3p 1.23E-03 8.53E-02 0.15 35.72 
hsa-miR-30c-1* 1.40E-02 3.74E-01 0.40 35.69 
hsa-miR-891b 4.72E-02 5.30E-01 1.71 33.77 
 
Supplemental Table 6: mRNA comparison: +/+ vs +/- 
  HCC827 PC-9 
Probe Id ILMN_Gene FC pVal qVal FC pVal qVal 
Downregulated 
ILMN_1738578 FILIP1L 0.22 2.95E-05 5.83E-03 0.55 1.10E-03 1.02E-01 
ILMN_1730906 FILIP1L 0.23 2.76E-05 5.83E-03 0.56 1.14E-03 1.03E-01 
ILMN_1761425 OLFML2A 0.25 3.62E-05 5.95E-03 0.63 2.37E-03 1.26E-01 
ILMN_2391150 FILIP1L 0.27 9.47E-05 8.46E-03 0.53 1.20E-03 1.03E-01 
ILMN_1810420 DYSF 0.27 1.22E-06 3.15E-03 0.51 9.45E-04 9.88E-02 
ILMN_2368530 IL32 0.28 6.31E-05 7.22E-03 0.38 1.90E-05 5.49E-02 
ILMN_1682775 EDN1 0.28 2.20E-05 5.61E-03 1.58 5.79E-03 1.72E-01 
ILMN_3307729 CXXC5 0.28 1.65E-04 1.07E-02 0.66 7.87E-03 1.91E-01 
ILMN_1732296 ID3 0.28 7.23E-05 7.62E-03 0.30 1.25E-07 6.03E-03 
ILMN_2121408 HBEGF 0.29 7.20E-05 7.62E-03 2.17 1.11E-03 1.02E-01 
ILMN_1810836 PDE5A 0.32 3.77E-05 6.07E-03 0.63 6.14E-05 6.57E-02 
ILMN_1778010 IL32 0.34 1.11E-04 9.01E-03 0.59 1.06E-02 2.15E-01 
ILMN_2235851 LINCR 0.34 1.19E-04 9.27E-03 0.50 1.20E-04 6.80E-02 
ILMN_2388547 EPSTI1 0.36 1.16E-04 9.16E-03 0.62 3.43E-04 7.91E-02 
ILMN_1719986 PIK3IP1 0.36 5.81E-05 7.02E-03 0.60 1.57E-03 1.09E-01 
ILMN_1815745 SOX4 0.36 4.74E-04 1.75E-02 0.61 1.36E-03 1.06E-01 
ILMN_1744381 SERPINE1 0.37 8.49E-05 8.03E-03 0.48 2.29E-04 7.75E-02 
ILMN_2376723 CDKN2B 0.37 3.03E-05 5.83E-03 0.54 6.66E-03 1.81E-01 
ILMN_1806733 COL18A1 0.40 5.37E-06 3.94E-03 0.66 2.05E-05 5.49E-02 
ILMN_1678671 KLHL24 0.40 4.70E-04 1.75E-02 0.63 6.11E-03 1.76E-01 
ILMN_1663080 LFNG 0.41 3.55E-05 5.94E-03 0.55 9.91E-03 2.09E-01 
ILMN_1806667 FRAS1 0.41 9.82E-06 4.50E-03 0.54 3.82E-04 8.06E-02 
ILMN_1705144 ULK1 0.41 8.92E-05 8.19E-03 0.54 1.90E-04 7.47E-02 
ILMN_1744949 RHOBTB3 0.41 1.79E-03 3.45E-02 0.58 3.42E-05 6.26E-02 
ILMN_2371055 EFNA1 0.42 2.19E-05 5.61E-03 0.57 1.34E-05 5.30E-02 
ILMN_1654696 C15ORF48 0.42 9.24E-04 2.40E-02 0.59 2.09E-03 1.20E-01 
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ILMN_1690040 TM7SF2 0.43 3.35E-05 5.91E-03 0.62 2.29E-03 1.24E-01 
ILMN_1735052 ULK1 0.44 5.35E-05 6.83E-03 0.58 1.04E-03 1.02E-01 
ILMN_1732071 HIST2H2BE 0.44 4.57E-04 1.73E-02 0.56 1.58E-03 1.09E-01 
ILMN_1723198 CDKN2B 0.45 1.56E-03 3.21E-02 0.52 1.48E-04 7.00E-02 
ILMN_1730670 FSTL3 0.45 4.39E-04 1.69E-02 0.65 3.76E-03 1.46E-01 
ILMN_3307693 WFDC2 0.45 8.67E-06 4.44E-03 1.58 1.17E-03 1.03E-01 
ILMN_1699631 GATS 0.46 9.91E-06 4.50E-03 0.65 5.68E-03 1.70E-01 
ILMN_1721876 TIMP2 0.46 3.38E-04 1.51E-02 0.65 1.04E-03 1.02E-01 
ILMN_2201678 FSTL1 0.46 1.43E-04 1.02E-02 0.61 1.16E-02 2.22E-01 
ILMN_1711069 YPEL5 0.47 1.11E-03 2.63E-02 0.63 4.09E-03 1.52E-01 
ILMN_2151281 GABARAPL1 0.47 2.21E-03 3.85E-02 0.58 3.06E-04 7.86E-02 
ILMN_1704154 TNFRSF19 0.47 3.18E-04 1.47E-02 0.67 3.45E-03 1.43E-01 
ILMN_1762561 PLA2G10 0.47 3.22E-05 5.83E-03 0.49 1.63E-04 7.15E-02 
ILMN_2391861 GSTM1 0.47 4.90E-04 1.79E-02 0.59 1.60E-03 1.10E-01 
ILMN_1792689 HIST1H2AC 0.47 7.10E-04 2.12E-02 0.63 9.11E-03 2.03E-01 
ILMN_1721626 ARID5B 0.48 3.80E-04 1.60E-02 0.57 2.39E-03 1.26E-01 
ILMN_1654398 RGL1 0.48 3.24E-04 1.48E-02 0.63 8.44E-04 9.76E-02 
ILMN_2144426 HIST2H2AA3 0.50 2.34E-03 3.99E-02 0.57 2.08E-03 1.20E-01 
ILMN_1691410 BAMBI 0.50 7.29E-05 7.62E-03 0.65 7.10E-04 9.31E-02 
ILMN_1666845 KRT17 0.50 6.10E-04 1.97E-02 0.64 5.66E-04 8.92E-02 
ILMN_1694432 CRIP2 0.50 5.00E-04 1.81E-02 0.54 7.48E-05 6.57E-02 
ILMN_1778668 TAGLN 0.51 3.84E-04 1.61E-02 0.63 2.21E-03 1.23E-01 
ILMN_1672605 C7ORF41 0.51 6.00E-04 1.95E-02 0.62 1.68E-03 1.11E-01 
ILMN_1791280 HSPB8 0.51 1.40E-03 3.02E-02 0.58 1.98E-02 2.74E-01 
ILMN_1657111 C14ORF78 0.52 3.25E-04 1.48E-02 0.42 2.50E-04 7.84E-02 
ILMN_1737561 LOC88523 0.53 5.65E-05 6.97E-03 0.64 1.87E-04 7.47E-02 
ILMN_1740772 APBB3 0.53 7.20E-05 7.62E-03 0.66 1.50E-03 1.08E-01 
ILMN_3243156 AHNAK2 0.54 5.73E-05 6.99E-03 0.46 1.37E-03 1.06E-01 
ILMN_1691884 STC2 0.54 1.98E-05 5.61E-03 1.52 5.15E-04 8.69E-02 
ILMN_1676213 SRPX2 0.55 2.46E-04 1.31E-02 1.60 1.43E-03 1.07E-01 
ILMN_1667295 VASN 0.55 3.19E-03 4.79E-02 0.65 7.26E-03 1.86E-01 
ILMN_1717326 SLC29A3 0.56 1.09E-03 2.62E-02 0.48 1.38E-04 6.90E-02 
ILMN_1778136 ZMYND15 0.56 2.05E-04 1.20E-02 0.66 1.22E-03 1.03E-01 
ILMN_1706531 ABCC5 0.56 1.36E-03 2.96E-02 0.58 1.04E-02 2.14E-01 
ILMN_1759792 CLIP4 0.56 6.30E-03 7.15E-02 0.60 1.46E-03 1.08E-01 
ILMN_2306189 MAGED1 0.57 7.77E-04 2.20E-02 0.62 2.39E-03 1.26E-01 
ILMN_1659047 HIST2H2AA3 0.57 1.10E-03 2.62E-02 0.53 1.09E-03 1.02E-01 
ILMN_1703335 LACTB 0.57 3.12E-03 4.73E-02 0.65 6.38E-03 1.78E-01 
ILMN_1800412 BMP1 0.58 1.11E-03 2.62E-02 0.65 5.98E-03 1.74E-01 
ILMN_2315979 LBH 0.58 1.76E-03 3.44E-02 0.46 6.13E-05 6.57E-02 
ILMN_2371458 CXCR7 0.58 3.89E-03 5.37E-02 0.63 4.69E-04 8.48E-02 
ILMN_2192072 MMP7 0.59 2.21E-03 3.85E-02 1.78 4.76E-04 8.48E-02 
ILMN_1739428 IFIT2 0.60 7.19E-03 7.77E-02 0.55 6.69E-03 1.81E-01 
ILMN_1709683 RASSF2 0.60 7.56E-03 8.04E-02 0.56 1.81E-04 7.42E-02 
ILMN_1685415 HBP1 0.60 5.84E-03 6.85E-02 0.61 2.24E-04 7.73E-02 
ILMN_1791147 YPEL3 0.60 5.69E-04 1.92E-02 0.62 2.13E-03 1.21E-01 
ILMN_2160764 HBP1 0.60 3.32E-03 4.90E-02 0.62 5.11E-03 1.65E-01 
ILMN_1720865 OSBPL7 0.60 5.15E-04 1.84E-02 0.54 7.04E-05 6.57E-02 
ILMN_2165354 DCLK1 0.61 1.09E-03 2.61E-02 0.63 1.02E-03 1.02E-01 
ILMN_1811574 MAPK8IP3 0.61 7.31E-04 2.14E-02 0.58 3.17E-03 1.39E-01 
ILMN_1812721 LOC728014 0.61 2.53E-04 1.32E-02 0.60 6.54E-04 9.21E-02 
ILMN_1710209 MFSD6 0.62 9.47E-03 9.21E-02 0.64 1.44E-03 1.07E-01 
ILMN_1757406 HIST1H1C 0.62 2.35E-03 3.99E-02 0.55 1.90E-04 7.47E-02 
ILMN_3242900 HIST2H2AA4 0.62 1.13E-02 1.03E-01 0.52 8.37E-04 9.76E-02 
ILMN_1651496 HIST1H2BD 0.63 1.62E-03 3.28E-02 0.56 2.97E-03 1.36E-01 
ILMN_1800540 CD55 0.63 1.54E-02 1.25E-01 0.56 5.52E-04 8.77E-02 
ILMN_2115218 ANKRD10 0.63 2.60E-04 1.34E-02 0.63 7.26E-05 6.57E-02 
ILMN_2384745 PSG4 0.63 1.27E-03 2.87E-02 0.65 5.89E-04 8.92E-02 
ILMN_1781386 WIPI1 0.63 1.79E-04 1.13E-02 0.61 5.80E-03 1.72E-01 
ILMN_2371053 EFNA1 0.63 5.63E-04 1.91E-02 0.60 9.57E-06 5.30E-02 
ILMN_1744937 PTPRM 0.64 1.52E-04 1.04E-02 0.66 1.63E-04 7.15E-02 
ILMN_1685403 MMP7 0.64 5.32E-04 1.86E-02 1.51 4.16E-03 1.53E-01 
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ILMN_1801043 GSN 0.64 1.90E-03 3.57E-02 0.64 6.77E-03 1.82E-01 
ILMN_1758719 NEDD9 0.64 1.91E-03 3.57E-02 0.62 9.64E-03 2.06E-01 
ILMN_2184373 IL8 0.64 5.05E-04 1.82E-02 3.52 8.35E-06 5.30E-02 
ILMN_1657760 SYT17 0.64 1.28E-03 2.88E-02 0.64 7.86E-03 1.91E-01 
ILMN_1781285 DUSP1 0.64 2.92E-04 1.41E-02 1.69 2.47E-03 1.27E-01 
ILMN_1810729 UBL3 0.65 9.50E-04 2.44E-02 0.60 4.20E-03 1.54E-01 
ILMN_1763144 NEU1 0.66 1.64E-03 3.31E-02 0.67 8.99E-04 9.84E-02 
ILMN_1682599 GPRC5A 0.66 4.75E-03 6.08E-02 0.52 2.88E-03 1.34E-01 
ILMN_1654262 ZMAT3 0.66 3.47E-02 2.04E-01 0.66 8.56E-04 9.76E-02 
ILMN_1804938 GPR175 0.66 1.85E-03 3.52E-02 0.58 3.21E-03 1.39E-01 
ILMN_1764201 MAP2 0.66 2.45E-03 4.08E-02 0.64 3.64E-05 6.26E-02 
ILMN_1810275 SLC7A7 0.66 1.42E-04 1.01E-02 0.47 2.03E-03 1.19E-01 
ILMN_2376859 PDGFD 0.66 2.65E-03 4.28E-02 0.65 1.36E-02 2.35E-01 
 
Upregulated 
 
ILMN_1804277 SPRED1 1.50 1.36E-02 1.15E-01 2.05 1.16E-05 5.30E-02 
ILMN_3307841 AGR2 1.53 5.57E-04 1.90E-02 2.27 6.86E-04 9.31E-02 
ILMN_1682799 STAMBPL1 1.53 4.26E-04 1.67E-02 1.60 3.85E-03 1.47E-01 
ILMN_1708936 EXOSC3 1.54 4.35E-04 1.69E-02 1.61 1.59E-03 1.10E-01 
ILMN_1795930 PTGER4 1.54 9.69E-05 8.50E-03 1.58 2.18E-04 7.73E-02 
ILMN_1672662 SLC20A1 1.54 1.10E-02 1.01E-01 1.80 1.62E-03 1.10E-01 
ILMN_1815169 MCM5 1.55 1.23E-03 2.82E-02 1.63 8.92E-04 9.84E-02 
ILMN_2143795 MGC4677 1.56 4.59E-04 1.73E-02 1.71 5.00E-04 8.61E-02 
ILMN_1782488 RNASEH2B 1.58 4.91E-04 1.79E-02 1.55 3.98E-05 6.38E-02 
ILMN_1736940 HPRT1 1.58 4.61E-03 5.96E-02 1.60 1.22E-02 2.26E-01 
ILMN_1658607 DLEU2 1.59 7.58E-03 8.05E-02 1.54 9.10E-03 2.03E-01 
ILMN_2056975 HPRT1 1.60 5.07E-05 6.71E-03 1.69 3.98E-04 8.12E-02 
ILMN_1663575 MGC87042 1.60 4.41E-04 1.70E-02 1.89 4.58E-04 8.48E-02 
ILMN_1791002 SKP2 1.60 9.27E-04 2.41E-02 1.58 8.25E-04 9.73E-02 
ILMN_1674706 MTHFD2 1.62 4.03E-04 1.64E-02 1.57 2.76E-03 1.32E-01 
ILMN_2224143 MCM3 1.63 6.76E-04 2.07E-02 1.51 6.45E-03 1.79E-01 
ILMN_1653856 STS-1 1.63 6.22E-05 7.21E-03 2.10 2.88E-04 7.86E-02 
ILMN_1798654 MCM6 1.63 1.63E-03 3.30E-02 1.84 9.22E-04 9.85E-02 
ILMN_1721901 CTNNAL1 1.63 1.64E-02 1.30E-01 1.68 8.11E-04 9.73E-02 
ILMN_2371700 UCHL5IP 1.64 1.88E-03 3.56E-02 1.60 9.51E-04 9.89E-02 
ILMN_1669523 FOS 1.65 4.70E-04 1.75E-02 4.89 1.66E-05 5.49E-02 
ILMN_2359287 ITGA6 1.65 1.49E-03 3.14E-02 1.76 5.17E-03 1.65E-01 
ILMN_2053415 LDLR 1.66 2.61E-05 5.70E-03 1.70 9.49E-04 9.89E-02 
ILMN_2048700 ATAD2 1.66 5.29E-03 6.46E-02 1.64 3.10E-04 7.86E-02 
ILMN_2044832 NOP56 1.68 6.60E-06 4.29E-03 1.57 2.64E-04 7.86E-02 
ILMN_1679267 TGM2 1.69 1.04E-03 2.57E-02 1.66 3.44E-04 7.91E-02 
ILMN_2396020 DUSP6 1.70 6.55E-05 7.27E-03 1.79 5.33E-04 8.73E-02 
ILMN_2364384 PPARG 1.70 3.43E-04 1.51E-02 1.61 2.77E-03 1.32E-01 
ILMN_1776577 DSCC1 1.71 2.17E-03 3.81E-02 1.59 8.80E-03 1.99E-01 
ILMN_1791232 SPRED2 1.72 1.66E-06 3.15E-03 1.64 3.09E-03 1.39E-01 
ILMN_3253579 HAUS8 1.72 9.40E-05 8.46E-03 1.51 1.72E-02 2.59E-01 
ILMN_1796074 C18ORF56 1.72 4.56E-04 1.73E-02 1.63 5.87E-03 1.73E-01 
ILMN_2338038 AK3L1 1.73 1.23E-04 9.42E-03 1.71 1.96E-03 1.17E-01 
ILMN_1779711 DTL 1.73 2.42E-03 4.06E-02 1.60 8.75E-03 1.99E-01 
ILMN_1699354 EPHA2 1.74 1.84E-03 3.51E-02 2.41 2.75E-04 7.86E-02 
ILMN_2108357 RPL39L 1.78 4.21E-03 5.65E-02 1.51 3.02E-03 1.37E-01 
ILMN_1778890 PPIL5 1.79 3.36E-04 1.51E-02 1.51 1.83E-02 2.67E-01 
ILMN_1809931 NDRG1 1.81 1.30E-04 9.73E-03 0.52 5.40E-04 8.73E-02 
ILMN_1736441 PDXP 1.82 1.44E-05 5.01E-03 1.51 1.03E-02 2.13E-01 
ILMN_1790537 C16ORF75 1.82 8.10E-04 2.24E-02 1.64 1.29E-03 1.04E-01 
ILMN_1754272 GINS3 1.83 3.87E-04 1.62E-02 1.74 1.41E-03 1.07E-01 
ILMN_1755834 FEN1 1.85 2.28E-05 5.61E-03 1.65 7.36E-03 1.86E-01 
ILMN_1814282 ISG20L1 1.85 1.48E-03 3.13E-02 1.81 6.24E-05 6.57E-02 
ILMN_2155172 BRIX1 1.85 2.33E-04 1.28E-02 1.66 7.16E-04 9.31E-02 
ILMN_1721833 IER5 1.89 4.95E-04 1.80E-02 1.61 9.86E-05 6.80E-02 
ILMN_1674231 CHAF1B 1.92 6.89E-06 4.30E-03 1.56 5.57E-03 1.70E-01 
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ILMN_1681503 MCM2 1.93 3.94E-05 6.17E-03 1.51 3.26E-03 1.40E-01 
ILMN_2362545 ZWINT 1.93 1.56E-03 3.22E-02 1.50 1.26E-02 2.28E-01 
ILMN_1712413 RPL39L 1.93 1.81E-03 3.47E-02 1.55 2.37E-03 1.26E-01 
ILMN_1794501 HAS3 1.93 2.04E-05 5.61E-03 1.55 3.38E-04 7.91E-02 
ILMN_2157240 MNS1 1.94 3.87E-04 1.62E-02 1.58 7.40E-03 1.86E-01 
ILMN_1658027 RAD54L 1.94 7.55E-06 4.30E-03 1.58 3.20E-03 1.39E-01 
ILMN_1716445 LOC727761 1.96 1.28E-03 2.87E-02 1.52 7.85E-03 1.91E-01 
ILMN_2413898 MCM10 1.97 2.29E-03 3.92E-02 2.03 4.25E-04 8.38E-02 
ILMN_2412384 CCNE2 1.97 2.20E-04 1.25E-02 1.71 1.38E-03 1.06E-01 
ILMN_2146761 FABP5 1.98 1.97E-05 5.61E-03 1.55 5.85E-04 8.92E-02 
ILMN_1724040 ANKRD57 2.00 4.35E-04 1.69E-02 1.58 7.61E-04 9.37E-02 
ILMN_1665510 ERRFI1 2.01 1.97E-04 1.18E-02 1.99 1.23E-04 6.80E-02 
ILMN_1711005 CDC25A 2.01 1.16E-04 9.16E-03 1.76 4.09E-04 8.19E-02 
ILMN_1668814 CENPM 2.02 6.36E-04 2.01E-02 1.66 4.84E-03 1.63E-01 
ILMN_1683120 UNG 2.03 4.82E-05 6.50E-03 1.61 5.25E-03 1.67E-01 
ILMN_1800225 PPARG 2.06 2.32E-04 1.28E-02 1.67 3.06E-04 7.86E-02 
ILMN_1738027 BRCA1 2.06 1.40E-03 3.03E-02 1.50 9.74E-04 1.00E-01 
ILMN_3266606 FABP5L2 2.06 9.33E-06 4.50E-03 1.65 8.57E-03 1.99E-01 
ILMN_2311089 BRCA1 2.07 4.53E-06 3.93E-03 1.57 3.41E-03 1.42E-01 
ILMN_2370365 RFC4 2.07 3.05E-04 1.44E-02 1.56 5.32E-03 1.67E-01 
ILMN_2160929 FEN1 2.11 2.71E-05 5.83E-03 1.80 6.31E-04 9.07E-02 
ILMN_2148796 MND1 2.12 8.30E-04 2.27E-02 1.76 2.60E-03 1.30E-01 
ILMN_1788462 AMD1 2.16 1.65E-03 3.32E-02 1.51 4.85E-03 1.63E-01 
ILMN_1694502 PRIM1 2.19 9.79E-05 8.54E-03 1.60 4.18E-04 8.33E-02 
ILMN_3176989 HAUS8 2.20 3.49E-06 3.57E-03 1.51 8.79E-04 9.77E-02 
ILMN_3298716 LOC729231 2.22 1.25E-05 4.85E-03 1.97 3.99E-03 1.50E-01 
ILMN_2043918 DLEU1 2.22 8.08E-05 7.93E-03 1.50 2.77E-03 1.32E-01 
ILMN_1737184 CDCA7 2.23 1.98E-03 3.64E-02 2.45 2.69E-04 7.86E-02 
ILMN_2235137 FANCD2 2.23 3.90E-04 1.62E-02 1.58 2.31E-03 1.24E-01 
ILMN_1774336 POLE2 2.24 4.11E-04 1.66E-02 1.67 1.10E-03 1.02E-01 
ILMN_1790100 C11ORF82 2.25 5.25E-04 1.84E-02 1.62 8.10E-03 1.94E-01 
ILMN_1731184 MELK 2.26 1.56E-03 3.22E-02 1.60 1.13E-02 2.20E-01 
ILMN_1704418 FOXD1 2.26 3.35E-05 5.91E-03 1.61 2.03E-02 2.76E-01 
ILMN_3203196 LOC100132240 2.28 1.37E-04 9.95E-03 1.55 8.66E-03 1.99E-01 
ILMN_2221564 LYAR 2.29 8.02E-06 4.30E-03 2.04 5.48E-04 8.77E-02 
ILMN_2181432 SPC24 2.29 5.80E-04 1.94E-02 1.75 1.46E-03 1.08E-01 
ILMN_1739222 ETV5 2.30 1.58E-04 1.06E-02 2.59 8.66E-04 9.77E-02 
ILMN_2141807 C15ORF23 2.31 1.26E-04 9.54E-03 1.54 1.13E-02 2.20E-01 
ILMN_1761486 C13ORF34 2.32 2.80E-04 1.38E-02 1.67 3.55E-04 7.91E-02 
ILMN_1656501 DUSP5 2.34 3.37E-04 1.51E-02 3.19 2.43E-05 5.76E-02 
ILMN_1715616 PPIL5 2.34 1.46E-04 1.02E-02 1.55 1.53E-03 1.09E-01 
ILMN_1671906 MND1 2.35 1.62E-05 5.30E-03 1.66 3.63E-03 1.45E-01 
ILMN_1678669 RRM2 2.36 2.94E-05 5.83E-03 1.54 1.67E-04 7.15E-02 
ILMN_1705407 NOP56 2.40 1.51E-03 3.15E-02 1.51 3.93E-02 3.65E-01 
ILMN_1784860 RFC3 2.40 1.85E-04 1.15E-02 1.69 8.71E-04 9.77E-02 
ILMN_2215545 C3ORF26 2.41 4.18E-04 1.66E-02 1.50 7.44E-03 1.87E-01 
ILMN_2210129 PRIM1 2.43 2.91E-05 5.83E-03 1.74 1.17E-02 2.23E-01 
ILMN_1697220 NT5E 2.46 2.20E-04 1.25E-02 1.71 1.44E-03 1.07E-01 
ILMN_1794875 AGPAT9 2.46 1.96E-03 3.62E-02 1.53 2.54E-02 3.04E-01 
ILMN_1737195 CENPK 2.49 5.73E-04 1.93E-02 1.63 5.61E-03 1.70E-01 
ILMN_1729115 LOC651816 2.51 1.86E-05 5.61E-03 1.53 3.38E-02 3.44E-01 
ILMN_1764362 LYAR 2.54 1.64E-04 1.07E-02 1.93 2.80E-04 7.86E-02 
ILMN_2212909 MELK 2.54 2.51E-05 5.67E-03 1.67 5.56E-03 1.69E-01 
ILMN_1654268 HMGB2 2.58 1.55E-05 5.24E-03 1.59 1.36E-03 1.06E-01 
ILMN_1711470 UBE2T 2.60 1.92E-04 1.17E-02 1.81 1.17E-03 1.03E-01 
ILMN_2362549 ZWINT 2.61 1.13E-04 9.05E-03 1.62 1.33E-03 1.05E-01 
ILMN_1719749 PTGES3 2.61 4.56E-04 1.73E-02 1.67 8.12E-03 1.94E-01 
ILMN_1695414 ASF1B 2.61 4.09E-06 3.86E-03 1.66 1.24E-03 1.03E-01 
ILMN_1786065 UHRF1 2.69 3.98E-05 6.17E-03 1.86 5.73E-03 1.71E-01 
ILMN_1673673 PBK 2.75 9.68E-06 4.50E-03 1.64 4.40E-03 1.56E-01 
ILMN_1720114 GMNN 2.81 1.11E-05 4.80E-03 1.95 2.67E-03 1.30E-01 
ILMN_3219455 LOC644745 2.81 1.04E-04 8.70E-03 1.50 3.00E-04 7.86E-02 
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ILMN_1703946 ADORA2B 2.88 1.46E-05 5.05E-03 2.11 8.06E-04 9.73E-02 
ILMN_1710428 CDC2 2.88 1.94E-05 5.61E-03 1.84 3.78E-03 1.47E-01 
ILMN_1719256 CKS1B 2.89 2.43E-05 5.66E-03 1.59 7.69E-04 9.41E-02 
ILMN_1796589 TRIP13 2.91 4.26E-05 6.29E-03 1.65 7.59E-04 9.37E-02 
ILMN_2041046 CKS1B 2.93 9.89E-06 4.50E-03 1.51 1.35E-03 1.06E-01 
ILMN_3275936 LOC100133277 3.00 7.53E-05 7.76E-03 1.50 3.04E-02 3.31E-01 
ILMN_1670353 RAD51AP1 3.03 2.60E-04 1.34E-02 1.77 9.85E-04 1.00E-01 
ILMN_1651237 CDT1 3.05 5.41E-05 6.83E-03 1.69 2.41E-03 1.26E-01 
ILMN_1771841 FOSL1 3.06 9.02E-05 8.25E-03 3.18 1.69E-04 7.15E-02 
ILMN_1806040 TYMS 3.13 2.16E-05 5.61E-03 1.79 5.51E-04 8.77E-02 
ILMN_1694177 PCNA 3.13 1.44E-05 5.01E-03 1.77 1.19E-03 1.03E-01 
ILMN_1777564 MAD2L1 3.15 3.43E-05 5.92E-03 1.96 6.45E-04 9.15E-02 
ILMN_2368718 CENPM 3.16 5.33E-05 6.82E-03 1.85 3.00E-03 1.37E-01 
ILMN_3220769 LOC729964 3.19 8.02E-04 2.23E-02 1.70 3.01E-04 7.86E-02 
ILMN_1728972 FAM64A 3.23 1.20E-06 3.15E-03 1.52 6.58E-06 5.30E-02 
ILMN_2215640 TUBA3D 3.27 5.33E-05 6.82E-03 1.59 1.09E-02 2.18E-01 
ILMN_1763907 C6ORF173 3.28 6.15E-05 7.21E-03 1.73 9.28E-03 2.03E-01 
ILMN_1670238 CDC45L 3.28 3.54E-05 5.94E-03 1.78 3.89E-04 8.06E-02 
ILMN_2357438 AURKA 3.30 5.42E-05 6.83E-03 1.57 8.56E-04 9.76E-02 
ILMN_1806037 TK1 3.40 1.17E-06 3.15E-03 1.54 4.40E-04 8.42E-02 
ILMN_1705750 TGM2 3.40 9.28E-06 4.50E-03 4.73 4.67E-05 6.57E-02 
ILMN_1809590 GINS2 3.42 4.62E-06 3.93E-03 2.00 5.01E-04 8.61E-02 
ILMN_1683450 CDCA5 3.46 5.41E-06 3.94E-03 1.64 1.41E-03 1.07E-01 
ILMN_1686097 TOP2A 3.49 8.44E-05 8.03E-03 1.55 3.00E-03 1.37E-01 
ILMN_1687978 PHLDA1 3.53 6.79E-05 7.39E-03 4.09 3.58E-05 6.26E-02 
ILMN_1728934 PRC1 3.54 3.11E-05 5.83E-03 1.50 4.83E-04 8.48E-02 
ILMN_1714730 UBE2C 3.54 2.34E-06 3.15E-03 1.68 2.06E-03 1.20E-01 
ILMN_2285996 KIAA0101 3.55 1.27E-05 4.85E-03 1.64 1.05E-02 2.15E-01 
ILMN_1781943 FAM83D 3.59 3.87E-06 3.79E-03 1.50 4.85E-04 8.48E-02 
ILMN_2063168 MALL 3.72 1.27E-05 4.85E-03 3.22 1.39E-04 6.90E-02 
ILMN_1684217 AURKB 3.78 1.75E-05 5.48E-03 1.55 3.54E-03 1.44E-01 
ILMN_1747911 CDC2 3.86 2.82E-05 5.83E-03 1.57 7.55E-04 9.37E-02 
ILMN_3205271 LOC100132863 3.87 1.38E-04 9.97E-03 1.81 2.40E-03 1.26E-01 
ILMN_2219712 HMGB2 4.04 9.56E-06 4.50E-03 1.51 1.11E-02 2.19E-01 
ILMN_2202948 BUB1 4.17 6.05E-07 3.15E-03 1.52 6.68E-05 6.57E-02 
ILMN_1786125 CCNA2 4.35 4.29E-05 6.30E-03 1.58 3.48E-05 6.26E-02 
ILMN_2051373 NEK2 5.81 8.87E-07 3.15E-03 1.60 5.06E-05 6.57E-02 
ILMN_1762899 EGR1 8.54 2.76E-06 3.24E-03 8.36 9.98E-07 1.60E-02 
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